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some aspects of growth in general are described. Secondly, the current state of art 
with regard to prediction modelling for growth analyses is given. Finally an outline of 
this thesis is presented. 
Growth 
Prenatal growth 
Human growth is most intense prenatally. In 40 weeks, the fetus gains on average 
3200 grams of weight and 50 cm in length. Fetal growth is the result of very complex 
metabolic and endocrine processes. The insulin-like growth factors (IGF’s) I and II 
and insulin are major determinants of fetal growth (1). The influence of growth 
hormone (GH) on prenatal growth is very moderate, particularly due to low 
sensitivity of the GH receptors (2, 3). Epidemiological and clinical studies reported 
the following determinants of fetal growth: height of parents, ethnicity, age of 
mother, gender of the fetus but also environmental factors such as social economic 
status of the parents, condition of the mother, smoking during pregnancy (4, 5). 
During the third trimester of gestation, the fetus grows very fast, with a maximum 
growth velocity of 100 cm/year (Figure 1). At the end of gestation, height velocity 
decreases to approximately 25 cm/year. 
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Figure 1. Pre- and postnatal growth; adapted from Widdowson 
Postnatal growth 
Postnatal longitudinal growth is also a complex biological process resulting from 
multiple interactions between endogenous factors, such as genetics, hormones, 
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nutrition, physical activity, and psychosocial influences.  
Normal growth requires the cooperation of several hormones, amongst which GH, 
thyroid hormones, sex steroids and corticosteroids. While fetal growth and early 
postnatal growth until the age of 3-6 months is mostly GH independent, there is a 
progressive increment in GH dependency after the first months when GH becomes 
the most important hormone in controlling longitudinal growth (6, 7). 
GH is secreted in a pulsatile pattern by the anterior pituitary gland (8). It 
stimulates various processes in the body (Figure 2). GH has a stimulatory effect on 
the production of IGF-I, which is considered as one of the main growth factors and is 
involved in a large number of cellular processes, such as cell proliferation, 
metabolism, differentiation, motility and migration and cell survival (9). 
 
 
Figure 2. The GH/IGF-I axis 
The growth velocity decreases during the first two years of life to 7 cm/year, and 
then slowly to less than 5 cm/year at start of puberty (Figure 1). During puberty, 
starting in girls at a mean age of 10.7 years and in boys at 11.5 years (10) there is a 
growth spurt with mean peak height velocity 8.3 cm/year in boys and 7.0 cm/year in 
girls (11). The total pubertal height gain is 29 cm in boys and 24 cm in girls (11). 
A child's height is usually evaluated relative to that of the reference population. A 
height measurement is expressed in standard deviation score (SDS), i.e. the 
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age and sex in the reference population, divided by the standard deviation (Figure 
3). 
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Figure 3. Reference chart for Dutch girls, with examples of height observations 
The endpoint of postnatal growth is adult height. In healthy persons, important 
determinants of adult height are gender (Dutch male adults are on average 13.4 cm 
taller than females(10)) and parental height, explaining 22 – 25% of the variance in 
adult height (12-14). In almost all industrialized countries, the average adult height 
showed an important increase during the last century, caused by improvement of 
nutritional, hygienic and health status (15-17). Between 1955 and 1997, this increase 
in adult height (called secular trend) was in the Netherlands 8.0 cm for males and 
7.75 cm for females (10) (Figure 4). 
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Figure 4. Secular differences in mean height between the 1997, 1980, and 1965  
growth studies in comparison to data from the 1955 growth study.  
From: FREDRIKS: Pediatr Res, Volume 47(3).March 2000.316-323 
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Growth hormone deficiency 
Growth retardation in children might be due to a subnormal level of growth hormone 
(GH). Estimates of the prevalence of children with growth hormone deficiency (GHD) 
cover a broad range from 18 to 287 per million (18), depending on the definition 
used. The prevalence in the Netherlands is estimated between 500 per million (19) 
and 200 per million [data of the Dutch Growth Foundation: treated children with GH 
max < 20 mU/l and IGF-I below the mean for age and sex, compared to the number 
of life born infants per year (20)]. GH secretion is a continuum between normality 
and abnormality (21). The diagnosis of severe GHD is usually straightforward, but 
diagnosing moderate GHD is difficult and is sometimes made on arbitrary grounds 
(22). 
In approximately 65% of the children diagnosed as GHD, the cause is idiopathic 
(unknown) [data from the Dutch National Registry of Growth Hormone Treatment in 
Children]. In the other 35%, a variety of identifiable causes has been shown, like 
genetic forms and organic lesions in the pituitary or the hypothalamic area 
(congenital defects, hydrocephalus, tumours like craniopharyngiomas). 
When GH deficiency is accompanied by one or more other pituitary hormone 
deficiencies, hypoglycaemia or prolonged neonatal jaundice, diagnosis is often made 
during the neonatal period. At an older age, children with GHD usually present with 
growth retardation and short stature compared to healthy children of the same age, 
sex and pubertal stage. Age at presentation can vary from a few days after birth until 
adolescence. The variability in height and age at presentation are highly influenced 
by the time of onset and the severity of GHD (23). 
Due to the pulsatile nature of normal GH-secretion (24), measurement of random 
serum GH concentrations is of little value in establishing a diagnosis of GHD. Usually, 
a GH provocation test is performed in order to assess the maximum GH release in 
response to a secretagogue, mainly a pharmacological agent (25). During the test, 
serum GH-levels are measured for two hours after the stimulus. If the maximum GH 
level exceeds a level of 7.7 µg/L (20 mU/L), a normal GH production is assumed. A 
GH response that remains below 7.7 µg/L, or a combination of GH response below 
11.5 µg/L and subnormal levels of IGF-I and IGFBP-3, is considered as too low (26). 
Unfortunately, it is has been reported that children without GHD might also “fail” one 
single GH provocation test (27). Therefore, two provocation tests are required to 
accurately diagnose GHD (22, 28, 29). 
If one would aim to determine spontaneous GH secretion, a 24- or 12-hours GH 
profile should be made, consisting of plasma GH measurements every 20-30 
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time-consuming. It is necessary in case of suspicion of neurosecretory dysfunction 
(NSD), since children with this diagnose have normal response to GH provocation 
tests but impaired spontaneous GH secretion (30, 31). 
GH-treatment 
Children (and adults) with GHD can be treated by subcutaneous injections with GH. 
Since the 1950’s, GH was isolated from human pituitaries obtained at obductions. 
Several pituitaries were required to obtain substantial quantities of the hormone for 
one injection. In 1985, treatment with human pituitary GH-injection was related to 
Creutzfeld-Jakob disease in some patients (32-34), with onset many years after the 
use of GH. Treatment with human pituitary GH was immediately stopped in nearly all 
countries. In 1986, biosynthetic GH, which is identical to the GH produced by healthy 
children, became available. Besides for children with GHD, treatment with GH also 
proved to be effective for other children with growth retardation, such as girls with 
Turner syndrome and short children born short for gestational age (35-37). 
In Europe, the accepted daily dose for treatment of children with GHD varies 
between 0.025 and 0.035 mg/kg·day. In the United States, doses between 0.025 
and 0.05 mg/kg·day are commonly used, in Japan 0.025 mg/kg·day or less (38, 39).  
For many children, growth response to the lower recommended doses is good (40, 
41). However, there is variation in response. Several studies found a GH dose-effect 
on the growth response during the first treatment years (40-42). For the long-term 
growth response, the dose-effect was smaller and less established (43, 44). 
GH therapy induces a significant increase in insulin like growth factor I (IGF-I) and 
insulin like growth factor binding protein-3 (IGFBP-3) levels and this increase is dose-
dependent (40, 45). The majority of children with GHD have IGF-I and IGFBP-3 
levels in the lower range prior to GH treatment. During GH treatment, some children 
display IGF-I values above the normal range for age and sex (SD scores > 2). In 
retrospective studies on healthy adults, serum levels of IGF-I and IGFBP-3 have been 
correlated with the risk of developing prostate and premenopausal breast cancers 
later in life (46, 47). However, until now no direct causative effect of IGF-I on cancer 
development has been demonstrated. A study on disease recurrence or death in 
survivors of childhood cancer revealed no increased risk for GH-treated subjects (48). 
Another study reported an increased incidence of cancer in patients treated with 
pituitary GH, but this was based on small numbers (49). Regular measurement of 
IGF-I and IGFBP-3 levels during GH treatment is recommended (29). In case of IGF-I 
levels above the normal range, lowering of GH dose should be considered (37). 
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should be pointed out that, in order to be efficacious, GH therapy should be daily 
administered by subcutaneous injection, for several years (50). GH treatment is 
expensive, the costs being on average € 15.000 – 25.000 per child per year, 
depending on the dosing and on the body surface of the child. 
Small for gestational age (SGA) 
Weight and length at birth are usually evaluated using reference charts taking into 
account gestational age at birth and sometimes gender (51, 52). Neonates with a 
birth weight and/or length at 2 standard deviations (SD) or more below the mean are 
classified as small for gestational age (SGA). By definition, 2.3% of the life-born 
neonates is SGA. 
Several factors have been mentioned as possible causes for the development of 
SGA. These include maternal factors as nutrition, smoking, or several diseases, fetal 
factors as chromosomal or congenital abnormalities, and placental factors such as 
infarctions or placental development aberrations. However, for the majority of 
children no underlying pathology can be identified. 
Most children born SGA show catch-up growth during the first two years of life 
and reach a height in the normal range (> -2 SDS) (53, 54). At the age of two years, 
15% still has a height below -2 SD scores, and the percentage of adults with a 
height below the normal range is only slightly smaller (54, 55). The underlying 
mechanism of inadequate catch-up growth is still not fully understood. Disturbances 
in the GH/IGF-I axis (Figure 2) may play a role. Sixty percent of SGA children with 
persistent short stature showed subnormal GH secretion measured over 24 hours, 
whereas 25% showed low GH peaks during GH provocation tests (56, 57). 
Short SGA children show a significant reduces lean body mass, fat mass skin fold 
measurements and body mass index (58, 59). They have a lower food intake than 
the recommended daily intake of children of the same age (58). Children born SGA 
might be at higher risk of a number of adult diseases like diabetes mellitus type II 
and cardiovascular diseases as birth weight is inversely associated with risks for 
these disorders (60). Several studies suggest that short children born SGA are 
psychosocially disadvantaged (61-65). They also have lower total IQ, performal IQ 
and verbal IQ compared to their peers (65). Another study showed subnormal 
intelligence and psychological performance in adult men born SGA, especially in 
those who remained short (66). 
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GH-treatment 
After the introduction of biosynthetic GH, in 1986, trials on GH treatment for short 
SGA children were started. It appeared that daily GH treatment, at a higher dosage 
than for children with GHD, caused a significant catch-up growth in height, at least 
on the short term (67-69). Randomised trials showed that during the first treatment 
years the growth response is related to the dose of GH treatment (68, 70-73). For 
the long-term growth response, the dose-effect was smaller, but still significant (38, 
39). The recommended GH dose for short SGA children is in the range 0.035 – 0.070 
mg/kg·day (35, 74). 
Since low birth weight has been associated with the development of diabetes 
mellitus type 2 and cardiovascular disease in later life, it is important to monitor the 
effect of GH treatment on risk factors for these diseases in children born SGA. A 
study on the effect on carbohydrate metabolism during 6 years of GH treatment in 
short SGA children showed no adverse effects on glucose levels but higher fasting 
insulin levels and glucose-stimulated insulin levels (75). The effects on body 
compostion, blood pressure and lipi metabolism were positive.(76) 
In a randomised trial, it was found that during the first year of GH treatment, 
caloric, carbohydrate and protein intake increased significantly, in contrast to 
untreated controls. In the group of treated children, lean body mass SDS and BMI 
SDS also showed a significant increase (58). Another study showed an increase in 
muscle tissue mass during 3 year of GH treatment (77). 
Furthermore, improvement in IQ, behavior and self-perception during GH 
treatment was reported (65). 
Prediction models for growth response to growth 
hormone treatment 
For as long as GH treatment is given, it has been investigated which factors influence 
the growth response and whether it is possible to predict the growth response before 
the start or in an early phase of treatment. These predictions aim to identify which 
children will benefit from GH treatment and to determine what would be the optimal 
dose for a child. 
 Most prediction models are developed for prediction of short-term response (71, 
78-80). These models have the advantage that, because of the short follow-up 
period, collection of data is relatively easy and the predictive performance of the 
model can be substantial. Other models aimed to predict growth response over 
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treatment is of major importance, as the final aim is to reach a satisfactory adult 
height. 
Most prediction models are build using linear relations between the determinants 
and the outcome and do not consider interaction terms. An exception are the models 
developed by Kriström et al (78, 82). They used a nonlinear method described as 
empirical curve fitting. Their algorithms for the predictions of first-year response to 
GH treatment, or response during the first two years, contain complex nonlinear 
terms and interactions. 
Modelling of continuous predictors 
When building a model, often only straight-line relations between predictors and 
outcome are considered. However, a non-linear relation between a predictor and the 
outcome is very well possible. Previously, quadratic or cubic polynomials have been 
used when linearity was not satisfactory. But the range of curve shapes afforded by 
conventional low order polynomials is limited. Royston and Altman (83) proposed a 
more general family of parametric models, called fractional polynomials. Here, one, 
two or more terms of the form Xp are fitted, the exponents p being chosen from a 
small pre-selected set of integer and non-integer values (Figure 5). Another method 
to fit more flexible relations is the use of spline functions (84-86). The idea is that 
the relation between predictor and outcome is best modelled with different 
polynomials within intervals of the predictor. The polynomials are connected in the 
endpoints of the intervals, called knots. A popular choice for the splines are the 
restricted cubic splines, build up by cubic polynomials, smoothly connected with each 
other, and linear before the first knot and after the last knot (Figure 6). Although 
both fractional polynomials and restricted cubic splines can be fitted with standard 
statistical software, employing them in model building will require extra efforts, 
especially when flexible modelling has to be considered for several continuous 
predictors (87). Furthermore, to conclude that another relation is significantly better 
than the linear relation will require a sufficiently large sample size. The complexity of 
the prediction rules when more flexible relations are allowed should not be a reason 
to avoid them. The relation between predictor and outcome can be plotted to check 
the plausibility. Computations to obtain a predicted value can nowadays easily be 
performed on a PC or applications can even be made available on websites. 
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Figure 5. Example of a relation modelled by a fractional polynomial.  
The dashed line gives the fitted quadratic curve. The solid line is the  
fractional polynomial y = a + b*LN(x). 
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Figure 6. Example of a relation modelled by a restricted cubic spline.  
The dashed line gives the fitted quadratic curve. The solid line is the fitted  
restricted cubic spline, with knots at x = 5, x = 24 and x = 50. 
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Interaction terms 
Another aspect not often considered in developing prediction models, is the use of 
interaction terms. Interaction means that the effects of two predictors in the model 
cannot be separated; that is, the effect of one predictor on the outcome depends on 
the level of another predictor. In a model with several predictors, many interaction 
terms could be tested. Therefore, the interactions to be considered should be pre-
specified and kept limited. Harrell (88) described types of interactions that can be 
important in biostatistics and (clinical) epidemiology. For models predicting growth 
response, especially the following will apply: Firstly, interactions between treatment 
and the severity of the disease (growth restriction). Generally, patients with mild 
disease may receive little benefit from treatment. The severity of growth restriction 
can be reflected by the height SD score at start, the difference between height SD 
score and target height SD score, the severity of growth hormone deficiency 
(maximum GH response to a GH provocation test), or possibly other parameters such 
as IGF-I and IGFBP-3. Other interactions to be considered are interactions of age at 
start of treatment with other predictors.  
Correction for overfitting 
Development of a prediction model is not finished when a well-fitting model is found. 
It is well known that a prediction model developed by selection of determinants and 
fitting of the coefficients, both in the same data set, suffers from overfitting (89). 
The degree of overfitting will be larger if the model is more complex. The predictive 
performance of a prediction model in other data sets than the set on which it is 
developed will be lower. The estimated regression coefficients of the model will be 
too extreme and so will be the predicted values when the model is applied to other 
data sets. This is illustrated in Figure 7, showing two calibration plots, where the 
observed values are plotted against the values predicted by a prediction model. 
Figure 7A shows a calibration plot of a model suffering from overfitting: for observed 
low values, the prediction is on average too low, while for observed high values, the 
prediction is on average too high. The plot in Figure 7B illustrates a model without 
overfitting, with the data points scattered around the line where the predicted value 
is equal to the observed value. 
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Figure 7. Calibration plots of (A) a prediction model suffering from overfitting and  
(B) a prediction model without overfitting 
Bootstrapping (89, 90) is a recently established method to determine the degree 
of overfitting of a model and to correct for it. This requires a strict protocol for the 
development of the model, because the same procedure must be repeated many 
times, so it must be possible to do this automatically. 
Software for bootstrapping of regression models is available in some statistical 
packages (Stata, SAS, S-Plus, R). However, for complex model-building strategies, 
including interaction terms and polynomials, additional programming is required.  
Investigators might be reluctant to correct a prediction model for overfitting, 
because, by definition, it will decrease the performance (91). A lower percentage of 
explained variability (R2) must be presented and the confidence intervals for 
predicted values will be wider. However, these corrected results give a more realistic 
presentation of the predictive ability of the model. 
Validation of prediction models 
To determine the usefulness of a prediction model, it should be established whether 
it works satisfactorily for other patient groups. This is called validation (91). 
Validation of prediction models for growth response is regularly performed, but 
mostly it only comprises testing whether the mean of the residuals (observed value 
minus predicted value) is not significantly different from zero, sometimes 
accompanied by a graphical inspection of the relation between residuals and 
observed outcomes. Testing the mean of the prediction errors is, however, only a 
check for a systematic prediction error (overall too low or too high predictions). 
Constructing a calibration plot, in which observed values are plotted versus predicted 
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their predictions. Fitting a regression line for this relation enables testing for 
deviations from the line of identity. 
Dealing with missing values 
Despite great efforts to achieve a complete dataset, most studies will face the fact of 
missing values. For analysis of prenatal growth, missings might for example occur in 
paternal characteristics, last menstruational period but also in variables dealing with 
social-economic status. For postnatal growth, data for birth length are often missing, 
because it was thought that briefly stretching the legs and knees in order to measure 
the length after birth, could be harmful for the development of the hip joints (92), or 
because of lack of medical staff. Parental height is often not available for adopted 
children. Also laboratory parameters and measurements of bone age are frequently 
not available for all subjects. 
The disadvantages of selecting only the cases with complete data for all the 
potential determinants (complete case analysis) are well known (93). This results not 
only in a smaller sample size, often the selected group is not representative for the 
population aimed for analysis. However, in many analyses of study data, including 
growth analyses, this is still how missings are handled. As crude guideline, this can 
only be sufficient if the proportion of cases with missing data is below 5% (88). If 
the percentage is larger, imputation of the missing values should be done. 
Preferably, the imputed value is obtained using relationships among determinants as 
well as between determinants and the outcome. Even single imputation and then 
performing an ordinary analysis as if the imputed values were real measurements is 
usually better than excluding subjects with incomplete data. Better is to perform 
multiple imputation (94, 95). This means that several data sets are created, with 
different imputed values. These values are random draws from the conditional 
distribution of the target variable, given the other variables. This reflects the 
uncertainty of the imputed value. Subsequently, each completed data set is analysed 
using standard methods and the results are combined, providing valid estimations 
and standard errors. 
Software for multiple imputation and analysis of imputed data sets is nowadays 
available in many statistical packages, although the possibilities and quality of the 
imputation methods vary (96-99). 
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Missing outcome measurements in growth studies 
Longitudinal studies can be classified into unbalanced and balanced studies (100). In 
an unbalanced study, the measurement times vary across subjects. In such a study it 
is usually not possible to identify non-response, unless scheduled measurement times 
are recorded, even when no measurement was actually taken. Nonetheless, presence 
or absence of measurements might not be random. In a balanced study, the number 
of measurements per subjects is fixed and the measurements are taken at specific 
time points. In this situation, missing observations can be identified without 
ambiguity. 
A specific case of missing data is dropout, i.e. after a certain point in time no 
measurements are available. This can be caused by loss to follow-up. It might also 
be due to censoring, i.e. at the time of analysis some cases have not yet reached the 
endpoint of interest, e.g. adult height or onset of puberty. 
If an analysis of repeated measurements (in growth studies often height 
observations) is performed, the results will be valid if the missing data are missing at 
random. This condition allows that the unobserved measurements depend on the 
observed measurements and observed determinants, but it requires that they do not 
depend on the value of the unobserved measurement itself. 
If a data analysis at a certain endpoint is required, like at adult height, but some 
cases do not have complete follow-up data, common practice is to perform the 
analysis on the subgroup of patients with observed adult height. However, adult 
height and the age at which this is attained are usually correlated. Patients reaching 
adult height at a relatively older age are more likely to have incomplete follow-up 
data until adult height. Therefore, the group of patients with complete follow-up 
usually is not representative for the total group. This selection not only occurs in 
clinical trials, in which it is not always possible to wait until all participants have 
reached adult height. It also accurs if all available adult heights are selected from a 
continuous longitudinal growth registration data base. To obtain unbiased results in 
this situation, a possibility is to carefully select the cases that should be used. 
Preferably, an analysis should be performed that uses all available data, including the 
incomplete follow-up of some cases, in a correct and efficient way. Such a method 
has been developed for medical cost-effectiveness analyses (101) but not yet for 
growth research. 
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Outline of this thesis 
Chapter 2 describes the validation of a prediction model used in clinical practice for 
first-year response to GH-treatment in children with GHD. For this validation, data 
from the Dutch National Registry of Growth Hormone Treatment in Children were 
used. Children were selected that fulfilled the inclusion criteria used for the 
development of the original model. Special attention was given to the problem of 
overfitting and the analysis results in a adjustment of the original model. 
This modified, calibrated model was validated in a third data set, described in 
chapter 3. The performances of both the original and the modified model, applied to 
these new data, were compared. 
In chapter 4, prediction models for the prediction of adult height of children with 
GHD treated with GH are presented. Data were used of a well-defined selection of 
children registered in the Dutch National Registry of Growth Hormone Treatment in 
Children. Because of clinical relevance, a model was developed that uses only 
information available at start of GH treatment, as well as a model using information 
available after one year of treatment. Separate models were developed for 
prepubertal as well as pubertal children. 
In chapter 5, a prediction model is presented for long-term growth response to GH 
treatment of children born short for gestational age without spontaneous catch-up 
growth. With this model, at start of GH treatment a prediction can be obtained for 
height at onset of puberty and for adult height. Data were used from two clinical 
trials, with patients randomised to two different doses for GH. This enables to fit a 
GH dosage effect. Predictions given by this model will give information about the 
expected adult height for an individual child and might be useful to decide on the GH 
dose to prescribe. 
In chapter 6, prepubertal growth is presented of children born short for 
gestational age and with a height still below the normal range at the age of 2 years. 
Aim was to describe which percentage of these children had catch-up growth before 
the age of 8 years and the factors related to this catch-up growth. A prediction 
model is presented for height SDS at the age of 8 years, which can be helpful for 
decisions about treatment with GH. 
Chapter 7 describes a method to get unbiased estimations on adult height, in case 
part of the study group does not yet have complete growth follow-up until adult 
height. The performance of this method was tested in data from a clinical trial on 
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Hormone Treatment in Children. 
Chapter 8 describes a study of intra-uterine growth. A model was fitted for the 
effects of physiological determinants, as gender, parity and parental height, on 
estimated fetal weights, derived from ultra-sound measurements, during pregnancy. 
Such a model enables to construct individually customised intra-uterine growth 
charts. Using these charts, fetal growth can be assessed, taking into account the 
characteristics of the fetus that determine its growth potential. Large deviations from 
the mean growth, given the characteristics, indicate pathological growth restriction 
or macrosomia. 
In chapter 9, the studies presented in this thesis are discussed and some 
directions are given for future research. 
  24
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n 
References 
 1. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic 
acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989 Feb;10(1):68-91. 
 2. Hill DJ, Riley SC, Bassett NS, Waters MJ. Localization of the growth hormone receptor, 
identified by immunocytochemistry, in second trimester human fetal tissues and in placenta 
throughout gestation. J Clin Endocrinol Metab 1992 Aug;75(2):646-50. 
 3. Gluckman PD, Harding JE. Fetal growth retardation: underlying endocrine mechanisms and 
postnatal consequences. Acta Paediatr Suppl 1997 Jul;422:69-72. 
 4. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. 
Lancet 1992 Feb 1;339(8788):283-7. 
 5. Mongelli M, Gardosi J. Longitudinal study of fetal growth in subgroups of a low-risk population. 
Ultrasound Obstet Gynecol 1995 Nov;6(5):340-4. 
 6. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth 
hormone on longitudinal bone growth. Endocr Rev 1987 Nov;8(4):426-38. 
 7. Hindmarsh PC, Brook CG. Normal growth and its endocrine control. In: Brook CG, editor. 
Clinical Paediatric Endocrinology. Oxford: Blackwell Scientific Publications; 1989. p. 57-73. 
 8. Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr 1996 
May;128(5 Pt 2):S32-7. 
 9. Rosenfeld RG. Insulin-like Growth Factors. In: Brook CG, editor. Clinical Paediatric 
Endocrinoloty. Oxford: Blackwell Science; 1995. p. 107-22. 
 10. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, et al. 
Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000 
Mar;47(3):316-23. 
 11. Gasser T, Muller HG, Kohler W, Prader A, Largo R, Molinari L. An analysis of the mid-growth 
and adolescent spurts of height based on acceleration. Ann Hum Biol 1985 Mar-Apr;12(2):129-
48. 
 12. Preece MA. The genetic contribution to stature. Horm Res 1996;45 Suppl 2:56-8. 
 13. Wright CM, Cheetham TD. The strengths and limitations of parental heights as a predictor of 
attained height. Arch Dis Child 1999 Sep;81(3):257-60. 
 14. Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9 years 
allowing for heights of parents. Arch Dis Child 1970 Dec;45(244):755-62. 
 15. van Wieringen JC. Secular growth changes. In: Falkner F, Tanner JM, editors. Human Growth. 
London: Bailliere Tindage; 1978. p. 445-73. 
 16. Hughes JM, Li L, Chinn S, Rona RJ. Trends in growth in England and Scotland, 1972 to 1994. 
Arch Dis Child 1997 Mar;76(3):182-9. 
 17. Hauspie RC, Vercauteren M, Susanne C. Secular changes in growth. Horm Res 1996;45 Suppl 
2:8-17. 
 18. Guyda HJ. Four decades of growth hormone therapy for short children: what have we 
achieved? J Clin Endocrinol Metab 1999 Dec;84(12):4307-16. 
 19. Wit JM, De Muinck Keizer-Schrama SMPF, Delemarre-Van de Waal HA. Groeistoornissen. 
Maarssen: Elsevier/Bungen; 1999. 
 20. Statistics Netherlands. http://statline.cbs.nl. 2007  
 25 
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n  21. Hindmarsh PC, Swift PG. An assessment of growth hormone provocation tests. Arch Dis Child 
1995 Apr;72(4):362-7; discussion 7-8. 
 22. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, et al. 
Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin 
Endocrinol Metab 1995 May;80(5):1532-40. 
 23. Adan L, Souberbielle JC, Brauner R. Diagnostic markers of permanent idiopathic growth 
hormone deficiency. J Clin Endocrinol Metab 1994 Feb;78(2):353-8. 
 24. Albertsson-Wikland K, Rosberg S. Analyses of 24-hour growth hormone profiles in children: 
relation to growth. J Clin Endocrinol Metab 1988 Sep;67(3):493-500. 
 25. Rose SR, Ross JL, Uriarte M, Barnes KM, Cassorla FG, Cutler GB, Jr. The advantage of 
measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of 
growth hormone deficiency. N Engl J Med 1988 Jul 28;319(4):201-7. 
 26. de Muinck Keizer-Schrama SMPF, Oostdijk W, Rikken B, Waelkens JJJ. Consensus Diagnostiek 
Kleine Lichaamslengte. Leiden: Bureau van de Groeistichting; 1995. 
 27. Rochiccioli P, Pienkowski C, Tauber MT, Uboldi F, Enjaume C. Association of pharmacological 
tests and study of 24-hour growth hormone secretion in the investigation of growth retardation 
in children: analysis of 257 cases. Horm Res 1991;35(2):70-5. 
 28. Carel JC, Coste J, Gendrel C, Chaussain JL. Pharmacological testing for the diagnosis of growth 
hormone deficiency. Growth Horm IGF Res 1998 Feb;8 Suppl A:1-8. 
 29. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in 
childhood and adolescence: summary statement of the GH Research Society. GH Research 
Society. J Clin Endocrinol Metab 2000 Nov;85(11):3990-3. 
 30. Spiliotis BE, August GP, Hung W, Sonis W, Mendelson W, Bercu BB. Growth hormone 
neurosecretory dysfunction. A treatable cause of short stature. Jama 1984 May 
4;251(17):2223-30. 
 31. Bercu BB, Shulman D, Root AW, Spiliotis BE. Growth hormone (GH) provocative testing 
frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab 1986 
Sep;63(3):709-16. 
 32. Koch TK, Berg BO, De Armond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with 
idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth 
hormone. N Engl J Med 1985 Sep 19;313(12):731-3. 
 33. Powell-Jackson J, Weller RO, Kennedy P, Preece MA, Whitcombe EM, Newsom-Davis J. 
Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet 1985 Aug 
3;2(8449):244-6. 
 34. Steendijk R, Stoelinga GB. [Growth hormone and Creutzfeldt-Jakob disease] Groeihormoon en 
de ziekte van Creutzfeldt-Jakob. Ned Tijdschr Geneeskd 1985 Jun 8;129(23):1101-2. 
 35. Chernausek SD. Treatment of short children born small for gestational age: US perspective, 
2005. Horm Res 2005;64 Suppl 2:63-6. 
 36. Fujieda K, Hanew K, Hirano T, Igarashi Y, Nishi Y, Tachibana K, et al. Growth response to 
growth hormone therapy in patients with different degrees of growth hormone deficiency. 
Endocr J 1996 Oct;43 Suppl:S19-25. 
 37. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, et al. Update of guidelines for 
the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society 
Drug and Therapeutics Committee. J Pediatr 2003 Oct;143(4):415-21. 
  26
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n  38. de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for 
gestational age: height gain is less dose dependent over the long term than over the short 
term. Pediatrics 2005 Apr;115(4):e458-62. 
 39. van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after 
long-term, continuous growth hormone (GH) treatment in short children born small for 
gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol 
Metab 2003 Aug;88(8):3584-90. 
 40. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG. Effects of dose and gender on 
the growth and growth factor response to GH in GH-deficient children: implications for efficacy 
and safety. J Clin Endocrinol Metab 2002 Jan;87(1):90-8. 
 41. de Muinck Keizer-Schrama S, Rikken B, Hokken-Koelega A, Wit JM, Drop S. Comparative effect 
of two doses of growth hormone for growth hormone deficiency. The Dutch Growth Hormone 
Working Group. Arch Dis Child 1994 Jul;71(1):12-8. 
 42. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, et al. 
Derivation and validation of a mathematical model for predicting the response to exogenous 
recombinant human growth hormone (GH) in prepubertal children with idiopathic GH 
deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin 
Endocrinol Metab 1999;84(4):1174-83. 
 43. Cutfield W, Lindberg A, Albertsson Wikland K, Chatelain P, Ranke MB, Wilton P. Final height in 
idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Acta 
Paediatr Suppl 1999 Feb;88(428):72-5. 
 44. Wit JM, Kamp GA, Rikken B. Spontaneous growth and response to growth hormone treatment 
in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996 
Feb;39(2):295-302. 
 45. de Muinck Keizer-Schrama SM, Rikken B, Wynne HJ, Hokken-Koelega AC, Wit JM, Bot A, et al. 
Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: 
effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group. J 
Clin Endocrinol Metab 1992 Apr;74(4):898-905. 
 46. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like 
growth factor-I and prostate cancer risk: a prospective study. Science 1998 Jan 
23;279(5350):563-6. 
 47. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating 
concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998 May 
9;351(9113):1393-6. 
 48. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence 
and second neoplasms in survivors of childhood cancer treated with growth hormone: a report 
from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002 Jul;87(7):3136-41. 
 49. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human 
pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002 Jul 
27;360(9329):273-7. 
 50. Lippe B, Frasier SD. How should we test for growth hormone deficiency, and whom should we 
treat? J Pediatr 1989 Oct;115(4):585-7. 
 27 
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n  51. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the Swedish 
reference standards for weight, length and head circumference at birth for given gestational 
age (1977-1981). Acta Paediatr Scand 1991;80(8-9):756-62. 
 52. Usher R, McLean F. Intrauterine growth of live-born Caucasian infants at sea level: standards 
obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of 
gestation. J Pediatr 1969 Jun;74(6):901-10. 
 53. Hokken-Koelega AC, de Ridder MA, Lemmen RJ, den Hartog H, de Muinck Keizer-Schrama SM, 
Drop SL. Children born small for gestational age: do they catch up? Pediatr Res 1995 
Aug;38(2):267-71. 
 54. Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from 
birth to final height. Pediatr Res 1995 Nov;38(5):733-9. 
 55. Paz I, Seidman DS, Danon YL, Laor A, Stevenson DK, Gale R. Are children born small for 
gestational age at increased risk of short stature? Am J Dis Child 1993 Mar;147(3):337-9. 
 56. Boguszewski M, Rosberg S, Albertsson-Wikland K. Spontaneous 24-hour growth hormone 
profiles in prepubertal small for gestational age children. J Clin Endocrinol Metab 1995 
Sep;80(9):2599-606. 
 57. de Waal WJ, Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Drop SL. 
Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II 
levels in prepubertal children with short stature after intrauterine growth retardation. The 
Dutch Working Group on Growth Hormone. Clin Endocrinol (Oxf) 1994 Nov;41(5):621-30. 
 58. Boonstra VH, Arends NJ, Stijnen T, Blum WF, Akkerman O, Hokken-Koelega AC. Food intake of 
children with short stature born small for gestational age before and during a randomized GH 
trial. Horm Res 2006;65(1):23-30. 
 59. Leger J, Carel C, Legrand I, Paulsen A, Hassan M, Czernichow P. Magnetic resonance imaging 
evaluation of adipose tissue and muscle tissue mass in children with growth hormone (GH) 
deficiency, Turner's syndrome, and intrauterine growth retardation during the first year of 
treatment with GH. J Clin Endocrinol Metab 1994 Apr;78(4):904-9. 
 60. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from 
ischaemic heart disease. Lancet 1989 Sep 9;2(8663):577-80. 
 61. Low JA, Handley-Derry MH, Burke SO, Peters RD, Pater EA, Killen HL, et al. Association of 
intrauterine fetal growth retardation and learning deficits at age 9 to 11 years. Am J Obstet 
Gynecol 1992 Dec;167(6):1499-505. 
 62. Pryor J, Silva PA, Brooke M. Growth, development and behaviour in adolescents born small-for-
gestational-age. J Paediatr Child Health 1995 Oct;31(5):403-7. 
 63. van der Reijden-Lakeman I, Slijper FM, van Dongen-Melman JE, de Waal WJ, Verhulst FC, 
Rosenfeld RG, et al. Self-concept before and after two years of growth hormone treatment in 
intrauterine growth-retarded children. Horm Res 1996 Oct;46(2):88-94. 
 64. van der Reijden-Lakeman IE, de Sonneville LM, Swaab-Barneveld HJ, Slijper FM, Verhulst FC. 
Evaluation of attention before and after 2 years of growth hormone treatment in intrauterine 
growth retarded children. J Clin Exp Neuropsychol 1997 Feb;19(1):101-18. 
 65. van Pareren YK, Duivenvoorden HJ, Slijper FS, Koot HM, Hokken-Koelega AC. Intelligence and 
psychosocial functioning during long-term growth hormone therapy in children born small for 
gestational age. J Clin Endocrinol Metab 2004 Nov;89(11):5295-302. 
  28
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n  66. Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T. Intellectual and psychological performance 
in males born small for gestational age with and without catch-up growth. Pediatr Res 2001 
Jul;50(1):91-6. 
 67. Albertsson-Wikland K. Growth hormone secretion and growth hormone treatment in children 
with intrauterine growth retardation. Swedish Paediatric Study Group for Growth Hormone 
Treatment. Acta Paediatr Scand Suppl 1989;349:35-41; discussion 53-4. 
 68. Chatelain P, Job JC, Blanchard J, Ducret JP, Oliver M, Sagnard L, et al. Dose-dependent catch-
up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. 
Belgian and French Pediatric Clinics and Sanofi-Choay (France). J Clin Endocrinol Metab 1994 
Jun;78(6):1454-60. 
 69. Stanhope R, Preece MA, Hamill G. Does growth hormone treatment improve final height 
attainment of children with intrauterine growth retardation? Arch Dis Child 1991 
Oct;66(10):1180-3. 
 70. Boguszewski M, Albertsson-Wikland K, Aronsson S, Gustafsson J, Hagenas L, Westgren U, et al. 
Growth hormone treatment of short children born small-for-gestational-age: the Nordic 
Multicentre Trial. Acta Paediatr 1998 Mar;87(3):257-63. 
 71. Ranke MB, Lindberg A, Cowell CT, Wikland KA, Reiter EO, Wilton P, et al. Prediction of 
response to growth hormone treatment in short children born small for gestational age: 
analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 
2003 Jan;88(1):125-31. 
 72. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, et al. Growth hormone treatment 
in children with short stature born small for gestational age: 5-year results of a randomized, 
double-blind, dose-response trial. J Clin Endocrinol Metab 1999 Sep;84(9):3064-70. 
 73. de Zegher F, Albertsson-Wikland K, Wilton P, Chatelain P, Jonsson B, Lofstrom A, et al. Growth 
hormone treatment of short children born small for gestational age: metanalysis of four 
independent, randomized, controlled, multicentre studies. Acta Paediatr Suppl 1996 
Oct;417:27-31. 
 74. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of 
the Child Born Small for Gestational Age Child (SGA) through to Adulthood: A Consensus 
Statement of the International Societies of Paediatric Endocrinology and the Growth Hormone 
Research Society. J Clin Endocrinol Metab 2007 Jan 2. 
 75. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, et al. Carbohydrate metabolism 
during long-term growth hormone treatment in children with short stature born small for 
gestational age. Clin Endocrinol (Oxf) 2001 Feb;54(2):243-51. 
 76. Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism 
before and during long-term growth hormone (GH) treatment in children with short stature 
born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 
2000 Oct;85(10):3786-92. 
 77. Leger J, Garel C, Fjellestad-Paulsen A, Hassan M, Czernichow P. Human growth hormone 
treatment of short-stature children born small for gestational age: effect on muscle and adipose 
tissue mass during a 3-year treatment period and after 1 year's withdrawal. J Clin Endocrinol 
Metab 1998 Oct;83(10):3512-6. 
 29 
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n  78. Kristrom B, Karlberg J, Albertsson-Wikland K. Prediction of the growth response of short 
prepubertal children treated with growth hormone. Swedish Paediatric Study Group for GH 
treatment. Acta Paediatr 1995 Jan;84(1):51-7. 
 79. Ranke MB, Guilbaud O, Lindberg A, Cole T. Prediction of the growth response in children with 
various growth disorders treated with growth hormone: analyses of data from the Kabi 
Pharmacia International Growth Study. International Board of the Kabi Pharmacia International 
Growth Study. Acta Paediatr Suppl 1993;82(Suppl 391):82-8; discussion 9. 
 80. Schonau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, et al. A new and accurate 
prediction model for growth response to growth hormone treatment in children with growth 
hormone deficiency. Eur J Endocrinol 2001;144(1):13-20. 
 81. Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, et al. The 
mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency 
suggests a moderate role of GH dose. J Clin Endocrinol Metab 2003 Oct;88(10):4748-53. 
 82. Albertsson-Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop AFM. Validated Multivariate 
Models Predicting the Growth Response to GH Treatment in Individual Short Children with a 
Broad Range in GH Secretion Capacities. Pediatric Research 2000;48(4):475-84. 
 83. Royston P, Altman DG. Regression using Fractional Polynomials of Continuous Covariates: 
Parsimonious Parametric Modelling. Applied Statistics 1994;43(3):429-67. 
 84. De Boor C. A Practical Guide to Splines. New York: Springer-Verlag; 1978. 
 85. Harrell FE, Jr., Lee KL, Pollock BG. Regression models in clinical studies: determining 
relationships between predictors and response. J Natl Cancer Inst 1988 Oct 5;80(15):1198-202. 
 86. Smith PL. Spines as a useful and convenient statistical tool. American Statistician 1979;33:57-
62. 
 87. Sauerbrei W, Royston P. Building Multivariable Prognostic and Diagnostic Models: 
Transformation of the Predictors by Using Fractional Polynomials. Journal of the Royal 
Statistical Society, Series A 1999;162(1):71-94. 
 88. Harrell FE, Jr. Regression modeling strategies. New York: Springer-Verlag; 2001. 
 89. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, 
evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 
1996;15(4):361-87. 
 90. Efron B. TR. An introduction to the bootstrap. New York; 1993. 
 91. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 
2000;19(4):453-73. 
 92. Engelberts AC, Koerts B, Waelkens JJ, Wit JM, Burger BJ. [Measuring the length of newborn 
infants] Lengtemeting bij de pasgeborene. Ned Tijdschr Geneeskd 2005 Mar 19;149(12):632-6. 
 93. Donner A. The Relative Effectiveness of Procedures Commonly Used in Multiple Regression 
Analysis for Dealing with Missing Values. The American Statistician 1982;36(4):378-81. 
 94. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York; 1987. 
 95. Schäfer JL. Analysis of Incomplete Multivariate Data. New York; 1997. 
 96. SAS Online Doc 9.1.3. Cary, NC: SAS Institute Inc.; 2006. 
 97. Royston P. ICE: Stata module for multiple imputation of missing values. S446602 ed: Boston 
College Department of Economics; 2006. 
 98. van Buuren S, Oudshoorn CGM. Multiple imputation by chained equations: MICE V1.0 User's 
Manual Leiden: TNO Preventie en Gezondheid; 2000. 
  30
Ch
ap
te
r 
1 
- 
In
tr
od
uc
tio
n  99. van Buuren S. www.multiple-imputation.com. 2005 
 100. Verbeke G, Molenberghs G. Linear Mixed Models in Practice. New York: Springer-Verlag; 1997. 
 101. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. 
Biometrics 1997 Jun;53(2):419-34. 
 
 
 
  
 
 
 
 
 
 
 
 
2 
Validation and 
calibration of the KIGS 
prediction model for 
children with idiopathic 
growth hormone 
deficiency 
  32
Ch
ap
te
r 
2 
- 
Va
lid
at
io
n 
of
 t
he
 K
IG
S 
pr
ed
ic
tio
n 
m
od
el
 
Abstract 
In 1999 a model was published  for prediction of growth in children with idiopathic 
growth hormone deficiency (IGHD) during GH therapy, derived using data from the 
KIGS database (Pharmacia & Upjohn, Inc., International Growth Database). We 
validated and calibrated this KIGS model for growth in the first year of GH therapy 
using data of 136 Dutch children with IGHD. Observed versus predicted outcomes 
were plotted and the fitted regression line was significantly different from the line of 
identity (p = 0.03). It appeared that the predictions were too extreme: relatively low 
predictions were too low, relatively high predictions too high. This is a well-known 
phenomenon in the context of prediction models, called over-optimism. For valid 
application to other data the KIGS predictions should be calibrated. Calibrated 
predictions are obtained using Ycal = Yorig + (2.153 - 0.192 * Yorig), where Ycal is the 
calibrated prediction and Yorig the KIGS prediction. The calibrated prediction will be 
higher than the original KIGS prediction when the original prediction was below 11.2 
cm/yr and lower otherwise. The variability of the prediction errors of the calibrated 
predictions was positively related to the value of the prediction (p < 0.001), 
described by the equation SDpred err = -1.017 + 0.286 * Ycal. Our calibrated model will 
give better predictions for children with IGHD fulfilling the same criteria. 
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Introduction 
Because of the variability of response to growth hormone (GH) treatment during the 
last decade several prediction models have been developed (1-4). It is well-known 
that prediction models often perform less well than expected when applied to new 
patients, either of the same population or other populations. According to recent 
statistical insights this is in many instances due to the problem of over-optimism, 
which results in predictions that are too extreme (5, 6). This over-optimism, also 
called overfitting, is more pronounced if the prediction model is developed by 
selecting the predictor variables from a group of possible candidate predictors and 
this selection is determined by the data. If a representative data set is used, and a 
proper modelling method is applied, there is practically no doubt that in the final 
model the selected variables will be related to the outcome, also in other data sets 
fulfilling the same criteria. But the selection of exactly these predictor variables and 
exactly these values of the estimated coefficients of the predictors will partly be 
determined by the accidental characteristics of the data set. This will give a model 
that is too much data-driven and will differentiate the subjects in predicted outcome 
too extremely. Even apart from this effect of variable selection, overfitting is likely to 
occur in each prediction model with two or more prediction variables (7). For valid 
application of a prediction model to new patients the predictions should therefore be 
calibrated by shrinking them to less extreme values. 
In this study we used data of Dutch children with idiopathic growth hormone 
deficiency (IGHD) to validate the prediction model derived on the database of the 
Kabi Pharmacia International Growth Study (KIGS; Pharmacia & Upjohn, Inc., 
International Growth Database) (8) for growth velocity of children with IGHD during 
the first year of GH therapy (2). This model, further referred to as the KIGS model, 
was developed on a data set containing data of 593 children and is widely used in 
clinical practice. A validation of the model, on data of subsequent children from the 
KIGS database (temporal validation) as well as on data from other studies (external 
validation) was described in the paper (2). Our study validated the model on a large 
external data set with special attention to the problem of overfitting. 
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Subjects and methods 
Patients 
For the validation of the model we used data from the database of the Dutch Growth 
Foundation, containing data of all Dutch children who have been or are being treated 
with GH. We applied the same in- and exclusion criteria as were used for the cohort 
from which the KIGS model for children with IGHD was derived, although other 
brands of biosynthetic GH than Genotropin ® were used too. Height measurements 
for calculation of first year height velocity (HV) were allowed to have been done 
between 0.8 - 1.25 year after the start of treatment, comparable with the validation 
described in the paper in which the KIGS model was presented (2). 
Observed and predicted outcomes 
HV was computed correcting for the time-interval between start of treatment and the 
actual date of the height measurement after one year of treatment. For the 
predictors used in the model the SD scores were computed with the same reference 
data as used for the KIGS cohort (9-11). The KIGS prediction was computed using 
the regression equation based on data at start of treatment: 
predicted HV (cm/yr) = 14.55 - 1.37 * maximum GH response (ln;µg/L) 
- 0.32 * age (yr) + 0.32 * birth weight SDS + 1.62 * GH dose (ln;IU/kg·wk) 
- 0.40 * (height SDS - midparental height SDS) + 0.29 * weight SDS. 
Statistical Analysis 
For the validation we followed the method described by Van Houwelingen (12). 
Observed HV was plotted versus predicted HV in a calibration plot. A regression 
analysis was done with observed HV as outcome and predicted HV as determinant 
and it was tested whether the regression line was significantly different from the line 
of identity (where observed HV is equal to predicted HV). The estimated coefficients 
from the regression analysis were then used to determine the calibration correction. 
Using the calibrated predictions, we tested the homogeneity of variance of the 
prediction errors using the Spearman rank correlation between the absolute values of 
the prediction errors and the values of the predictions (13). In case of a significant 
correlation the relation was modelled (14). In searching for the regression model for 
absolute residuals depending on predicted values, we allowed for fractional 
polynomials (15). 
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Results 
136 cases of the Dutch database fulfilled the in- and exclusion criteria. The 
characteristics of this Dutch cohort were well within the ranges of the KIGS cohort 
(Table 1). 
Table 1. Characteristics of children with IGHD from the KIGS cohort and the Dutch cohort 
 KIGS cohort  Dutch cohort 
 Mean Min Max  Mean Min Max 
Age (yr) 7.3 2.1 11.9 6.8 2.0 11.9 
Height SDS -2.6 -5.4 -0.4 -2.1 -5.3 -0.3 
Weight SDS -2.2 -3.8 -0.7 -1.9 -4.6 0.8 
MPH SDS -0.6 -3.4 2.3 0.4 -2.1 3.4 
Height SDS - MPH SDS -1.9 -6.2 1.7 -2.5 -6.6 0.0 
BW SDS -0.5 -2.0 3.6 -0.3 -1.9 3.1 
Max GH-peak (µg/L) 5.6 0.3 10.0 5.2 0.5 10.0 
GH dose (IU/kg·wk) 0.6 0.2 1.3 0.6 0.3 1.3 
HV in first year (cm/yr) 9.2 3.5 16.8 10.2 5.4 17.4 
MPH = midparental height 
BW = birth weight  
 
The prediction errors (observed HV minus predicted HV) had a mean of 0.25 cm/yr 
and a standard deviation (SD) of 1.95 cm/yr. Observed versus predicted values were 
plotted in Figure 1, together with the line of identity (where observed HV is equal to 
predicted HV, dotted line) and the fitted regression line. The figure shows that 
relatively low predictions tended to be underestimated and relatively high predictions 
tended to be overestimated. The deviation of the regression line from the line of 
identity was statistically significant (p = 0.03) and the estimated slope was 0.808. To 
get a fitted regression line with slope 1 (line of identity), which is preferred, points at 
the left, so relatively low predictions, should be shifted a little to the right, and points 
at the right, relatively high predictions, should be shifted a little to the left. This 
calibration correction is described by the formula: 
Ycal = Yorig + (2.153 - 0.192 * Yorig) 
where Ycal is the calibrated prediction and Yorig is the original KIGS prediction. 
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Figure 1. First year HV (cm/yr): observed versus KIGS predicted values,  
together with the line of identity (dotted) and the fitted regression line (solid) 
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Figure 2. Prediction errors versus predicted value of the calibrated model 
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The correction term, (2.153 - 0.192 * Yorig), has a positive value for predictions below 
11.2 cm/yr (point of intersection of the regression line and the line of identity) and a 
negative value for predictions above 11.2 cm/yr. 
Using the calibrated model the prediction errors had a mean of zero and an SD of 
1.91 cm/yr. When prediction errors were plotted versus calibrated predictions (Figure 
2) an increase in variance of the prediction errors was seen with increasing value of 
the prediction. The absolute values of the prediction errors turned out to be 
positively related to the value of the predictions (p < 0.001). The relation between 
the calibrated predictions and the variability of their prediction errors was described 
with the model: 
SDpred error = -1.017 + 0.286 * Ycal 
The differences between the predictions of the original KIGS model and the 
calibrated model are illustrated by two examples (Table 2). Example 1 shows that for 
a child with a relatively low prediction (predicted HV using the KIGS model is 7.0 
cm/yr)  the calibrated prediction is higher (7.8 cm/yr) whereas the 95% prediction 
interval (PI) is smaller than the PI using the KIGS model. Example 2 demonstrates 
that a relatively high prediction decreases after calibration (KIGS prediction 14.0 
cm/yr, calibrated prediction 13.5 cm/yr) whereas the 95% PI becomes much wider. 
Table 2. Examples of predictions and 95% prediction intervals using the KIGS model and 
using the calibrated model 
 Original KIGS model  Calibrated model 
 Prediction 
(cm/yr) 
95% PI Width of PI  Prediction 
(cm/yr) 
95% PI Width of PI 
Example 1 7.0 4.1 - 9.9 5.7  7.8 5.4 - 10.2 4.8 
Example 2 14.0 11.1 - 16.9 5.7  13.5 7.9 - 19.0 11.1 
 
For the calculation of the SD scores of the auxological characteristics used in the 
KIGS model, UK reference data (9,10) were used. When for our validation in the 
Dutch cohort national reference data were used, namely for height and weight at 
start of treatment the reference data of 1997 of Fredriks et. al. (16) and for height of 
the parents the reference data of 1965 of Van Wieringen (17), the mean of the 
prediction errors was 0.23 cm/yr . The overfitting was again significant (p < 0.001) 
and the estimated slope in the calibration plot was 0.791. If the 1997 reference data 
was also used for height of the parents the estimated slope was simular but the 
mean prediction error increased to 0.60 cm/yr and was significantly different from 
zero (p = 0.001). 
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Discussion 
In this paper for the first time a validation according to modern statistical insights 
into the behaviour of prediction models was applied to a widely used prediction 
model for first year response to GH therapy. Special attention was given to the 
problem of overfitting. The analysis resulted in a calibrated model with a better fit 
when applied to new data. 
The method of validation we have used is based on and illustrated by a calibration 
plot where observed values are plotted versus predicted values, in our case observed 
HV in the first year of GH treatment versus the prediction given by the KIGS model. 
Four examples of calibration plots are shown in Figure 3. In all figures the line of 
identity, where the observed outcome is equal to the predicted outcome, is drawn.  
Perfect predictions will all lay on the line of identity (Fig. 3a). If the predictions are 
not perfect, but unbiased, the plot will show points scattered randomly around the 
line of identity (Fig. 3b). Any other pattern in the calibration plot indicates that the 
prediction model does not fit well to the validation data. As an example Figure 3c 
shows a scatter plot with points too much on the right side of the line of identity. 
While the vertical position of the points is fixed, determined by the observed value, 
the horizontal position should be corrected by shifting all points a little to the left. 
This indicates that the original predictions are on average too high. Another, 
frequently occurring pattern is that the scatter plot shows a relation between 
observed and predicted outcomes with a lower slope than the line of identity (Fig. 
3d). Now a correction should be done by shifting the points at the left side a little to 
the right and the points at the right side a little to the left. This indicates 
underestimation of the lowest  predictions and overestimation of the highest 
predictions. The model classifies too extremely into good and bad responses and 
therefore this phenomenon is called overfitting or over-optimism. Overfitting is 
common when the selection of predictors and the estimation of their coefficients are 
both guided by the same data set (18, 19). The occurrence of overfitting is not the 
result of differences between the modelling group and the validation group. Suppose 
we start with one data set, and split this randomly up into a modelling group and a 
validation group, so without systematic differences between the two groups. If we 
develop a prediction model on the modelling group, applying the model to the 
validation group will very likely show overfitting too. 
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Figure 3. Examples of calibration plots of prediction models for which the predictions are 
perfect (A), unbiased (B), too high (C) and overfitted (D) 
In our validation of the KIGS model the calibration plot showed a pattern like Figure 
3d, although less extreme. The slope of the regression line was 0.808 and the line 
was significantly different from the line of identity. The overfitting could be corrected 
using the formula: 
Ycal = Yorig  + (2.153 - 0.192 * Yorig) 
 This leads to a correction of the predictions from the KIGS model ranging from + 
0.92 cm/yr for a prediction of 6.4 cm/yr (the lowest KIGS prediction in our validation 
group) to - 1.2 cm/yr when 17.3 cm/yr was predicted (highest predicted value). 
Corrections for predictions of in-between values will be smaller, and for a predicted 
HV of 11.2 cm/yr the correction term is zero. 
The validation performed on the KIGS model as described in the paper of Ranke 
et. al. (2), consisting of  testing whether there was a significant difference between 
observed and predicted values, is only a check for a systematic prediction error 
(overall too low or too high predictions) and will not disclose overfitting. 
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In the Dutch cohort the SD of the prediction errors of the calibrated model was 
higher than the published SD of 1.46 cm/yr of the prediction errors found in the KIGS 
cohort (2). This was to be expected because a prediction model will be less precise 
for new data than for the data on which it was derived. Another important finding 
was the dependency of variance of the prediction error on the magnitude of the 
prediction. We found that the prediction error SD was ranging from 1.07 cm/yr for a 
prediction of 7.3 cm/yr (our lowest calibrated prediction) to 3.58 cm/yr when the 
predicted outcome was 16.1 cm/yr (highest calibrated prediction). This means that 
the accuracy of a high prediction of HV is less than the accuracy of a low prediction, 
as reflected in the 95% PI accompanying the predicted response. 
When developing the KIGS model, the analysts also checked for a relation 
between the variance of the prediction error and the prediction, by plotting 
Studentized residuals versus predicted HV (2). In contrast to our findings, they did 
not find a relation. We cannot explain the discrepancy between their and our 
findings. 
For the calculation of the SD scores for the KIGS cohort, UK reference data (9, 10) 
were used. Dutch children and adults are known to be among the tallest an earth 
(20). Moreover the secular trend in the Netherlands is relatively large (16, 10). If 
Dutch reference data were used, for parents dated back one generation, the 
predictions were not much different from the original predictions, but if we calculated 
the SD scores ignoring the secular trend, the predictions were signifantly too low. In 
both situations the overfitting remained. Thus, to apply the KIGS model correctly, 
one should use the UK reference data. 
The KIGS model is a well-defined and easily applicable model, developed on a 
population of sufficient size. The percentage explained variability (R2 = 0.61) might 
improve if more flexibility of the relations was allowed, or other patient 
characteristics could be used, but the aim might have been to restrict to simple 
modelling with widely available characteristics. However, the problem of overfitting, 
very likely to be present if model selection and estimation are done using the same 
data set, was not taken into account. 
As a consequence of our calibration and of modelling the dependency of the 
prediction error SD, we propose that a KIGS prediction for the first year growth 
response in children with IGHD should be modified using the formula: 
Ycal = Yorig + 2.153 - 0.192 * Yorig 
where Ycal is the calibrated prediction and Yorig is the original KIGS prediction. 
The 95% PI is given by: 
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Ylow = Ycal - 1.96 * (-1.017 + 0.286*Ycal) 
 Yhigh = Ycal + 1.96 * (-1.017 + 0.286*Ycal) 
where again Ycal is the calibrated prediction, Ylow is the lower limit of the PI and Yhigh 
is the upper limit of the PI. Figure 4 presents the calibrated predictions versus the 
original KIGS predictions, with 95% PI. It shows that for instance an original 
prediction of 14 cm/yr should be modified to 13.5 cm/yr, with 95% PI 8 - 19 cm/yr. 
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Figure 4. Relation between the calibrated prediction and the value of the KIGS prediction, 
with 95% prediction interval 
Our validation and calibration of the KIGS model is quite different from developing a 
new model. In our calibrated model we maintained the relative contribution of the 
predictor variables as determined for the original model, but the outcomes were 
adjusted using a correction term which depends on the value of the original 
prediction. Clearly these calibrated predictions fitted better to the data of the Dutch 
cohort. Whether both the data from the KIGS cohort, used for modelling, as well as 
the data from the Dutch cohort, used for calibration, are representative for other 
cohorts of children with IGHD fulfilling the same in- and exclusion criteria is not yet 
known. We, however, postulate that our modification of the KIGS prediction rule will 
give better predictions for these children as well. 
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When new prediction models are developed in the future, they should be 
evaluated as to whether a calibration is required. The best way to examine this is by 
validation of the model on external data. This will improve the accuracy and benefit 
of prediction models for clinical practice.  
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Abstract 
Background 
Prediction models, e.g. for prediction of response to growth hormone treatment, 
need validation in appropriate independent cohorts, comparing predicted and 
observed outcomes. In a previous validation of a model for predicting the first-year 
response to growth hormone treatment in children with idiopathic growth hormone 
deficiency, overfitting was observed. We modified the prediction formula and now 
report validation of this modified model. 
Patients and Methods 
The modified and original prediction models were applied to a group of patients 
selected from Lilly’s GeNeSIS database using the same inclusion and exclusion 
criteria as for the original model. For both prediction methods, observed first-year 
height velocity was plotted vs. predicted height velocity in a calibration plot. For a 
valid prediction, the regression line should correspond to the line of identity 
(observed outcome is equal to predicted outcome); the regression lines for each 
prediction model were tested for significant differences from this line of identity. 
Results 
The number of patients fulfilling the criteria was 226. The regression line in the 
calibration plot of the modified model was not significantly different from the line of 
identity (p = 0.43), in contrast to the original model (p < 0.001). For the modified 
model the mean (SD) prediction error was -0.11 (2.05) cm/yr and for the original 
model 0.28 (2.11) cm/yr. 
Conclusion 
The modified prediction method, obtained after calibration of the original model, 
performs well in an independent patient sample and gives more accurate predictions 
than the original model. 
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Introduction 
It is widely recognized that the validity of a clinical prediction model should be 
evaluated by applying the model to an independent group of patients. This group 
should be selected using the same inclusion criteria as used for the development of 
the model. Observed and predicted outcomes of this validation group should be 
compared. Often, the main item of the validation is to test whether the mean of the 
prediction errors (differences between observed and predicted outcomes) is not 
significantly different from zero (1–3). However, this procedure only tests whether 
there is a systematic error in the predictions but does not evaluate the individual 
prediction errors, which are very relevant in clinical practice. To examine whether the 
observed outcomes are consistent with the predicted outcomes, a simple and clear 
approach is to produce a scatter plot of observed vs. predicted outcomes (4). If the 
data are close to the line of identity, the prediction model is considered valid, 
whereas if the regression line is significantly different from the line of identity, the 
model needs further calibration. 
In 2003, we used this procedure to validate the model developed by Ranke et al. 
(1) to predict height velocity (HV) of prepubertal children with idiopathic growth 
hormone (GH) deficiency in the first year of GH treatment, based on data of the Kabi 
International Growth Study database. We observed overfitting in this validation, 
which resulted in modification of the model that should lead to less prediction errors 
(5). The aim of this study was to validate this modified prediction formula using a 
new group of patients and compare results using both the original and modified 
models.  
Patients and Methods  
Patients were selected from the Genetics and Neuroendocrinology of Short Stature 
International Study (GeNeSIS) database of Eli Lilly and Company, which contains 
data of children treated with Humatrope. The same inclusion and exclusion criteria 
were applied as used for development of the original model (1), namely: idiopathic 
GH deficiency, GH treatment throughout at least 1 year, 6 or 7 GH injections per 
week, age at start between 2 and 10 years for girls and between 2 and 12 years for 
boys, prepubertal during the first year of treatment, no use of other medication that 
may influence growth and normal size at birth. 
The prediction model is based on data known at start of the GH treatment. The 
predictions using the original model were calculated with the formula:  
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predicted HV (cm/yr) = 14.55 - 1.37 * maximum GH response (ln; µg/L) 
- 0.32 * age (yr) + 0.32 * birth weight SDS + 1.62 * GH dose (ln; IU/kg·week) 
- 0.40 * (height SDS - midparental height SDS) + 0.29 * weight SDS. 
The predicted values using the modified prediction formula are calculated as: 
modified prediction = 2.153 + 0.808 * original prediction 
resulting in: 
predicted HV (cm/yr) = 13.91 - 1.12 * maximum GH response (ln; µg/L) 
- 0.26 * age (yr) + 0.26 * birth weight SDS + 1.31 * GH dose (ln; IU/kg·week) 
- 0.32 * (height SDS – midparental height SDS) + 0.23 * weight SDS. 
Prediction errors with each method were calculated as observed HV - predicted HV. 
For both prediction methods, observed first-year HV was plotted vs. predicted HV in 
calibration plots. The resulting regression lines were tested for significant differences 
from the line of identity using an F-test. 
Results 
There were 226 patients fulfilling the criteria for inclusion in the study. 
Characteristics of this group are given in table 1. For the modified prediction method 
the mean (SD) of the prediction errors was –0.11 (2.05) cm/yr while for the original 
prediction formula it was 0.28 (2.11) cm/yr. 
Figure 1 shows the calibration plots for the modified and the original models. In 
each plot, the dotted line is the line of identity and the solid line is the regression 
line. For the modified prediction method the regression line was not significantly 
different from the line of identity (p = 0.43). The equation of the regression line was 
HVobs = 0.693 + 0.916 * HVmod pred 
where HVmod pred represents the predictions using the modified model. For the original 
model, the equation was 
HVobs = 2.665 + 0.740 * HVorig pred 
where HVorig pred represents the predictions using the original model. This regression 
line was significantly different from the line of identity (p < 0.001).  
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Table 1. Characteristics of the validation group (n = 226) and of the original cohort, from 
which the model was derived (n = 593) 
 Validation cohort Modelling cohort 
 Mean SD Mean SD 
Age at start (yr) 7.6 2.6 7.3 2.4 
Height SD score -2.5 0.9 -2.6 0.8 
Weight SD score -2.3 1.3 -2.2 1.3 
Mid-parental height (MPH) SD score -0.6 1.3 -0.6 1.0 
Height SD score - MPH SD score -1.9 1.4 -1.9 1.4 
Birth weight SD score -0.5 1.0 -0.5 0.9 
Maximum GH peak (µg/L) in 
stimulation tests 
5.9 2.7 5.6 2.8 
GH dose (IU/kg·week) 0.6 0.2 0.6 0.2 
Height velocity in first year (cm/yr)  9.5 2.6 9.2 2.3 
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Figure 1. Calibration plot of observed and predicted height velocities using the modified 
model (A) and the original model (B). Solid lines represent the regression lines, dotted lines 
the line of identity. 
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Discussion 
The study presented in this paper is a continuation to our earlier work of validation 
and calibration of a prediction model (5), modified from a previously published model 
(1), namely checking the validity of our modified model. The results showed that the 
predictions of this modified model are more accurate than the predictions of the 
original model. 
Although a substantial number of prediction models have been developed (1, 3, 
6–10), the procedure of validation of these models needs to be improved. If a 
sufficiently large number of patients is obtained that fulfil the inclusion criteria, and 
for whom all determinants used in the model are known and the outcome is 
observed, the best information can be obtained by producing a calibration plot. This 
plot shows the relation between observed and predicted values and, for a valid 
model, the points should be close to the line of identity. 
Predictions often tend to be too extreme near the boundaries of the range of 
predicted values. Patients with low observed outcomes generally have predictions 
that are too low, whereas the opposite is found for patients with high observed 
outcomes; we observed this effect when validating the prediction model developed 
by Ranke et al. (1). This phenomenon was not due to an error in the selection of 
predictors or in the estimation of the coefficients, but is a common finding (11). 
Using the results from a validation of the model with new data, one can adjust for 
this overfitting (4). Our present study showed that this approach is practical, simple 
and reliable, and leads to a model with high value for clinical practice. 
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Abstract 
Context 
Several studies have searched for factors that significantly influence adult height 
(AH) of children with GH deficiency (GHD) who have been treated with biosynthetic 
GH, but a prediction model for AH has not yet been presented. 
Objective 
Our objective was to develop models for prediction of AH SDS, using information 
available at the start of GH treatment or after 1 year of treatment. 
Design and Setting 
For this retrospective study, data were collected from the National Registry of 
Growth Hormone Treatment in Children, which contained data of Dutch children 
treated with GH. 
Patients/Intervention 
Patients included males born before 1985 and females born before 1987 with either 
diagnosis of GHD (syndromes, tumors, and other diseases were excluded) or a 
maximal GH response during provocation tests of less than 11 ng/ml, treated with 
biosynthetic GH for at least 1 year. To be able to use the complete group of 342 
children for the development of the models, multiple imputation was used for missing 
values. 
Results 
Each prediction model contained both target height SDS and current height SDS. The 
change in height SDS during the first year proved an important predictor for AH. In 
all models, addition of GH dose was not significant. The percent explained variance, 
after correction for overfitting, ranged from 37% (prepubertal children, prediction at 
start) to 60% (pubertal children, prediction after 1 year). 
Conclusion 
The presented prediction models give accurate predictions of AH for children with 
GHD at start and after 1 year of GH treatment. They are useful tools in the treatment 
of these children. 
 55 
Ch
ap
te
r 
4 
- 
AH
 a
ft
er
 G
H
 t
he
ra
py
 in
 c
hi
ld
re
n 
w
ith
 G
H
D
 
Introduction 
Treatment with biosynthetic growth hormone (GH) is successful in improving adult 
height (AH) in children with GH deficiency (GHD). The reported mean AH SD scores 
range from -1.6 to -0.7, and the mean changes in height SDS during GH treatment 
from 1.1 to 2.0 (1-6). 
Several prediction models have been developed for short-term growth response to 
GH treatment in children with GHD (7-9). For example Ranke et al. (8) developed 
models for prepubertal children predicting height velocity (HV) (in cm/yr) during the 
first, second, third and fourth years of treatment. In the models predicting HV during 
the second year or later, the HV in the previous year was the most prominent 
predictor (7, 8). Cole et al. (10) analysed first- and second-year growth response to 
GH treatment. They found that the maximum GH response during provocation tests 
was the most predictive factor for the first-year response, whereas the first-year 
response was much more important for the second-year response. 
The following predictive factors for AH SDS were described: sex, birth weight SDS, 
age at start of GH treatment, height SDS at start for chronological age, height SDS at 
start for bone age (BA), weight SDS at start, target height (TH) SDS or mid-parental 
height SDS, maximum GH response during provocation tests, presence of multiple 
pituitary hormone deficiencies (MPHD), BA delay at start, pubertal stage at start, age 
at onset of puberty, height SDS at onset of puberty, HV in the first year of treatment, 
total GH dose, number of GH injections per week, duration of treatment and 
completion of treatment until AH (1-4, 6, 11-14). 
In three studies, a regression model was developed for AH SDS or change in 
height SDS during GH treatment in a group of children with GHD treated with 
biosynthetic GH (1, 2, 6). These studies, however, also included patient 
characteristics during long-term follow-up, for example height SDS at onset of 
puberty, duration of treatment, and mean GH dose during treatment. 
Therefore, until now, an accurate model for the prediction of AH SDS at start or 
after 1 year of GH treatment has not been developed. 
In this study, we developed models for the prediction of AH SDS. We will first 
present a model using only information available at start of the GH treatment and 
then second a model using information available after 1 year of treatment, for 
prepubertal as well as pubertal children. 
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Patients and methods 
Patients 
We used data from the National Registry of Growth Hormone Treatment in Children 
by the Dutch Growth Foundation, which contains data of more than 2200 Dutch 
children treated with GH. Registration started in 1992 and has been obligatory since 
1997. We selected males born before 1985 and females before 1987, to ensure a 
representative group with AH. Other selection criteria used were diagnosis of GHD or 
a maximum GH response during provocation tests of less than 11 ng/ml and 
treatment with biosynthetic GH for at least 1 year. Children with syndromes, tumors 
or other diseases were excluded (Figure 1). 
Children in database DGF (dd. 01-01-05)
n = 2210
Boys born before 1985
Girls born before 1987
n = 932
Children with more recent 
date of  birth
n = 1278
Treated initially with human 
GH
n = 96
Treated only with 
biosynthetic GH
n = 836
Diagnosis of
Turner syndrome n = 92
Syndrom, skeletal dysplasia n = 50
Tumour, ALL, AML n = 169
Other diseases n = 73
Maximum GH peak > 11 n = 80
GHD, IGHD or maximum 
GH peak < 11
n = 372
GH treatment > 1 year
n = 342
GH treatment <= 1 year
n = 30
Eligible for analysis
n = 342
Prepubertal
during 1st 
treatment year
n = 208
Puberty onset 
during first year 
of treatment
n = 45
Puberty onset 
before start n = 89
 
 
Figure 1. Description of cohort 
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For the development of the prediction models for application at start of GH 
treatment, the group was divided into two subgroups, one including prepubertal 
children and one including pubertal children. For the models to be applied after 1 
year of GH treatment, the pubertal stage at that moment determined the prepubertal 
and pubertal subgroups. 
Outcome and potential determinants 
AH was defined as the height reached when growth velocity was less than 2 cm/yr 
and age above 14 years. AH SDS was calculated using references for Dutch adults, 
i.e. a mean (SD) of 184.0 (7.1) cm for males and 170.6 (6.5) cm for females (15). 
The potential determinants were as follows 1. initial characteristics included sex, 
TH SDS and birth weight SDS (16), 2. characteristics at start of GH treatment 
included age, height SDS, weight SDS (15), body mass index (BMI) SDS (17), BA and 
BA delay, maximum GH response during provocation tests, diagnosis (idiopathic GHD 
or GHD with abnormalities on pituitary magnetic resonance imaging), presence of 
MPHD, IGF-I SDS and starting dose of GH; and 3. additional characteristics after 1 
year of treatment included height SDS and change in height SDS during the first 
year, weight SDS and change, BMI SDS and change, change in BA during the first 
year and mean GH dose during the first year. 
First-year changes in height and weight SDS were corrected for the actual time 
between the two measurements (range 0.7 - 1.3 year). 
Eighty-seven percent of the BA were determined according to Greulich and Pyle. 
When the BA was determined according to the TW2 or RUS method, it was 
converted to Greulich and Pyle estimations (18). BA delay was computed as 
chronological age minus BA. Bone maturation during the first year was computed as 
the ratio of the change in BA and the exact difference between the chronological 
ages at time of the BA measurements. 
In 80% of patients an arginine test was used to determine the maximum GH 
response, in 40% L-dopa and in 24% clonidine. Eighty-two percent of children had 
GHD defined as a failure to increase serum GH levels above 11 ng/ml in two or more 
tests, whereas 18% had only one test. 
Eighty percent of the IGF-I measurements were centrally performed in a 
laboratory with published reference values (19). For the remaining 20% the 
laboratory-specific reference values for IGF-I were used to calculate the SDS. IGF-I 
measurements after 1 year of treatment were not used, because these were very 
scarce (11%). 
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Multiple imputation 
It is unavoidable that in a registry database some data are missing for some 
patients. For example birth data and the height of parents can be missing for 
adopted children and BA data are not complete because these measurements were 
not always performed in former years. Using only cases with complete data for all 
the potential determinants would result in a sample much smaller and likely not a 
representative group of the population. 
To develop the prediction models on the complete group, we used multiple 
imputation for missing values in the outcome or in the potential determinants (20, 
21). For each missing variable, a value was imputed, using the relations between the 
variables in the data set. Because an imputed value does not have the same 
accuracy as an observed value, the imputation procedure was executed five times to 
generate five completed data sets. In each data set, a different value was imputed, 
thus reflecting the uncertainty of the imputed value. For the multiple imputation we 
used the procedure SAS Proc MI (22), which assumes that the variables have a 
multivariate normal distribution. Variables with a non-normal distribution were 
transformed to normality during the imputation procedure. 
Each step in the data analyses was performed on each imputed data set 
separately, and the results were combined (20, 21). 
Truncation of extreme values of potential determinants and outcome 
Extreme values of the outcome or determinants can highly influence the estimation 
of regression coefficients in a model. To avoid this, the 1% lowest values of all 
continuous determinants were truncated to the first percentile and the 1% highest 
values to the 99th percentile. 
Development of prediction model  
For the development of the prediction model, we used forward selection with an 
inclusion criterion of p = 0.05. After the selection of the predictor variables, for each 
continuous predictor, it was tested whether adding the quadratic term or another 
transformation of the variable improved the model significantly (23). 
We tested possible interactions of age or BA at start with TH SDS and with change 
in height SDS during first year, if both main terms were selected in the model. 
A possible relation between the predicted outcomes and the residuals was 
examined by evaluation of the scatter plots and by fitting the linear regression with 
the absolute value of the residuals as determinant and the predictions as outcome. 
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Internal validation 
It is well-known that a prediction model suffers from over-optimism (24, 25). The 
predictive performance of a prediction model in other data sets than the set on which 
it is developed will be lower. The predicted values generated by the model will tend 
to be too extreme. 
To remove the over-optimism of the derived model, we used bootstrap techniques 
(24, 26), shortly explained as follows. From the data set used for the development of 
a prediction model, a random sample was drawn, representing another but 
comparable data set. This sampling was done with replacement, so each subject 
could be selected several times, and consisted of the same number of subjects as the 
original data set. On this data set, called a bootstrap sample, a prediction model was 
developed, using the same procedure as for the development of the model in the 
original data set. The predictive performance of this model developed in the 
bootstrap sample was evaluated by calculating R2, which gives the percentage of 
variance explained by the model, and by calculating the mean of the squared 
residuals. This evaluation was done in both the bootstrap sample and the original 
data set. The predictive performance is always better in the bootstrap sample, on 
which this model is developed, than in the original data set (higher R2 and smaller 
residuals). The difference between these predictive performances is called the 
optimism. We generated 200 bootstrap samples and used the average optimism to 
correct the predictive performance of the original model (26). Furthermore, a linear 
regression was performed in each bootstrap sample with the observed values as 
outcome and the predicted values as determinant. The coefficient for the slope will 
usually be below one. This procedure is the same as for the validation of a model on 
external data (25). The mean of the 200 slopes was used as shrinkage factor for the 
estimated regression coefficients in the original derived prediction model. The 
intercept was adjusted to get the same mean predicted value (27). This resulted in a 
calibrated model that provides predictions less extreme than the predictions from the 
original model. The predictions calculated with the calibrated model will be accurate 
in new patients with GHD. 
Results 
The study group consisted of 342 children, of whom 208 were prepubertal for at 
least 1 year after the start of GH treatment, and 89 were pubertal at start of 
treatment. In 45 children puberty started during the first year of treatment. Table 1 
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shows the characteristics of the study group and for each variable the percentage of 
patients with a missing value. 
Table 1. Characteristics of the study group 
 Prepubertal at start Start of puberty  
 and during first 
year of treatment 
(n = 208) 
During first year 
of treatment 
(n = 45) 
Before start 
of treatment 
(n = 89) 
Percentage 
with missing 
value 
Male (%) 60 44 45 0 
Birth weight SDS -0.73 ± 1.31 -0.80 ± 1.13 -0.54 ± 1.37 14 
TH SDS -0.97 ± 0.96 -1.22 ± 0.91 -0.90 ± 0.87 5 
At start     
Age (yr) 9.0 ± 3.3 12.8 ± 1.9 14.0 ± 2.0 0 
Maximum GH peak (ng/ml) 4.5 ± 2.9 5.7 ± 3.0 5.2 ± 2.8 6 
IGF-I SDS -3.67 ± 2.76 -3.54 ± 3.44 -2.93 ± 3.18 37 
Idiopathic GHD (%) 83 99 88 0 
Presence of MPHD (%) 41 24 30 0 
Height SDS -3.40 ± 1.01 -3.32 ± 0.97 -2.92 ± 1.14 0 
Weight SDS -2.54 ± 1.48 -2.01 ± 1.44 -1.79 ± 1.68 0.3 
BMI SDS -0.35 ± 1.21 -0.06 ± 1.20 -0.10 ± 1.36 0.3 
BA (yr) 6.5 ± 3.0 10.4 ± 2.0 12.0 ± 1.6 11 
BA delay (yr) 2.6 ± 1.5 2.4 ± 1.3 2.0 ± 1.5 11 
GH dose (mg/m2⋅day) 0.71 ± 0.24 0.72 ± 0.26 0.73 ± 0.26 1 
After first year     
Height SDS -2.69 ± 0.95 -2.88 ± 1.05 -2.34 ± 1.13 0 
Weight SDS -2.08 ± 1.39 -1.74 ± 1.51 -1.44 ± 1.59 0.3 
BMI SDS -0.51 ± 1.24 -0.12 ± 1.28 -0.08 ± 1.34 0.3 
Change in height SDS 0.71 ± 0.51 0.44 ± 0.36 0.58 ± 0.38 0 
Change in weight SDS 0.45 ± 0.51 0.27 ± 0.49 0.35 ± 0.47 0.3 
Change in BMI SDS -0.17 ± 0.57 -0.06 ± 0.49 0.01 ± 0.46 0.3 
Mean GH dose (mg/m2⋅day) 0.71 ± 0.23 0.75 ± 0.27 0.75 ± 0.27 0.6 
Adult height     
Duration GH treatment (yr) 7.9 ± 3.3 3.9 ± 1.3 3.3 ± 1.2 4 
Mean GH dose 
(mg/m2⋅day) 
0.77 ± 0.21 0.80 ± 0.27 0.80 ± 0.24 8 
AH SDS -1.71 ± 0.91 -2.02 ± 1.08 -1.68 ± 0.94 20 
Change in height SDS 1.72 ± 1.10 1.36 ± 0.81 1.18 ± 1.16 20 
AH SDS – TH SDS -0.74 ± 1.04 -0.68 ± 0.75 -0.85 ± 0.88 22 
Results expressed as mean ± SD or percentage 
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Prediction models at start of GH treatment 
For the prediction of AH SDS using the characteristics available at the start of 
treatment (Start model) the final model for prepubertal patients included six 
variables. Predictors with a positive effect were height SDS at start, TH SDS, female 
gender and presence of MPHD, whereas maximum GH response during provocation 
tests and BA at start had a negative effect. The relation between height SDS at start 
and AH SDS (corrected for the other predictors) was quadratic. Starting dose of GH 
was not a significant predictor. In Table 2, the estimated coefficients of the model 
are given. The percentage explained variance (R2*100%) of the derived model was 
43%. The optimism estimated by bootstrapping was 6%, so the corrected 
percentage is 37%. Corrected for optimism, the residual SD was 0.84. The estimated 
shrinkage factor for the correction of the regression coefficients was 0.94. The final 
prediction formula is given in Table 2. 
Table 2. Results of the final models for prediction of AH at start of treatment (Start model) 
 Prepubertal (n = 253) Pubertal (n = 89) 
Predictor variable Est. 
coef. 
SE P Partial 
r2 
Est. 
coef. 
SE P Partial 
r2 
Intercept 1.399 0.502 0.006  -0.645 0.226 0.006  
Height SDS at start 1.092 0.260 <0.0001 0.239 0.456 0.080 <0.0001 0.281 
(Height SDS at start)2 0.082 0.035 0.02      
TH SDS 0.282 0.060 <0.0001 0.086 0.428 0.100 <0.0001 0.188 
Max GH peak (ng/ml; ln) -0.158 0.064 0.02 0.022     
Gendera 0.278 0.108 0.01 0.022     
MPHDb 0.323 0.124 0.01 0.023     
BA at start (yr) -0.051 0.017 0.003 0.031     
BA delay at start (yr)    0.265 0.058 <0.0001 0.213 
R2 corrected for 
optimism (original) 
0.37 (0.43) 0.41 (0.53) 
Residual SD corrected 
(original) 
0.84 (0.79) 0.83c (0.72d) 
Shrinkage factor 0.94 0.91 
Prediction formulas after bootstrap-correction are as follows: 
for the prepubertal group, AH SDS = 1.186 + 1.021*H SDSstart + 0.077*H SDSstart
2 + 0.264*TH SDS 
- 0.148*ln(max GH) + 0.260*gender + 0.302*MPHD - 0.047*BA; 
for the pubertal group, AH SDS = -0.746 + 0.416*H SDSstart + 0.391*TH SDS + 0.242*BA delay 
aMale = 0, Female = 1 
bNo = 0, Yes = 1 
cAccounting for relation with predicted value: corrected residual SD = √((0.38 -0.19*predicted value)2+0.17) 
dIdem: original residual SD = 0.38 -0.19*predicted value 
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For patients already pubertal at start, age at onset of puberty is also a potential 
determinant. For boys, we reduced the age at onset by 0.8 year, according to the 
difference in mean age at onset of puberty between boys and girls in the Dutch 
population, as found by Fredriks et al. (15). For this group the Start model included 
three variables; height SDS at start, TH SDS and BA delay at start, all with positive 
effect (Table 2). Again, starting dose of GH was not in the final model. The 
percentage explained variance was 53% and after correction for optimism, 41%. For 
this prediction model, there was a significant relation between the predicted values 
and the residual SD. The residual SD was decreasing with increasing predicted value, 
according to the equation 
residual SD = 0.38 - 0.19 *predicted value. 
This residual SD has to be adjusted using the optimism estimated by bootstrapping 
(see note at Table 2). The estimated shrinkage factor for the correction of the 
regression coefficients was 0.91. 
Prediction models after 1 year of treatment 
Using the characteristics available after 1 year of treatment (First-year model), the 
prediction model for prepubertal patients included height SDS after the first year 
(quadratic relation), TH SDS, female gender, presence of MPHD, BA delay at start 
and change in height SDS during the first year, all with a positive effect. The 
estimated coefficients are given in Table 3. As in the Start model, addition of starting 
dose of GH was not significant, nor was mean GH dose during the first year. If the 
latter was added to the final model, its influence on AH SDS was negative, the 
estimated coefficient being -0.35 (p = 0.11), whereas the coefficients of the other 
predictors did not change substantially (all changes < 10%). The percentage 
explained variance of the final model was 51% and after correction for optimism, 
43%. The residual SD after correction for optimism was 0.76. The estimated 
shrinkage factor for the correction of the regression coefficients was 0.94. 
The predictors in the First-year model for children who are pubertal after 1 year of 
GH treatment were height SDS after the first year, TH SDS, BA delay at start, and 
change in height SDS during the first year. The mean GH dose during the first year 
was not a significant predictor. The explained variance was 66% and after 
bootstrapping was reduced to 60%. Corrected for optimism, the residual SD was 
0.69. The estimated shrinkage factor for the correction of the regression coefficients 
was 0.95. 
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Table 3. Results of the final models for prediction of AH after one 1 of GH treatment (First-
year model) 
 Prepubertal (n = 208) Pubertal (n = 134) 
Predictor variable Est. 
Coeff. 
SE P Partial 
r2 
Est. 
Coeff. 
SE P Partial 
r2 
Intercept 0.075 0.330 0.82  -0.866 0.189 <0.0001  
Height SDS after first year 1.250 0.213 <0.0001 0.336 0.527 0.064 <0.0001 0.385 
(Height SDS after first year)2 0.114 0.035 0.001      
TH SDS 0.200 0.057 0.0006 0.065 0.347 0.074 <0.0001 0.162 
Gendera 0.348 0.106 0.001 0.054     
MPHDb 0.309 0.107 0.004 0.043     
BA delay at start (yr) 0.100 0.038 0.008 0.039 0.164 0.044 0.0003 0.103 
∆ height SDS in first year 0.308 0.105 0.004 0.044 0.500 0.163 0.003 0.070 
R2 corrected for optimism 
(original) 
0.43 (0.51) 0.60 (0.66) 
Residual SD corrected 
(original) 
0.76 (0.69) 0.69 (0.62) 
Shrinkage factor 0.94 0.95 
Prediction formulas after bootstrap-correction are as follows: 
for the prepubertal group, AH SDS = -0.049 + 1.169*H SDS1yr + 0.107*H SDS1yr
2 + 0.187*TH SDS + 
0.325*gender + 0.289*MPHD + 0.094*BA delaystart + 0.288* ∆ H SDS1yr; 
for the pubertal group, AH SDS = -0.915 + 0.502*H SDS1yr + 0.331*TH SDS + 0.156*BA delay + 
0.477*∆ H SDS1yr 
aMale = 0, Female = 1 
bNo = 0, Yes = 1 
 
 
In Table 4 and Figure 2, examples are given of the use of the prediction models for 
prepubertal children. Without any model, we would predict the AH SDS of each 
individual prepubertal child with GHD and GH treatment as -1.77 (being the mean AH 
SDS of the children prepubertal at start) with a 95% prediction interval of -3.61 to 
0.07. Table 4 gives the characteristics and the predictions of a (hypothetical) child 
with relatively positive prospects (child 1) and a child with less favourable 
characteristics (child 2). In Figure 2, the distributions of the predictions with the 
First-year model are plotted for the children in this example. For child 1, the 
predicted probability of reaching an AH SDS above -2 is 85%, and for child 2, this is 
only 11%. 
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Table 4. Examples of predictions for prepubertal children 
 Child 1 Child 2 
Characteristics   
Height SDS at start -3.0 -4.0 
TH SDS -1.0 -2.0 
Maximum GH peak (ng/ml) 2.0 7.0 
Gender Girl Boy 
MPHD Yes No 
BA at start (yr) 6.0 8.0 
BA delay at start (yr) 2.6 0.0 
Height SDS after first year -2.2 -3.3 
Change in height SDS in first year 0.8 0.7 
Predictions (95% prediction interval)*   
Without any model -1.77 (-3.61 to 0.07) -1.77 (-3.61 to 0.07) 
Start model -1.27 (-2.92 to 0.38) -2.86 (-4.50 to -1.21) 
First-year model -1.20 (-2.69 to 0.28) -2.92 (-4.41 to -1.43) 
*The prediction intervals are calculated using the relevant SD, i.e. 0.94 without model, 0.84 for the Start 
model and 0.76 for the First-year model. 
Example of calculation, child 1, start model: predicted AHSDS = 1.186 + 1.021*(-3) + 0.077*(-3)2 
+ .264*(-1) - 0.148*ln(2) + 0.260*1 + 0.302*1 - 0.047*6 = -1.27 
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Child 1
Child 2
probability AH SDS > -2 = 0.85
probability AH SDS > -2 = 0.11
predicted value
predicted value
95% prediction interval
95% prediction interval
 
 
Figure 2. Examples of the distribution of the predicted value for AH SDS after 1 year of 
treatment. For the characteristics of the children used in these examples, see text. 
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Discussion 
In the present study, we have developed prediction models for AH SDS for 
prepubertal and pubertal children with GHD treated with GH, according to state-of-
the-art statistical methods. This includes dealing with missing data, investigation of 
more flexible relations between continuous determinants and the outcome and 
correction for over-optimism (24). 
A prediction model for AH SDS is a useful tool for the clinician to become informed 
about the prospective long-term results of GH treatment. A prediction is desired 
before start of treatment. Application of the prediction model gives a patient his or 
her individual predicted value with prediction interval. It can identify patients with 
high or low chance of benefit from GH treatment. After 1 year of treatment, the 
expectations can be refined, which is useful for decisions about the continuation of 
GH treatment. 
The prediction models presented in this paper explain percentages of variance in 
AH SDS from 37% (prepubertal group, Start model) to 60% (pubertal group, First-
year model). The outcome is usually several years ahead from the moment of 
prediction. During childhood, many factors may influence the growth of a child, so 
we could expect that a substantial part of the variance remains unexplained. 
As expected, all models show height SDS (at start or after 1 year of GH treatment) 
and TH SDS as most important predictive factors. A positive effect of female gender 
was found, in line with Carel et al. (1). They attributed this to sex-dependent 
differences in pubertal age. It is also possible that girls have a better compliance 
than boys. Children with MPHD had a more favourable outcome compared to 
children with isolated GHD, as previously reported by Reiter et al. (6). The negative 
coefficient for BA in the model for prepubertal children reflects  that start of GH 
treatment at a younger age gives a higher growth response. It appeared that BA is a 
more informative predictor than chronological age. The positive coefficients for BA 
delay in the other models reflect that children with delayed BA have more growth 
potential.  
Maximum response to GH provocation tests is included in the Start model for 
prepubertal children (negative effect) but is not significant anymore in the First-year 
model. A similar finding was reported by Cole et al.(10). The First-year models 
include change in height SDS during the first year, which is in line with several other 
studies (2, 3, 6, 11). 
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In none of the models GH dose was selected as significant predictor variable. 
Notably, this has also been reported by others (1, 6). For clinical practice, it might 
have been desirable if the prediction models could lend support in finding the optimal 
GH dose. A practical and logical question is what would be the predicted AH SDS if a 
higher or lower dose than the standard dose is prescribed? A significant positive 
effect of GH dose on short-term growth response is often found (8, 28, 29), but the 
dose-effect on long-term response is less established (3, 6, 30). For the patients in 
our data set, the GH dose at start and during treatment was assessed by the clinician 
based on unknown criteria. In 80% of the patients, the mean GH dose during 
treatment was in the range 0.5 - 1.0 mg/m2⋅day (median 0.72 mg/m2⋅day). It is 
possible that higher initial doses were prescribed to patients with supposed worse 
prospects, like children close to or entering puberty, children with only mild GHD or 
children with very small parents. During treatment, a change of GH dose might have 
been guided by the obtained growth response. Our data are therefore not suitable to 
estimate the effect of GH dose on AH SDS. This would only be possible if the 
dosages given were randomly assigned and had remained unchanged during 
treatment, as in randomised controlled trials. 
One of the arguments for developing the First-year models was to investigate if 
such a model could provide a criterion for the first-year growth response needed for 
an AH in the desired (normal) range. Indeed, our study shows that change in height 
SDS during the first year of treatment is highly related to the AH attainment. 
Because a positive correlation between GH dose and first-year response is well 
established, one might tend to give a high GH dose in order to increase the first-year 
response, with the idea that this will subsequently increase AH. However, we found 
an inverse relation between first-year GH dose and AH, although this did not reach 
significance. This means that a first-year growth response obtained by a high GH 
dose gives a lower predicted AH than the same response obtained by a low GH dose. 
We performed internal validation of the prediction models by bootstrapping. This 
results in models corrected for overfitting. It is not necessary to validate or calibrate 
the models with an external validation. Applying the models to data of an 
independent cohort is still interesting. In conclusion, the prediction models presented 
in this study can be a useful tool for decisions about GH treatment of children with 
GHD. 
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Abstract 
Context 
GH treatment is approved for short children born SGA. The optimal dose is not yet 
established. 
Objective 
To develop a model for prediction of height at onset of puberty and of adult height 
(AH). 
Design and Setting 
Two GH studies in short SGA children. 
Patients/Intervention 
150 SGA children with height SDS < -2, age ≥ 3, no signs of catch-up growth, 
available height at onset of puberty and at least one year of GH treatment prior to 
onset of puberty. In one study, patients were randomly assigned to either 0.033 or 
0.067 mg/kg·day, in the other study all received 0.033 mg/kg·day. In 71 children, 
AH was reached. 
Results 
Determinants positively related to height SDS at onset of puberty were: height SDS 
at start, target height (TH) SDS and GH dose, whereas age at start and female 
gender were negatively related. Positively related to AH SDS were: height SDS and 
chronological age minus bone age (CA-BA) at start, TH SDS and GH dose, whereas 
serum IGFBP-3 SDS at start was negatively related. There was a significant 
interaction between GH dose and IGFBP-3 SDS, indicating a smaller GH dose effect 
for higher levels of IGFBP-3. The final model explained 57% of the variance in height 
SDS at onset of puberty and 41% of AH SDS. 
Conclusion 
The prediction model for height SDS at onset of puberty and AH SDS of short SGA 
children treated with GH provides useful information about the expected long-term 
growth. Because GH dosage is one of the determinants, the model aids in 
determining the optimal GH dose for each child. 
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Introduction 
Children born small for gestational age (SGA) with persistent short stature can be 
effectively and safely treated with growth hormone (GH) (1-6). Patient characteristics 
found to be related to short-term response were: chronological age (CA) or bone age 
(BA) at start, weight SDS at start and mid-parental height SDS (7, 8). For long-term 
response, TH SDS, height and weight SDS at start, CA-BA at start and maximum GH 
response to a stimulation test were identified as significant factors (4, 9). 
In Europe, the recommended dose for the approved indication (EMEA, 2003) is 
0.035 mg/kg⋅day. In the US, the FDA-approved indication describes a dose of 0.070 
mg/kg⋅day. Several studies found a dose-effect on growth response during the first 
treatment years (7, 8, 10-15). For the long-term growth response, the dose-effect 
was smaller, but still significant (4, 5). The optimal dose for individual short SGA-
children is not yet established. Some investigators stated that a dose of 0.033 
mg/kg⋅day results in significant gains in long-term growth, with IGF-I levels in the 
normal range and at lower costs (16). Others argued that the lower dose might be 
sufficient for children without extremely short stature (above -3 SDS), but that 
shorter or older children might better start with a higher dose (≥ 0.050 mg/kg⋅day), 
with tapering of the dose per kg when the absolute GH dose (in milligrams) is 
maintained over the years (5). 
In the present study, we developed a model to predict height at onset of puberty 
and AH for short children born SGA who will start GH treatment. Determinants were 
various baseline characteristics and GH dose. The predictions from this model can be 
used as information about the expected adult height for an individual child in order 
to decide on the prescribed GH dose. 
Subjects and methods 
Subjects 
We used data from two GH trials in short SGA children (8, 17). These studies 
included children with birth length SDS for gestational age below -2.00 (18), height 
SDS for CA at start below -2.00 (19) and height velocity (HV) SDS for CA below zero 
(19, 20), to exclude children with spontaneous catch-up growth. In both studies, CA 
at the start had to be 3 years or older. Study I (8) included prepubertal children, 
defined as Tanner breast stage I for girls and a testicular volume <4 ml for boys 
(21), and age below 12 years in boys and below 10 years in girls. Study II (17) 
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studies excluded children who had had a complicated neonatal period, endocrine or 
metabolic disorders, chromosomal disorders, growth failure caused by other disorders 
(emotional deprivation, severe chronic illness, or chondrodysplasia) or syndromes 
(except for Silver-Russell syndrome), as well as children who used or had used drugs 
that could interfere with GH treatment. 
In study I, children were randomly assigned to either 0.033 mg GH / kg·day (= 1 
mg/m2·day, n = 41) or 0.067 mg GH / kg·day (2 mg/m2·day, n = 38). The 
prepubertal children in study II were randomised into either a GH group or a control 
group that remained untreated for three years and started treatment afterwards. In 
the older age group, all children were treated from start. The GH dose in study II 
was 0.033 mg/kg·day. The inclusion period for study I was between April 1991 and 
January 1993 and for study II between October 1996 and December 1998. 
For the present analysis, we selected children who were prepubertal for at least 
one year after start of GH treatment and had started or completed puberty at the 
time of analysis (December 2006). Birth year for boys had to be prior to 1993 and for 
girls prior to 1994. AH was used of boys born prior to 1988 and girls born prior to 
1989. 
Assays 
Serum IGF-I and IGFBP-3 levels were measured in one central laboratory, using a 
specific RIA (22). The intraassay coefficient of variation (CV) was 4% and the 
interassay CV was 6%. IGF-I and IGFBP-3 values were converted into SD scores 
(23). 
Measurements 
Standing height was measured every 3 months using a Harpenden stadiometer. The 
mean of four measurements was used for analysis. Heights were converted into 
height SD scores (19). AH SDS was computed using the reference values of adults 
(age > 20 years). Bone age (BA) at start was determined according to the Tanner 
and Whitehouse radius, ulna, short bones score (RUS TW-2) (24). At each visit, 
pubertal stages were assessed according to the method of Tanner (21). The onset of 
puberty was defined as a breast stage II for girls and a testicular volume ≥ 4 ml for 
boys. 
AH was defined as the height reached when HV had decreased below 0.5 cm 
during the previous 6 months and a BA of 15 years or older for girls and 16.5 years 
or older for boys. 
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Imputation of missing values and truncation of extreme values 
Missing values were imputed using multiple imputation (25, 26). We generated five 
imputed data sets using the procedure SAS Proc MI (27). Variables with a non-
normal distribution were transformed to normality during the imputation procedure. 
To restrict the influence of outlying values, the lowest values of the outcome and 
of the determinants were truncated to the first percentile and the highest values to 
the 99th percentile. 
Development of prediction model 
The potential determinants were 1) initial characteristics included sex, birth length 
SDS and birth weight SDS (18), gestational age, TH SDS (19), and 2) characteristics 
at start of GH treatment included CA, height SDS, weight SDS, BMI SDS (19), BA and 
CA-BA, maximum GH response to GH stimulation tests, serum IGF-I SDS and 
IGFBP-3 SDS and GH dose. 
We first developed separate models for height SDS at onset of puberty and for AH 
SDS, using forward selection with an inclusion criterion of p < 0.05. 
Next we constructed a model for both outcomes (height SDS at onset of puberty 
and AH SDS), using repeated measurements analysis. We started with all 
determinants selected in the two separate models as covariables, and the interaction 
terms for each determinant with time (0 = onset of puberty, 1 = AH), to allow for 
different effects on the two outcomes. Non-significant (p > 0.05) terms were 
excluded stepwise. After this selection, possible interactions between GH dose and 
each determinant in the model were tested. 
Analysis of residuals 
Using the model obtained by the previously described procedure, we calculated 
predicted outcomes and residuals (observed outcome minus predicted outcome). A 
possible relation between these values was assessed by examining the scatter plots 
and by fitting the linear regression with the absolute values of the residuals as 
dependent and the predictions as independent variable. 
Internal validation 
For internal validation of the derived model, we used bootstrap techniques (28, 29). 
This is an important step in the procedure of development of a prediction model, 
needed to make the model less dependent from the data set. The predictive 
performance of a model applied to other data sets than the set on which it is 
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random samples from the original data set. The models derived on these samples are 
consequently applied to the sample and to the original data set, and the 
performances are compared. The mean of the differences, called the optimism, is 
used to correct the residual standard deviation and the R2 of the original model. 
Another result from bootstrapping is the shrinkage factor for the estimated 
coefficients of the model, which can be used to obtain the final prediction formula, 
corrected for over-optimism. For the internal validation of our model, we used 200 
bootstrap samples. 
Results 
The study group consisted of 150 children of whom 115 (35 in study I, 80 in study 
II) received GH treatment in a dose of 0.033 mg/kg·day (dose 1) and 35 in a dose of 
0.066 mg/kg·day (dose 2). Characteristics are listed in Table 1. At onset of puberty, 
129 (86%) of the children had a height above -2.00 SDS. Seventy-one children had 
AH available (38 children with dose 1 and 33 children with dose 2). Fifty-five (77%) 
of them reached an AH above -2.00 SDS. 
For height SDS at onset of puberty, the significant determinants were height SDS 
at start, TH SDS, GH dose (positive effects), age at start, gender and IGF-I SDS at 
start (negative effects). For AH SDS, the significant determinants were height SDS at 
start, TH SDS, GH dose, CA-BA at start (positive effects), and IGFBP-3 SDS at start 
(negative effect). 
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Table 1. Descriptives 
 Total group (n = 150)  AH group (n = 71) 
 n Median 10th-90th 
percentile 
 n Median 10th-90th 
percentile 
Male/female  150 87/63   71 47/24  
Gestational age (wk)  150 38.0 31.0 to 40.0  71 38.0 31.0 to 40.0 
Birth length SDS  123 -3.4 -5.0 to -2.1  68 -3.2 -6.0 to -2.1 
Birth weight SDS  150 -2.4 -3.8 to -1.0  71 -2.6 -3.8 to -1.2 
Target height SDS  147 -0.5 -1.5 to 0.7  71 -0.7 -2.0 to 0.4 
At start of GH treatment        
CA (yr)  150 7.5 4.9 to 10.3  71 7.9 4.1 to 10.7 
Height SDS  150 -3.0 -3.8 to -2.1  71 -3.1 -4.0 to -2.2 
Weight SDS  150 -2.7 -3.4 to -1.7  71 -2.8 -3.5 to -1.7 
BMI SDS  150 -1.2 -2.7 to 0.3  71 -1.2 -2.8 to 0.2 
IGF-I SDS  146 -0.8 -2.3 to 0.6  70 -1.2 -2.6 to 0.3 
IGFBP-3 SDS  144 -1.3 -2.8 to 0.0  70 -1.3 -3.4 to -0.1 
Maximal GH peak (ng/ml)  129 8.3 4.1 to 15.7  66 9.2 3.6 to 15.8 
Bone age (yr)  139 6.5 3.5 to 9.1  71 7.0 3.1 to 9.8 
CA-BA (yr)  139 0.9 -0.4 to 2.3  71 0.8 -0.9 to 1.9 
GH dose (single/double)  150 115/35   71 38/33  
At start puberty        
CA (yr) - boys  87 12.1 10.9 to 13.3  47 11.9 10.7 to 13.2 
   - girls  63 10.8 9.5 to 12.2  24 11.2 9.7 to 12.9 
Height SDS  150 -1.2 -2.2 to 0.1  71 -1.0 -2.0 to 0.2 
Duration GH treatment (yr)  150 4.0 1.6 to 6.7  71 4.0 1.5 to 7.2 
∆ height SDS since GH start  150 1.9 0.9 to 3.0  71 2.1 1.1 to 3.6 
Adult height        
Duration GH treatment (yr)     71 8.0 6.0 to 11.9 
AH SDS     71 -1.4 -2.5 to -0.3 
∆ height SDS during puberty     71 -0.4 -1.8 to 0.5 
∆ height SDS since GH start     71 1.6 0.7 to 2.7 
AH SDS – TH SDS     71 -0.5 -2.1 to 0.4 
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started with candidate predictors TH SDS, GH dose, gender, age, CA-BA, height SDS, 
IGF-I SDS and IGFBP-3 SDS (all measured at start of treatment) and the interactions 
of these variables with time. In the backward selection, IGFBP-3 SDS was significant 
but IGF-I SDS was removed, because it had no significant contribution to the model. 
IGFBP-3 SDS was correlated with IGF-I SDS (r = 0.47, p < 0.0001) but proved to be 
a stronger determinant. The interactions of height SDS at start, TH SDS and GH dose 
effects with time (onset of puberty or AH) were not significant, indicating that the 
effects of these determinants are equal for both outcomes. The effects of age at 
start and gender were only significant for height SDS at onset of puberty, whereas 
IGFBP-3 SDS was only significant for AH SDS. For CA-BA, the effect on height at 
onset of puberty was much smaller than the effect on AH SDS. There was a 
significant interaction between GH dose and IGFBP-3 SDS. This indicated that there 
was not one constant dose effect, but the dose effect was depending on the value of 
IGFBP-3 SDS at start. A higher IGFBP-3 was related to a smaller effect of GH dose. 
The relation between the GH dose effect and the level of IGFBP-3 is illustrated in 
Figure 1. We plotted the outcomes (height SDS at onset of puberty in Figure 1A and 
AH SDS in Figure 1B), adjusted for gender, TH SDS, height SDS, age and CA-BA at 
start, against the IGFBP-3 SDS value. Through these scatter plots, separate splines 
were drawn for cases treated with dose 1 and cases treated with dose 2. The 
distance between the splines, which is decreasing with increasing value of IGFBP-3 
SDS, represents the dose-effect on the outcome. The dose-effect is plotted at the 
bottom of each figure. The plots also show that there is only a minority (15%) of 
children with IGFBP-3 below -2.5 SDS, where the GH dose effect is substantial. 
 79 
 C
ha
pt
er
 5
 -
 P
re
di
ct
in
g 
ad
ul
t 
he
ig
ht
 a
t 
st
ar
t 
of
 G
H
 in
 S
G
A 
IGFBP-3 SDS at start
A
B
Residual
-3
-2
-1
0
1
2
-5 -4 -3 -2 -1 0 1 2
0
1
Residual
-3
-2
-1
0
1
2
3
IGFBP-3 SDS at start
-5 -4 -3 -2 -1 0 1 2
0
1
2
Difference in height SDS between GH doses
Difference in height SDS between GH doses
 
 
 
Figure 1. Illustration of the effects of GH dose in relation to IGFBP-3 levels (SDS). Plotted 
are height SDS at onset of puberty (A) and AH (B), both adjusted for gender, TH SDS, height 
SDS, age and CA-BA at start against IGFBP-3 SDS at start, dose 1 (+) and dose 2 (0). The 
distance between the splines indicates the dose-effect and is plotted at the bottom. 
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68% of the variance in AH SDS. After correction for overfitting these percentages 
were 57% and 41%. Table 2 shows the results of the repeated measurements 
model. 
Table 2. Results of the final model for prediction of height at onset of puberty and adult 
height 
 Height SDS at onset of puberty Adult height SDS 
Predictor variable Estimated 
coefficient 
SE P-value Estimated 
coefficient 
SE P-value 
Intercept 3.17 0.29 <0.0001 0.014 0.43 0.97 
Height SDS at start 0.71 0.07 <0.0001 0.71 0.07 <0.0001 
Target height SDS 0.13 0.05 0.009 0.13 0.05 0.009 
IGFBP-3 SDS at start 0.003 0.040 0.95 -0.14 0.07 0.06 
GH dosea 0.16 0.14 0.25 0.16 0.14 0.25 
GH dose*IGFBP-3 SDS at startb -0.29 0.08 0.0003 -0.29 0.08 0.0003 
Genderc -0.34 0.08 <0.0001 0.09 0.15 0.57 
Age at start -0.27 0.02 <0.0001 0.02 0.04 0.57 
CA-BA at start (yr) 0.07 0.04 0.07 0.23 0.07 0.002 
Residual SD corrected (original) 0.49 (0.45) 0.72 (0.62) 
R2 corrected (original) 0.57 (0.74) 0.41 (0.68) 
Shrinkage factor 0.97 0.92 
After correction for overfitting and removal of non-significant terms, the prediction formulas are: 
H SDS at onset of puberty = 3.10 + 0.70 * H SDS0 + 0.13 * TH SDS - 0.004 * IGFBP-3 SDS 
+ 0.16 * GH dose - 0.28 * GH dose * IGFBP-3 SDS + 0.070 * (CA-BA) - 0.34 * Gender - 0.27 * Age, 
AH SDS = 0.11 + 0.66 * H SDS0 + 0.12 * TH SDS - 0.11 * IGFBP-3 SDS + 0.15 * GH dose 
- 0.27 * GH dose * IGFBP-3 SDS +0.21 * (CA-BA). 
a Dose 0.033 mg/kg⋅d = 0, 0.066 mg/kg⋅d = 1 
b This interaction term indicates that the GH dose effect is related to the value of IGFBP-3 SDS at start. Because 
of the negative coefficient of this term, the relation is: for lower values of IGFBP-3 the GH dose effect is higher. 
c Male = 0, Female = 1 
 
 
To obtain prediction formulas, we refitted the model using for each outcome only the 
relevant terms (p < 0.20) and applied the shrinkage factor determined by 
bootstrapping. The prediction formulas are also given in Table 2. 
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Data at start of GH therapy 
Child 
   
Age (yr) H SDS IGFBP-3 SDS CA-BA 
1 Female -0.5  4 -3.1 -2.0 1.0 
2 Male -2.0  6 -4.0 0.0 0.5 
3 Male 0.0  5 -3.7 -2.5 0.0 
4 Female -0.5  8 -3.0  0.5 -2.0 
Predictions 
H SDS at onset of 
puberty 
H SDS at AH  THcAH SDSa  H SDS gain 
Child Dose 1b Dose 2b  Dose 1 Dose 2  Dose 1 Dose 2  Dose 1 Dose 2 D2-D1c 
1 -0.48 0.24  -1.57 -0.88  -1.07 -0.38  1.53 2.22 0.69 
2 -1.55 -1.39  -2.67 -2.52  -0.67 -0.52  1.34 1.49 0.15 
3 -0.83 0.03  -2.06 -1.23  -2.06 -1.23  1.64 2.47 0.83 
4 -1.71 -1.69  -2.41 -2.39  -1.91 -1.89  0.60 0.61 0.01 
a Target Height corrected AH SDS = AH SDS – THSDS 
b Dose 1 = 0.033 mg/kg·day, Dose 2 = 0.066 mg/kg·day 
c D2-D1 is the difference in H SDS gain between Dose 2 and Dose 1 
 
 
In Table 3 and Figure 2, examples of predictions for four children are shown, 
presuming that either 0.033 mg GH / kg⋅day (dose 1) or 0.067 mg GH / kg⋅day (dose 
2) is given. The predicted height SDS at onset of puberty and the predicted AH SDS 
were plotted, both with 95% prediction interval. A reference line was drawn at -2 
SDS and the TH range (defined as the TH SDS +/- 1.3) of the child was marked. For 
each child, AH SDS is lower than height SDS at onset of puberty. This decrease in 
height SDS during puberty is mainly related to age at start (for late starters the 
decrease is lower), and to less extent to gender (more decrease for males) and 
IGFBP-3 SDS (more decrease for higher levels). At the right of each plot, the total 
gain in height SDS during treatment is plotted. 
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Figure 2. Examples of predictions for four children (see also Table 3). Predicted values at 
onset of puberty and at AH and 95% prediction interval are plotted for dose 1 (connected 
with solid lines) and for dose 2 (connected with dashed lines). The TH range 
(TH SDS +/- 1.3) is marked. At the right, the gain in height SDS is plotted. 
 
Applying the prediction formula, it is expected that child 1 will achieve an AH 
above -2 SDS, with any of the GH dosages. For both dosages, predicted AH lies 
within the TH range, and the total gain in height SDS during treatment will be more 
than 1.5. Treatment with a GH dose of 0.033 mg/kg⋅day is likely to be sufficient for 
this child. Child 2 has a predicted AH below –2 SDS, even when dose 2 is given. 
However, with any dose, the predicted AH lies within the TH range. Dose 1 will result 
into a gain in height SDS of 1.34, whereas for dose 2 the predicted gain is 1.49 SDS. 
The small difference (1 cm) in the predicted growth response between the two doses 
is related to the relatively high serum level of IGFBP-3 (0 SDS). Therefore, for child 
2, it seems not reasonable to prescribe the higher dose. On the contrary, for child 3, 
the dose effect is expected to be substantial. With dose 1, an AH below -2 SDS is 
predicted, whereas the prediction is -1.23 SDS with dose 2, so within the normal 
range and within the TH range. This may justify prescribing a dose of 0.067 mg GH / 
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higher dose is limited, again because of the relatively high level of IGFBP-3 (0.5 
SDS). The predicted gain in height SDS is below 1, with either dose. One may doubt 
if GH treatment will be beneficial for this child. 
Discussion 
We have developed a model to predict height SDS at onset of puberty and adult 
height (AH SDS) for children born SGA with persistent short stature, in case GH 
treatment is considered. For height SDS at onset of puberty, the model explains 57% 
of the variance and for AH SDS 41%. These percentages are corrected for 
overfitting, in order to give a realistic presentation of the performance of the model 
in general practice. 
Our model includes generally available factors as TH SDS and height SDS and BA 
at start of treatment. Serum IGFBP-3 levels are not always available for short 
children born SGA. When we removed IGFBP-3 SDS as potential determinant, the 
model included IGF-I SDS as a significant determinant (estimated coefficient = -0.08, 
p = 0.03). This model had an 11% lower explained variance compared to our final 
model including IGFBP-3 SDS. There was no significant interaction between IGF-I 
SDS and GH dose. 
We found a significant interaction between GH dose and IGFBP-3 SDS, with a 
negative coefficient. This means that the effect of a higher dose is depending on the 
level of IGFBP-3 of the child: a lower IGFBP-3 SDS at start is related to a larger dose-
effect. For a child with an IGFBP-3 SDS of -2, the expected difference in AH is 0.65 
SDS (approximately 4.6 cm) when treated with 0.067 mg GH / kg⋅day compared to 
0.033 mg GH / kg⋅day. For a child with an IGFBP-3 SDS of 0, this difference is only 
0.11 SDS (0.8 cm). So estimating the effect of a higher dose of GH treatment for an 
individual child requires a measurement of serum IGFBP-3 at start of treatment. We 
therefore recommend measurement of IGFBP-3 and calculation of its SDS in SGA 
children for whom GH treatment is considered. 
When a model was constructed only for the outcome height at onset of puberty 
(the first step in our procedure), IGF-I SDS was selected as significant predictor. 
However, in the model only for the outcome adult height, IGFBP-3 SDS was superior 
over IGF-I SDS as predictor. There was a significant correlation between IGFBP-3 
SDS and IGF-I SDS. Also in the repeated measurement model, where we applied 
backward selection and started with both IGF-I SDS and IGFBP-3 SDS as candidate 
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model. 
Internal validation of the prediction model was performed by bootstrapping. With 
this procedure, the model is corrected for overfitting and will give valid predictions 
with correct confidence limits for new patients. It is not necessary to perform an 
external validation. Applying the model to data of an independent cohort is still 
interesting. 
Ranke et al. (7) developed prediction models for short-term growth response to 
GH treatment in short children born SGA. For both first and second year response (in 
cm/yr), the predicting factors were: age at start (negatively related), weight SDS at 
start, mid-parental height SDS and GH dose (all positively related). In a Swedish 
study (9), a regression model for AH SDS was presented with paternal height SDS, 
height SDS at start (both positively related), age at start and maximal GH response 
during provocation tests (both negatively related) as predictors. The Swedish study 
group differed from our group with respect to the percentage of children with GH 
deficiency (37% with a maximal GH response below 5.3 µg/L, versus 21% in our 
study group) and the age range (2.5 to 15.1 years versus 3.0 to 11.2 years in our 
study group). In addition, dosage of GH treatment was only randomised during 
puberty and no significant influence of GH dose on the AH was found. 
The interpretation of a predicted value for AH SDS depends on the objective of GH 
treatment. Firstly, the goal might be to achieve an AH within the normal range 
(above -2 SDS). Secondly, the aim could be an AH in the TH range, usually defined 
as the TH +/- 1.3 SDS. Thirdly, a substantial gain in height SDS during treatment 
might be regarded as a reasonable goal. When, for an individual child, the AH 
predicted for a GH dose of 0.033 mg/kg·day is unsatisfactory, a higher dose should 
be considered. Our study included only two fixed dosages (0.033 or 0.066 
mg/kg·day). Therefore, for estimating results of intermediate doses, we have to 
specify the type of relation between GH dose and the effect on height SDS. Two 
assumptions are reasonable: a linear relation, meaning that each extra mg of GH has 
the same additive effect, or a loglinear relation, used in some studies (30, 31), 
meaning that the effect of an extra mg GH decreases with increasing dose. For 
example, the effect of 0.040 mg/kg·day compared to 0.035 mg/kg·day is than larger 
than the effect of 0.065 mg/kg·day compared to 0.070 mg/kg·day. According to our 
model, for a child with IGFBP-3 SDS at start of -2, the effect of 0.066 mg/kg·day 
compared to 0.033 mg/kg·day is 0.65 SDS. If the effect of GH dose is linear, the 
effect of a dose in the middle between these two doses, so 0.050 mg/kg·day, is half 
of 0.65, so 0.325 SDS. However, if the effect of GH dose is loglinear, the effect of a 
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mg/kg·day, the difference between the two assumptions (linear or loglinear) is, 
however, small and for simplicity a linear relation can be assumed. Only for doses 
outside this range (extrapolation of dose-effect), the difference might become large. 
We therefore recommend the following: For a child born SGA, the predicted AH SDS 
for a GH dose of 0.033 mg/kg·day should be computed. If this prediction is 
satisfactory, according to the considerations mentioned above, the child is treated 
with this dose. If not, the predicted AH SDS for dose 0.066 mg/kg·day is computed. 
If this prediction is still relatively low, the benefit of any GH treatment should be 
doubted. If this prediction is in the desired range, the child is treated with this double 
dose. If the prediction is too far above the aimed AH SDS, the dose can be computed 
using the following formula: 
GH dose (mg/kg·day) = 0.033 * ((aimed AH SDS - 0.11 - 0.66 * Ht SDS 
- 0.12 * TH SDS + 0.11 * IGFBP-3 SDS - 0.21 * (CA - BA)) 
/ (0.15 - 0.27 * IGFBP-3 SDS) + 1). 
For example, a child with a height SDS of -3.86, age 7.35 years, BA 6 years, 
IGFBP-3 SDS -2.46 and TH SDS -1.57, has a predicted AH SDS for dose 0.033 
mg/kg·day of -2.07, so still outside the normal range. If a dose of 0.066 mg/kg·day 
will be used, the predicted AH SDS is -1.26. If the aimed AH SDS is -1.5, the required 
GH dose is computed as 0.056 mg/kg·day. 
The prediction formulas given in Table 2, as well as the formula for calculation of 
the suitable GH dose, described above, will be implemented in the next update of the 
Growth Analyser (www.growthanalyser.org). 
In conclusion, the presented model predicts the expected AH of a short child born 
SGA who will be treated with GH. This may help in determining the optimal GH dose 
for each child. 
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SGA children without 
early catch-up growth: 
spontaneous growth and 
prediction of height at 8 
years 
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Abstract 
Background/Aim 
About 10-15% of children born SGA has at the age of 2 years a height SDS (HSDS2y) 
still below -2. There is no model to predict which children will catch-up in height after 
two years of age. The aim of this study was to determine the percentage of children 
with catch-up growth to a normal height after the age of 2 years and to develop a 
prediction model for growth after that age. 
Methods 
In a cohort of 724 SGA children, the percentage of children with HSDS > -2 at 8 
years of age was determined. In data of 97 children with HSDS2y < -2, a prediction 
model was developed for growth between 2 and 8 years. 
Results 
Thirty-nine percent of children with HSDS2y < -2 reached a HSDS above -2 between 2 
and 8 years (6% of the total group). Determinants of growth after age 2 years, all 
with a positive influence, were the difference between TH SDS and HSDS2y, change 
in height SDS during first 2 years of life, female gender and multiple birth. 
Conclusions 
Catch-up growth to a normal height occurred in 91% of SGA children, in 6% 
between 2 and 8 years of age. The difference between TH SDS and HSDS2y was the 
most important determinant. The presented prediction model can identify children 
with low or high probability of catch-up growth after the age of 2 years. This may 
assist to determine which children require medical follow-up. 
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Introduction 
Studies have shown that growth hormone (GH) treatment improves adult height of 
short children born SGA (8-12). A product licence is available in EU and USA for the 
GH treatment of SGA children with persistent short stature. To manage GH treatment 
properly and efficiently, it is important to determine at a young age which children 
have a reasonable chance to reach an adult height above -2 SDS and for which 
children this chance is very low (13). 
Previously, we have reported about the postnatal growth of 724 premature and 
full-term SGA infants of whom 85% showed catch-up growth to a height above -1.88 
SDS during the first 2 years of life (3). Of the 111 with a height still below -1.88 SDS 
at the age of 2 years, 109 had a height below -2 SDS. The current study was 
performed to investigate which percentage of these children had catch-up growth 
after the age of 2 years and which factors determined this catch-up growth. We 
developed a prediction model for this growth, which is helpful for decisions if and 
when treatment with GH might be started. 
Subjects and methods 
The original cohort consisted of 724 infants born SGA, defined by a birth length (BL) 
below the third percentile for gestational age (14) (-1.88 SDS). In this group, 613 
infants (85%) had catch-up growth to a height at or above the -1.88 SDS during the 
first 2 years of life (3). 
Of the remaining 111 infants, 109 had a height < -2 SDS and 97 of them (52 
boys, 45 girls) were enrolled in the present study. Ten children were lost to follow-up 
and the parents of two children refused to participate in our follow-up study. The 
remaining group (n = 97) consisted of premature as well as full-term infants. 
Twenty-one children were enrolled in a GH trial, at a mean age (range) of 7.2 years 
(4.2 - 12 years). 
Data of height measurements between 1980 and 1991 were obtained from patient 
records at the Departments of Pediatrics of the participating hospitals and from Child 
Health Care Units/Area Health Authorities. From 1991, growth data were collected 
prospectively. Data were obtained at different ages and at different intervals for each 
child. Height measurements were performed with a Harpenden stadiometer or a 
standard measuring board and expressed as height SDS (15). The growth data used 
for analysis was restricted to the prepubertal stage, defined by breast development 
Tanner stage 1 in girls and by genital development Tanner stage 1 or testicular 
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of 10 years for boys and 9 years for girls were not used. The growth data of children 
who started GH therapy were used until the last height SDS before start of GH 
treatment. 
The study was approved by the Medical Ethics Committees of the participating 
hospitals. Written informed consent was obtained from the parents. 
Statistics 
Student-t-test was used for comparing continuous outcomes between different 
groups and the chi-square test for categorical outcomes. 
Catch-up growth was defined as a height > -2 SDS at the age of 8 years. For 
children with prepubertal height measurements beyond that age, height SDS at 8 
years (HSDS8y) was interpolated using the two adjacent observations. For children 
without a measurement at of after the age of 8 years, a repeated measurements 
analysis was performed to obtain an estimate of HSDS8y. In this analysis, the 
available prepubertal growth data of all children was used. For each height 
measurement, the change in height SDS relative to the height SDS at the age of 2 
years (dHSDS) was computed. A model was developed on these repeated outcomes. 
Firstly, we investigated if the pattern of these data could be described by a linear 
relation with age or whether use of a transformation of age would fit better. The 
growth curves were best described by a linear relation between dHSDS and the 
natural logarithm of age-1. Next, we developed a model including significant 
determinants of growth as fixed effects and a random age-effect for each child, 
reflecting the child-specific growth. Furthermore, the correlation between serial 
measurements of a child was taking into account. As potential determinants of 
growth, we considered age and its interactions with sex, premature/full-term, 
multiple birth, birth weight SDS, BL SDS (14), target height (TH) SDS, change in 
weight SDS during the first six months of life, height SDS at 2 years of age (HSDS2y), 
change in height SDS during the first 2 years of life (dHSDS0-2y), the difference 
between TH SDS and BL SDS (TH-BLSDS) and the difference between TH SDS and 
height SDS at 2 years of age (TH-HSDS2y) (15). Missing values for the determinants 
were imputed using multiple imputation . 
Forward selection was used to build a model with significant effects (p < 0.05). 
This model provided estimated HSDS8y for the children in the data set, based on the 
determinants in the model and the available growth data of a child. Combining the 
observed HSDS8y of part of the group and the estimated HSDS8y of the other part, 
we reported the proportion of children with catch-up growth at 8 years of age. 
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additionally the standard deviation (SD) for the predicted HSDS8y was determined. 
Comparing this SD with the SD of all estimated HSDS8y, the percentage explained 
variance was computed. Prediction and SD define the distribution of HSDS8y, based 
on patient characteristics at 2 years of age. This enables to determine, for a child of 
at least 2 years of age, the probability to reach a HSDS8y > -2. 
Results 
Clinical data are summarized in Table 1. Sixty-nine infants were born premature 
(before 37 weeks) and 28 were born full-term (between 37 and 43 weeks). Mean BL 
SDS (corrected for gestational age) was significantly lower for premature infants than 
for full-term infants (p = 0.001). The growth data between 2 and 10 (9) years of age 
are plotted in Figure 1. 
Table 1. Characteristics of the study group 
 Total Premature Full-term P-valuea 
Total number of patients 97 69 28  
Male (%) 54% 57% 46% 0.37 
Gestational age (wk) 34.4 ± 3.5 32.6 ± 2.2 38.8 ± 1.4 < 0.0001 
Multiple births 17 14 3 0.38b 
Target height SDS -0.58 ± 0.94 -0.44 ± 0.92 -0.92 ± 0.91 0.02 
Birth weight (g) 1347 ± 563 1069 ± 355 2031 ± 361 < 0.0001 
Birth weight SDS -3.09 ± 0.92 -3.19 ± 0.96 -2.85 ± 0.78 0.10 
Birth length (cm) 38.6 ± 4.9 36.0 ± 3.6 44.0 ± 1.7 < 0.0001 
Birth length SDS -4.05 ± 1.34 -4.37 ± 1.41 -3.29 ±0.75 < 0.0001 
Target height SDS - Birth length SDS 3.49 ± 1.70 4.03 ± 1.62 2.27 ± 1.19 < 0.0001 
Height SDS at age 2 years -2.62 ± 0.58 -2.68 ± 1.66 -2.47 ±0.31 0.04 
Target height SDS - Height SDS at 2 yr 2.04 ± 1.03 2.25 ± 1.01 1.53 ± 0.93 0.002 
Height SDS at 2 yr - Birth length SDS 1.44 ± 1.19 1.70 ± 1.23 0.81 ± 0.80 0.0001 
Data expressed as mean ± SD 
aTest of null-hypothesis: Means (or percentages) of premature and full-term children are equal 
bFisher's exact test 
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Figure 1. Growth charts of the children in the study group. Bold lines indicate the reference 
lines at -2, -1, 0 +1 and +2 SDS of healthy Dutch children (15). 
 95 
 C
ha
pt
er
 6
 -
 S
po
nt
an
eo
us
 g
ro
w
th
 a
nd
 p
re
di
ct
io
n 
of
 h
ei
gh
t 
at
 8
 y
ea
rs
 in
 S
G
A 
ch
ild
re
n 
Catch-up growth in the study group 
Thirty-eight (39%) of the children who were short at 2 years of age, had catch-up 
growth to a HSDS8y > -2. Twenty-seven of them were born premature and 11 were 
born full-term. Table 2 shows the percentages of premature and full-term SGA 
children with catch-up growth in three age periods: from birth until 2 years of age, 
from 2 until 8 years of age and from birth until 8 years of age. The percentages are 
corrected for the number of children lost to follow-up. In the first 2 years of life, the 
percentage with catch-up within the full-term infants (88.4%) was higher compared 
to the premature infants (82.5%) (p = 0.03). In the period from 2 until 8 years of 
age, the percentage in the full-term children (4.5%) was lower compared to those 
born preterm (6.9%) (p = 0.22). Over the entire period from birth until 8 years of 
age, the group of children born premature showed catch-up growth in 89.4%, versus 
92.9% in the group of full-term children (p = 0.09). The overall percentage of SGA 
children with catch-up growth to a height > -2 SDS before the age of 8 years was 
90.8%. 
Table 2. Percentages of SGA children with catch-up growth to a height SDS > -2 in different 
age periods 
 Percentage with catch-up growth > -2 SDS 
  Age-period (years) 
 N 0 – 2 2 – 8 0 – 8 
Premature infants 423 82.5 6.9 89.4 
Full-term infants 301 88.4 4.5 92.9 
    
Total group 724 84.9 5.9 90.8 
 
 
Prediction model for growth after 2 years of age 
The prediction model for growth after 2 years of age included age (transformed) and 
its interactions with TH-HSDS2y, sex, dHSDS0-2y and multiple birth. The estimated 
coefficients are given in Table 3. 
In the right column in Table 3, the coefficients are given when the age of 8 years 
is filled in. These coefficients determine the prediction rule for HSDS8y: 
HSDS8y =  HSDS2y – 0.72 + 0.26*TH-HSDS2y + 0.25*Sex +0.33*MultiB 
+ 0.10*dHSDS0-2y 
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they will have more catch-up between 2 and 8 years of age compared to children 
with a HSDS2y close to their TH SDS. HSDS8y will be 0.26 SDS greater for each SDS 
difference between TH SDS and HSDS2y. Female gender is another positive factor. 
The difference in HSDS8y between girls and boys, with equal values for the other 
characteristics, will be on average 0.25. HSDS8y of children from multiple births will 
be 0.33 greater than of children from single births. The catch-up growth in height 
between birth and 2 years of age has a small positive effect on HSDS8y, being 0.10 
SDS for each SDS catch-up growth before the age of 2 years. 
Table 3. Estimated coefficients of the final model for delta height SDS relative to height SDS 
at 2 years of age 
Determinant Estimated 
coefficient 
SE P-value 
 
 Coefficient for 
HSDS8y
d 
AgeTra -0.3695 0.1031 0.0004  -0.7189 
AgeTr* (TH SDS - HSDS2y) 0.1348 0.0288 <0.0001  0.2623 
AgeTr*Sexb 0.1298 0.0561 0.02  0.2525 
AgeTr*Multiple birthc 0.1683 0.0765 0.03  0.3274 
AgeTr*(HSDS2y - BL SDS) 0.0519 0.0244 0.03  0.1010 
aAgeTr = ln(Age - 1), Age in years 
bMale = 1, Female = 2 
cSingle birth = 0, Multiple birth = 1 
dFor Age = 8: AgeTr = ln(8-1) = 1.95 
 
 
The SD of the predicted values of HSDS8y was 0.54. The percentage variance in 
HSDS8y explained by the model was 44%. With a predicted value and SD, 
probabilities can be computed, for example, the probability to reach a HSDS8y > -2.5, 
or to reach a HSDS8y > -2.0. 
In Figure 2, three examples are shown. The three (hypothetical) children, all 
single birth and all with HSDS2y equal to -2.5, have different predicted growth after 
the age of 2 years, due to their different characteristics. Figure 2A shows predicted 
growth of a girl with a TH SDS of 1.5 and a BL SDS of -4.5. At 2 years of age, her 
height SDS had increased by 2 relative to birth, but her height was still 4 SDS below 
TH. The predicted HSDS8y for this girl is -1.46, and the probability that her HSDS8y 
will be above -2 is 84%. Figure 2B shows a girl with a TH SDS of -0.5 and BL SDS of 
-4. The predicted HSDS8y for this girl is -2.04. This prediction is close to -2 SDS, and 
the probability that HSDS8y will be above -2 is 47%. Figure 2C shows predicted 
growth of a boy with TH SDS equal to -2 and BL SDS equal to -3. So there was only 
a minor change in height SDS during the first two years of life and HSDS2y is only 0.5 
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n below TH SDS. His predicted HSDS8y is -2.78 and the probability of reaching a height 
> -2 SDS is only 7%. 
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Figure 2. Examples of predicted growth. For the characteristics of the three examples see 
text. At the left of the vertical line, the predicted growth between 2 and 8 years of age is 
plotted. The Gauss-curve at the right of each plot gives the distribution of the predicted 
HSDS8y. The marked area represents the probability to reach a HSDS8y > -2. 
In Figure 3, the probability to reach a normal height > -2 SDS at 8 years of age, in 
relation to the predicted HSDS8y, is depicted as line A. For the indication to start GH 
treatment, however, the height should be less than -2.5 SDS. The probability to 
reach the -2.5 SDS at 8 years of age is given as line B. For example, for a child with 
a predicted HSDS8y of -3.2, the probability to reach a normal height > -2 SDS is 1%, 
according to line A, whereas the probability to reach a height > -2.5 SDS is 10%, 
according to line B. 
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Figure 3. Relation between the predicted HSDS8y and the probability to reach a HSDS8y > -2 
(line A) or to reach a HSDS8y > -2.5 (line B) 
Discussion 
Our study described longitudinal growth of a cohort of 724 healthy premature and 
full-term children born SGA. Catch-up growth occurred in 90.8%, in 6% between 2 
and 8 years of age. So some SGA chidren with persistent short stature at 2 years of 
age will have spontaneous catch-up growth to a normal height after that age. For 
growth after the age of 2 years, the predicting factors, all with a positive influence, 
were: the distance between HSDS2y and TH SDS, female gender, multiple birth and 
the difference between HSDS2y and BL SDS. With these determinants, a prediction 
formula was derived for HSDS8y. The large effect of the distance between HSDS2y 
and TH SDS reflects the importance of the genetic growth potential of the children. 
The characteristics used in the prediction formula are generally available. In the 
Netherlands, infants are regularly measured in well-baby clinics, including 
measurement of height and weight at the age of 2 years. 
The total percentage of SGA children with catch-up growth to a height > -2 SDS 
(90.8%) is in line with the previously reported percentage of 89.8% catch-up growth 
before the age of 8 years (1, 17). Whereas during the first 2 years the percentage of 
catch-up growth was higher in the group of full-term children (88.4%) compared to 
the percentage in preterm children (82.5%), during the period after 2 years of age, 
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than for premature children (6.9%). The variable premature/full-term was not a 
significant predictor in the model. The difference in catch-up growth between 
premature and full term children is due to predictors that are different between the 
two groups: distance between HSDS2y and TH SDS and difference between HSDS2y 
and BL SDS. Qvigstad et al. also demonstrated a continuing catch-up growth in very 
preterm and very low-birth-weight infants after the age of 2 years (17). 
In this study, we used HSDS8y as main outcome to prevent bias due to the 
beginning of puberty. SGA children with short stature at 8 years of age can be 
expected to remain short until adult height, when they remain untreated. Chaussain 
et al. reported a correlation of 0.81 between height at onset of puberty and adult 
height in SGA children.(18) For boys born SGA, a rather modest pubertal growth 
spurt is reported (19) and for girls a normal growth spurt (2, 19-21). 
Based on longitudinal growth data, we developed a prediction model for HSDS8y, 
including variables that are known at the age of 2 years. The repeated 
measurements analysis leads to valid results although the follow-up measurements 
were done at irregular time points and not all children had complete follow-up data 
until 8 years of age. With the model, the probability of catch-up to a normal height 
SDS > -2 or to a height SDS > -2.5 can be derived. This information can be used to 
determine further surveillance. For instance, when the probability to reach a height > 
-2 is high (arbitrarily > 80%), the frequency of follow-up visits might be low. It is 
very likely that children with this prospect will not become candidates for GH 
therapy. When the probability is, however, very low (arbitrarily < 10%), more 
frequent follow-up and referral to a pediatric endocrinologist for further diagnostics 
are desirable. When the probability to reach a height > -2.5 is < 10%, one may start 
to discuss with the parents the possibility of treatment with GH after the age of 4 
years. 
The explained variance of our model was 44%. Further analyses on larger data 
sets may lead to prediction models with higher accuracy. However, long-term follow-
up of untreated SGA children becomes increasingly scarce as many SGA children are 
nowadays treated with GH. For that reason, more effort should be made to register 
pre-treatment growth data of SGA children. 
In conclusion, 90.8% of a cohort of children born SGA (n = 724) showed catch-up 
growth to a normal height. This catch-up occurred mainly during the first 2 years of 
life but in 6% after the age of 2 years. For children with a height SDS at the age of 2 
years still less than -2, the presented model enables prediction of future growth. 
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Abstract 
Background/Aim 
In long-term growth studies with adult height (AH) as outcome, reporting is often 
required while data are incomplete because some participants have not yet reached 
AH whereas others might be lost to follow-up. Current practice is to analyse only 
participants who did reach AH, which can easily give biased results. We introduce a 
new method into the area of growth research. 
Methods 
We used data of patients from a registration database and a growth study. The new 
method uses growth data in time intervals. The percentage of children still growing 
and the mean growth in each interval are used to determine mean AH. 
Results 
With the new method, estimated mean AHs had smaller bias and standard error than 
with commonly used methods. The method is not hampered by a correlation 
between AH and age at reaching AH, unlike methods merely using patients who have 
reached AH. 
Conclusion 
In contrast to commonly used methods, the new method provides valid results on 
mean AH when complete actual measurements of AH are not (yet) available, 
provided that drop-out, if any, is not related to (disappointing) growth. As it also 
uses observed data of children with incomplete follow-up, the method employs the 
data more effectively. 
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Introduction 
In many growth studies the final outcome of interest is adult height (AH). However, 
when AH is the endpoint, incomplete data can easily cause a problem. Patients might 
be lost to follow-up or simply have not yet reached AH at the time of reporting. 
Current practice in the medical literature is to base the analysis on the subgroup 
of patients with complete follow-up until AH (Uncensored Cases method) (1-3). The 
mean AH of these patients is only unbiased if these patients are a random sample of 
the complete group, so patients with incomplete follow-up do not have another 
growth pattern compared to the patients with complete follow-up. However, because 
AH and the age at which AH is reached are usually correlated and patients reaching 
AH at a relatively older age are more likely to have limited follow-up data, the group 
of patients with complete follow-up is usually not representative for the whole group. 
A correct method of analysis should take the information on patients with limited 
data (censored cases) into account. 
Another method, less frequently used, is to include the actual height of the whole 
group, even though part of them have not yet reached AH (Full Sample method). In 
practice this is of course only done when all patients are at or very close to AH 
("near-adult-height") (4-6). This method will always give an underestimation of the 
(unknown) mean AH of the complete sample, with the size of the bias highly 
depending on the percentage of patients censored and the ages at censoring. 
Standard methods for the analysis of censored data, such as the well-known 
Kaplan-Meier method (7), do not work in this situation since the assumption of 
independent censoring is not fulfilled. 
So the currently used statistical methods in growth research are inappropriate, 
and more sophisticated methods are needed. This problem of incomplete follow-up 
of growth data is completely analogous to the problem of estimating total medical 
costs (e.g. from the time of diagnosis until death) for a group of patients who may 
have censored survival times. In the area of cost-effectiveness research, a new 
statistically correct method for handling this type of data was recently developed by 
Lin et al. (8). This method uses the follow-up data of all patients, censored and 
uncensored, and properly accounts for the incompleteness of the data. In this paper 
we will show that the currently used methods for analysing AH are biased. We 
applied the new method (Lin's method) in order to get results that are more precise 
and valid, provided that loss to follow-up, if any, is not related to disappointing 
growth. 
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Patients and methods 
The first group of patients (group I) was selected from the database of the Dutch 
Growth Foundation, containing data of all Dutch children treated with growth 
hormone (GH). Inclusion criteria were: boys born before January 1, 1980, girls born 
before January 1, 1982, available growth follow-up from at least the age of 14 until 
AH, and AH reached (defined as height velocity of < 2 cm/year) before January 1, 
2000. The children usually had height measurements every 3 or 6 months during 
GH-treatment, which was routinely continued until AH was reached. If treatment was 
stopped before AH was attained, height measurements were usually done every 
year. This data set was used to show the effect of censoring in a large data set 
where the complete data are known. The mean AH for males and females was 
computed. Subsequently we used artificially censored data at time points where only 
a certain percentage of the patients (from 50% on) had reached AH. Using these 
censored data we calculated the mean AH of the patients who had reached AH 
before that date with the Uncensored Cases method and we calculated the mean AH 
with Lin’s method using all follow-up data available at that date. We compared these 
estimated mean AHs with the mean of the actually measured AHs of the complete 
group. 
The second group of patients (group II) consisted of 39 children participating in a 
clinical trial and treated with biosynthetic GH until AH (defined as growth of < 0.5 cm 
during the previous 6 months and bone age 15 years or more for girls and 16.5 years 
or more for boys). We evaluated this group because it represents a realistic situation 
of a growth study. The participants of this study were measured every 3 months. We 
computed the estimated mean AH for males and females using the data known at 
time points with 2-year intervals during the last years of follow-up of the study. 
Again we compared the results with the mean AH of the complete data. 
Statistics 
Lin’s method requires growth data at fixed time intervals during follow-up. A data 
example is given in Table 1. For the first interval the attained height at the end of 
this interval is used and for subsequent intervals the growth during the interval. For 
each individual it must be known whether at the end of the last observed interval AH 
was reached or whether growth follow-up was censored. 
Condition for valid application of the method is that censoring (stop of follow-up) 
of an individual is not related to his or her growth. However, it should be realised 
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that any other method of analysing the data fails as well if this condition is not 
satisfied. Secondly Lin’s method requires consistency of growth patterns during the 
total observation period. If there is a time trend, such as changes in treatment or in 
measurement protocol during a study, results from data colleted early might not be 
fully representative for the final result. 
Table 1. Example of growth follow-up data 
Subject Interval* Age at end of 
interval (yr) 
Growth in interval 
(cm) 
AH reached at end of 
interval 
1 1 14.0 150.2 no 
1 2 14.5 4.9 no 
1 3 15.0  3.3 no 
1 4 15.5 1.3 no 
1 5 16.0 0.2 no 
1 6 16.5 0.2 no 
1 7 17.0 0.2 no 
1 8 17.5 0.1 yes 
2 1 14.0 151.3 no 
2 2 14.5 2.9 no 
2 3 15.0 2.7 no 
2 4 15.5 2.1 no 
2 5 16.0 1.8 no 
2 6 16.5 0.8 no 
2 7 17.0 0.6 no 
3 1 14.0 158.4 no 
3 2 14.5 2.8 no 
3 3 15.0 2.8 no 
3 4 15.5 1.7 no 
3 5 16.0 0.1 yes 
*Interval 1 covers the time from conception until age 14 years, following intervals cover 0.5 years 
 
 
Table 2 shows how Lin’s method works. The first step in the analysis is to carry 
out a survival analysis for the outcome age at reaching AH (ageAH), where cases 
with incomplete follow-up are considered as censored at the age of last observed 
height (7). This gives, for all intervals 1 to K, estimations Sk  (k = 1, …., K) for the 
proportion of patients that is still growing at the start of each interval. The second 
step is to calculate for each time interval the mean growth using the data of all 
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individuals contributing to that interval (Gk). In the next step, for each interval Sk is 
multiplied by Gk and the result for the mean AH is the sum of these products over all 
intervals: 
Ê = ∑ Sk⋅Gk 
For mathematical details, including the calculation of the standard error and the 
statistical proof of validity, the reader is referred to Lin et al. (8). 
Table 2. Illustration of Lin’s method 
Interval 
(k) 
Age at end of 
interval (yr) 
Proportion of patients 
still growing 
Sk 
Mean growth in 
interval (cm) 
Gk 
Contribution of interval to 
estimation of mean (cm) 
Sk⋅Gk 
1 12 1.00 148 148.00 
2 13 1.00 6 6.00 
3 14 0.98 7 6.86 
4 15 0.84 7 5.88 
5 16 0.63 6 3.78 
6 17 0.49 4 1.96 
7 18 0.34 3 1.02 
8 19 0.15 2 0.30 
9 20 0.10 1 0.10 
12 21 0.00 0 0.00 
   Estimation of AH 173.90 
 
Simulation study 
Because Lin’s method has never been applied to growth data before, we illustrate its 
validity for growth data by applying it to artificially generated growth data in a 
simulation process. In that situation we know the true mean and standard deviation 
(SD) of AH in the population. 
1. We generated AHs of 100 imaginary children, using a normal distribution with a 
mean of 170 cm and an SD of 10 cm. So an estimation of the mean of these AHs 
should ideally give 170 cm. 
2. Next we used five different imaginary growth scenarios. In each scenario there 
was a different relation between AH and ageAH: no correlation 
(r (AH, ageAH) = 0), a (weak and strong) positive correlation, meaning that tall 
AH tends to be related to older ageAH (r = 0.19 and r = 0.36), and a negative 
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correlation (tall AH related to younger ageAH), again weak and strong (r = -0.19 
and r = -0.36). According to this correlation we generated ageAHs for the 100 
children. 
3. For each scenario, growth data were generated from age 12 years until ageAH 
using a model based on real growth curves. Each child got a height at 12 year 
related to its AH. Growth data in between were generated using a quadratic 
curve, with random deviations from this curve. 
4. Next we gave each child a random censoring age (drawn from a uniform 
distribution with range 15 - 25). If the censoring age was younger than the 
ageAH, growth data of this child were restricted to the intervals preceding the 
censoring age. If ageAH fell before the censoring age, the complete follow-up 
data of the child were included. This resulted in about 27% of children with 
incomplete follow-up data for each correlation scenario. 
These four steps were repeated 5,000 times, resulting in 5,000 random data sets for 
each scenario. A large number of simulations is needed to compensate for possible 
accidental results if only one or a few simulations are done. The results of this 
simulation study are shown in Table 3. 
For the complete data (without censoring) we computed for each simulated data 
set the mean AH, and calculated the average over the 5,000 simulations and the 
corresponding SD (Table 3, column 2). Since the estimation is unbiased for complete 
data sets, the average of the estimated means from the 5,000 simulations should be 
very close to 170 cm. In Table 3 we give the average bias (difference from the true 
mean of 170 cm), which, for the complete data, is of course almost zero in all 
scenarios. The SDs are very close to 1.0 cm (SD of 10 cm of the used distribution 
divided by the square-root of the sample size of 100) and the coverage probabilities 
of the 95% confidence intervals are indeed 95%. 
For the censored data we first determined the mean AH using the mean of the full 
sample, i.e. using the AHs of the cases who have reached AH and the last observed 
height of the cases with incomplete follow-up (Full Sample method, Table 3, column 
3). Using this method the calculated means (again for each correlation pattern the 
average over the 5,000 simulations) are always too small (negative bias), the SDs 
are larger than 1.0 cm and the coverage probabilities are much too low. 
Secondly we computed the mean of the uncensored cases (Uncensored Cases 
method, Table 3, column 4). This is quite adequate when there is no correlation 
between AH and ageAH (r = 0: bias -0.013 cm, coverage probability 96%). However, 
in data sets with a correlation between AH and ageAH, a substantial bias is shown 
and the coverage probability is too low. 
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Thirdly we performed a standard survival analysis using all last observed heights, 
indicating AHs as events and last observed heights of the censored cases as 
censored (Kaplan-Meier method, Table 3, column 5). These results have substantial 
positive bias, large SDs and coverage probabilities that are too low. 
Finally we used Lin’s method (Table 3, column 6). In all situations we found only a 
very small bias (< 0.2 cm). The SDs are smaller than those of the other methods for 
censored data, showing that Lin’s method is statistically more efficient. The SDs of 
Lin’s method are only slightly larger than 1 (the best possible value for this data set, 
which can only be reached if complete data are observed), indicating that the data of 
the censored cases are used in a very efficient way. The coverage probabilities are 
very close to 95%. These results illustrate that Lin’s method gives more valid and 
reliable results than currently used methods. 
Table 3. Comparison of the various methods 
Method of analysis  
 
Scenario Complete Data Full Sample 
Uncensored 
Cases 
Kaplan-Meier Lin’s method 
r = -0.36  -0.02 (1.01) 
 95% 
 -2.50 (1.20) 
 44% 
 1.03 (1.16) 
 86% 
 2.16 (1.39) 
 65% 
 -0.16 (1.03) 
 95% 
r = -0.19  -0.02  (0.99) 
 95% 
 -2.50 (1.14) 
 42% 
 0.51 (1.16) 
 93% 
 1.82 (1.42) 
 72% 
 -0.16 (1.01) 
 96% 
r = 0 
 
 0.01 (1.00) 
 95% 
 -2.49 (1.12) 
 39% 
 -0.01 (1.16) 
 96% 
 1.57 (1.42) 
 79% 
 -0.14 (1.02) 
 96% 
r = 0.19 
 
 0.00 (1.02) 
 95% 
 -2.52 (1.11) 
 36% 
 -0.53 (1.18) 
 92% 
 1.25 (1.42) 
 84% 
 -0.15 (1.04) 
 95% 
r = 0.36 
 
 0.02 (1.02) 
 95% 
 -2.54 (1.06) 
 33% 
 -1.02 (1.17) 
 86% 
 0.99 (1.44) 
 87% 
 -0.14 (1.04) 
 95% 
Each cell contains the bias of the estimated mean (cm) averaged over the 5,000 simulations, the standard 
deviation of the mean (in parentheses) and the coverage probability of the estimated 95% confidence interval 
(= percentage of the 5,000 confidence intervals containing the true mean). r is the correlation between AH and 
ageAH. 
 
Results 
Group I consisted of 194 patients (42% male) who started GH treatment at a median 
(25th; 75th percentile) age of 11.9 (9.9; 13.3) years and reached AH after treatment 
for 4.3 (3.1; 6.4) years. Thirty seven percent of the children had idiopathic GH 
deficiency (GHD), 32% had GHD with known cause, 7% had Turner syndrome, and 
 111 
Ch
ap
te
r 
7 
- 
M
ea
n 
AH
 f
ro
m
 in
co
m
pl
et
e 
fo
llo
w
-u
p 
da
ta
 
24% another diagnosis. The mean height SDS at start was -2.75 (9), mean height 
SDS at the age of 14 years (which was the starting point of the follow-up data we 
used) was -2.08 and mean height SDS of AH was -2.05. The median number of 
measurements per child (after age 14 years) was 11 (8; 15). The results for boys 
and girls are presented in Figure 1. On the x-axis is the percentage of patients who 
have reached AH. The calculated mean AHs are based on the data known at the 
corresponding date. The horizontal line indicates the value of the mean AH computed 
when the follow-up is complete. 
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Figure 1. Estimated means for group I versus percentage of patients with complete follow-
up. × −  − × −  − × Uncensored Cases method +−−+−−+ Lin’s method 
The Uncensored Cases method gives calculated means with larger deviation from 
the final mean AH than Lin’s method. For the boys (Figure 1a), the final mean AH is 
167.84 cm. The largest deviation when using the Uncensored Cases method is 
1.46 cm, when 60% of the boys have reached AH. Lin’s method has at the same 
time point a deviation of only 0.23 cm. For the girls (Figure 1b), the largest deviation 
using the Uncensored Cases method is 0.76 cm, and using Lin’s method 0.30 cm. 
From the time point when 75% of the patients have reached AH, the result of Lin’s 
method is within 0.10 cm of the mean of the complete data, for boys and girls. 
Of the 39 children in group II (29 boys, 10 girls) calculated means are given in 
Table 4 which could be obtained at respectively 7, 9 and 11 years after start of the 
study (for girls the results at 11 years are omitted because after 9 years the follow-
up was complete). In Table 4 the difference between the calculated mean and the 
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actual mean of the whole group (delta) is a good indicator of the validity of each 
method. For both boys and girls the delta of Lin’s method is closer to zero than the 
delta of the Uncensored Cases method at each point in time presented. The standard 
error (SE) of Lin’s method is smaller than the SE of the Uncensored Cases method, 
since the latter does not use all available data. 
The obtained means might be converted to SD scores to make it possible to 
combine the results for boys and girls. 
Discussion 
In this paper we show that current methods used in growth research to analyse AH 
data are biased. The magnitude of the bias depends on the percentage of subjects 
who have dropped out or have not yet reached AH yet at the time of analysis and 
also on the correlation between AH and ageAH. We have shown that a more 
advanced method used in cost-effectiveness analyses can be applied to growth data 
to get valid results, provided that eventual loss to follow-up is not related to the 
outcome AH. If drop-out is due to disappointing growth, the method can not correct 
for this loss, nor can any other method. 
Until now there has not been any effort to analyse the follow-up of growth data in 
a more sophisticated way than simply using the uncensored cases: to report the AH 
results of a growth study, the investigators wait until a sufficiently large percentage 
of the study group (ideally the number required for sufficient power) has reached AH 
and will then analyse the observed AHs of this subgroup. When reporting is done for 
patients from, e.g., a registry, the number of subjects who have reached AH is 
usually high, and one does not worry that this group in fact is a (non-representative) 
selection. However, this can give biased results because the patients who did reach 
AH early in follow-up might be different from the other patients. It also ignores all 
observed follow-up of the patients who had not yet reached AH, despite the fact that 
these data contain valuable information. 
Since 1958 statistical techniques for censored data have been developed (7). 
These techniques are mostly used for the analysis of survival times, but can also be 
used for other censored data, e.g. bioassays dealing with a detection limit (left 
censored data). However, these techniques are not appropriate for the analysis of 
incomplete growth follow-up. In this situation there is censoring in two dimensions, 
namely growth and time. The time to reach AH is censored and that is the cause of 
observing incomplete data on growth. In this situation standard survival analysis 
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cannot be applied because the assumption that the attained outcome at censoring is 
independent of the outcome for complete data is violated. 
In medical cost-effectiveness analyses the same phenomenon occurs, when the 
mean total costs of patients, e.g. from diagnosis until death, is estimated. Censoring 
occurs because not all patients have died at the time of analysis or some patients 
have been lost to follow-up, so for some of the patients total medical costs were not 
observed. Lin et al. (8) provided two methods to estimate mean total costs correctly, 
one for which no cost history is required and another (preferable) that requires 
observed costs over time for all patients within small intervals. The latter situation is 
analogous to growth studies where the height of the participants is usually measured 
at regular time intervals. Based on theoretical statistical considerations, Lin et al. (8) 
showed the method to be valid, as long as censoring on ageAH is uninformative. In 
practice this assumption will be fulfilled, since almost all censoring is due to the 
patients not having reached yet adult height at the time of the analysis. The validity 
of the method was illustrated in our simulation example. We showed that Lin’s 
method gives estimated means with only very small bias, even in the case of a 
correlation between AH and ageAH. The efficiency of Lin’s method is higher than 
currently used methods, as reflected by a smaller SD of the estimations. When there 
is no correlation between AH and ageAH, the Uncensored Cases method gives a valid 
estimation, but with 27% of the 100 cases censored the estimation has the accuracy 
of a study with 73 cases with complete data. The accuracy of Lin’s method is 
comparable to a study with 87 cases. In simulations with 15% and with 40% 
censoring the accuracy of Lin's method was comparable to studies with n = 91 and 
n = 78, respectively. 
In the first application of the method, to data from the registration database of 
the Dutch Growth Foundation, we analysed the follow-up data at various levels of 
censoring. The method we introduce here gave results closer to the mean AH of the 
complete data than the mean of the uncensored cases. 
For the subjects in group II, we performed analyses using data available at 
different points in time, to see how the methods would perform if the data of a study 
were analysed when not all follow-up data are complete. Lin’s method gave better 
results compared to the Uncensored Cases method. 
In conclusion, when complete actual measurements of AH are not (yet) available 
and loss to follow-up, if any, is not related to growth, Lin’s method provides valid 
results on the mean AH, in contrast to the commonly used methods and is also more 
accurate. Using also the observed data of study-participants with incomplete follow-
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up, it makes more effective use of the data collected. To execute the computations 
for the method, standard statistical software is sufficient. 
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Individually customised 
fetal weight charts 
derived from ultrasound 
measurements. The 
Generation R Study 
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Abstract 
Objective 
To develop a model for individually customised growth charts for estimated fetal 
weight, which takes account for physiological fetal and maternal determinants that 
are fixed at the start of pregnancy. 
Methods 
Data was used from the Generation R Study, a prospective, population-based cohort 
study from early pregnancy onwards. In total, 8,162 singleton pregnancies were 
eligible for the present analysis, having excluded those with major congenital 
anomalies, termination of pregnancy or perinatal mortality. Of these, 5,473 had 
complete data on all determinants in our final model.  
Results 
The final model for estimated fetal weight included the following fetal and maternal 
determinants: gestational age, fetal gender, parity, ethnicity, maternal age, height, 
weight and smoking. At a gestational age of 20 weeks, the effects of the 
determinants were small and not significant, but at 30 weeks the effects were 
significant. By entering the characteristics into the model equation, we developed 
individually customised growth charts. In our study population, of the 495 fetuses 
who were classified as growth restricted (below the P10) when fetal weight was 
evaluated using the unadjusted reference chart, 80 (16%) were in the normal range 
when individually customised growth charts were used. On the other hand, 550 were 
classified as growth restricted using individually customised growth charts, and 135 
(25%) were missed if the unadjusted reference was used. 
Conclusion 
We developed a model to construct individually customised growth charts, adjusted 
for physiological determinants. This is the first study using ultrasound measurements 
in a large population-based study to fit such a model. The use of these customised 
fetal growth charts may improve growth monitoring and prenatal care. 
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Introduction 
Early and accurate detection of fetal growth restriction or macrosomia is important 
for prenatal and early postnatal care (1, 2). In clinical practice, size and weight of 
fetuses are evaluated using standard reference tables for fetal biometry 
measurements. These references do not take into account individual characteristics 
of the fetus. However, it is shown that gender, parity, ethnicity, maternal weight, 
maternal height, paternal height and maternal age are important determinants of 
non-pathological fetal growth variation (3-9). Using standard reference growth charts 
neglects normal variation in fetal growth due to these characteristics, which hampers 
the identification of fetuses with pathological growth abnormalities. Customisation of 
fetal growth charts attempts to adjust for physiological characteristics and so to 
estimate optimal fetal growth or growth potential for an individual. It is shown that 
the use of individually customised growth charts improves the distinction between 
physiological variation and pathological smallness and reduces the false-positive rate 
for the diagnosis of growth restriction (10-14). 
Gardosi et al. developed a method to construct individually customised fetal 
growth charts (www.gestation.net) (15), based on a regression model for birth 
weight, using the determinants gender, parity, maternal height, maternal weight at 
booking and ethnic origin. In this method, the growth curve for estimated fetal 
weight for an individual is derived from the estimated optimal birth weight, using a 
formula for estimated fetal weight depending on gestational age (16). So the 
correctness of the growth curves is depending on the correctness of this formula. 
Furthermore, it is assumed that the effects of all determinants on fetal weight are 
proportional throughout pregnancy. 
To overcome these limitations, we estimated the influences of physiological 
characteristics on fetal growth directly, using ultrasound measurements from a large 
population-based prospective cohort study. We modelled estimated fetal weight 
throughout pregnancy, obtained by an equation using abdominal circumference, 
head circumference and femur length (17), because this is the best overall measure 
of fetal size. In clinical practice estimated fetal weight is mostly used to describe 
growth anomalies (18). We identified which determinants are relevant to be included 
in a multiple regression model, considering statistical and clinical significance and 
availability. Subsequently, using this model, we constructed the individually 
customised growth charts for the participants in our study. We evaluated how their 
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fetal growth is assessed using these customised growth charts, compared to 
assessment using an unadjusted chart. 
Material and methods 
Design 
The Generation R Study is a population-based prospective cohort study, designed to 
study growth, development and health from early fetal life until young adulthood 
(19, 20). Eligible mothers were resident in Rotterdam, the Netherlands, at their 
delivery date (between April 2002 and January 2006). In total, 9,778 mothers were 
enrolled, of which 8,880 during pregnancy. The response rate in the study, 
calculated at birth, was 61% (20). The mean maternal age and other characteristics 
at enrolment were similar to that of all pregnant women in the study area (21). 
During the prenatal period, data were collected from physical examinations, 
questionnaires and fetal ultrasound assessments. The first visit usually took place 
before the 18th week of the pregnancy as part of routine care. Further ultrasound 
assessments took place in mid- (gestational age 18-25 weeks) and late-pregnancy 
(gestational age ≥ 25 weeks) in a research setting (20). Pregnancy outcome was 
obtained from the midwife or physician who attended the delivery. 
The Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam, 
approved the Generation R Study. Pregnant women and their partners received 
written and oral information about the study and gave written consent for use of the 
data. 
Ultrasound measurements 
Ultrasound examinations were carried out in a research setting at a regional health 
facility in early (before the 18th week of gestation), mid (18 - 25 weeks) and late 
(after 25 weeks) pregnancy. Fetal biometry including biparietal diameter (BPD), head 
circumference (HC), abdominal circumference (AC), and femur length (FL) was 
measured during each ultrasound examination using a transabdominal probe. Crown-
rump length (CRL) was measured in early pregnancy if feasible. 
Dating of the pregnancy was performed using the first ultrasound measurement of 
CRL (in case of a CRL measurement <65 mm, corresponding to 13 weeks of 
gestation) or BPD, using dating curves derived from this cohort. Establishing 
gestational age with fetal ultrasound examinations is the most accurate method for 
pregnancy dating (22-25). 
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Standardized ultrasound planes for HC, AC, and FL are described elsewhere (26-
28). Estimated fetal weight was calculated using the formula of Hadlock with 
parameters AC, HC and FL (in cm): estimated fetal weight = 10**(1.326-
0.00326*AC*FL+0.0107*HC+0.0438*AC+0.158*FL) (17). The time period was 
restricted to gestational age of 18 weeks (earliest reliable estimated fetal weight) to 
36 weeks. Visits after 36 weeks were excluded since they were probably performed 
because of suspected pathology. 
Ultrasound exams were performed using an Aloka Model SSD-1700 (Tokyo, 
Japan) or the ATL-Philips Model HDI 5000 (Seattle, Washington, USA) equipped 
with a 5.0 MHz, high frequency curved array transducer. 
Determinants 
As determinants of fetal growth, we considered physiological factors that are fixed at 
the start of pregnancy: fetal gender (coded as male = 1, female = -1), gravidity 
(primigravida = -1, other = 1), parity (nullipara = -1, other = 1), ethnicity, maternal 
age (age groups: ≤ 27 yr, 28 to 32 yr, ≥ 33 yr), height and pre-pregnancy weight as 
well as paternal height. The pathological determinant maternal smoking was used 
because it has a substantial effect on fetal growth (29, 30). For the multivariate 
model, we excluded paternal height, because of its relatively low availability (in our 
study 73%). Because of the high correlation between gravidity and parity, only the 
one with the largest effect was used as potential determinant in the multivariate 
model. 
Information about previous pregnancies, pre-pregnancy weight of the mother, 
smoking habits before pregnancy and ethnicity was collected by a questionnaire at 
enrolment. The response rate for this questionnaire was 91%. In questionnaires in 
mid- and late pregnancy mothers were asked whether they smoked in the past two 
months. Maternal smoking was coded as: smoking in mid or late pregnancy = 1, 
other = 0. Ethnicity of mothers was defined according to the classification of 
Statistics Netherlands (31), using country of birth of her parents. Mothers with 
Moroccan or Surinamese background were asked about their ethnic origin and 
further classified as Surinamese-Hindustani, Surinamese-Creole, Moroccan-Arabic or 
Moroccan-Berber. Height of mother and partner was examined at the first prenatal 
visit. 
Population eligible for analysis 
Of the total of 8,880 mothers who were enrolled during pregnancy, pregnancies were 
excluded in case of multiple pregnancy (n = 93), major fetal anomalies (n = 41), 
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termination of the pregnancy (n = 26) or perinatal mortality (n = 68). Because of 
difficulty in pregnancy dating, women who joined the study after the 24th week of 
pregnancy were excluded as well (n = 339). In 151 pregnancies ultrasound 
observations were only limited, making calculation of estimated fetal weight 
impossible. This resulted in 8,162 pregnancies eligible for analysis with 16,018 
estimated fetal weight observations. 
Statistics 
An unadjusted reference curve for estimated fetal weight was constructed by 
modelling the relation between gestational age and estimated fetal weight, using 
repeated measurement analysis and fractional polynomials (32). Next, the effect of 
each determinant was estimated separately by adding the main term and its 
interaction with gestational age to the model. If the interaction term was significant 
(p < 0.05) it was tested whether adding the interaction with square of gestational 
age was significant. If the interaction term was not significant it was removed from 
the model. 
For the multivariate model, we started with including the potential determinants 
together with maternal smoking, to get estimated effects adjusted for maternal 
smoking. For the construction of a customised growth chart, the term for smoking 
should be set to zero, whether the pregnant woman smokes or not. This provides 
that non-smoking is used as reference. As in the univariate models, interactions of 
the determinants with gestational age were included. Non-significant terms (p > 
0.05) were removed using backward selection. Subsequently, we tested whether an 
additional interaction of a determinant and gestational age squared was significant. 
Because of the increasing effects of the determinants during pregnancy, we 
computed, from the univariate models as well as from the multivariate model, 
estimated differences in estimated fetal weight at gestational ages of 20 and 30 
weeks. For comparison, we also computed estimated differences in birth weight, 
obtained from models using the data of the neonates born after a gestation of 36 
weeks or more. These models included a linear term for gestational age at birth. 
Using the multivariate model, we virtually constructed customised growth charts 
for the participants in our study. Of each participant, the first observation of 
estimated fetal weight after 27 weeks of gestation was assessed, using the 
unadjusted growth reference, derived from our data, as well as using the individually 
customised growth chart. 
For all analyses SAS 8.2 (SAS Institute Inc., Cary, NC, USA) was used. 
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Results 
Table 1 depicts descriptives of the study population. Table 2 provides estimated 
mean, SD, 5th and 95th percentile and width of the 90% reference interval for 
estimated fetal weight at gestational ages of 20 and 30 weeks. For comparison, the 
same descriptives are given for birth weight at 40 weeks. 
In the univariate models, all considered determinants had significant influence and 
all effects were significantly increasing with advancing gestational age. In Table 3, 
the estimated differences in estimated fetal weight between categories of the 
determinants are given for three time points during gestation. At 20 weeks gestation, 
the differences were small and only significant for maternal weight. At 30 weeks, 
almost all differences were significant. 
There were 5,473 subjects with complete data on all candidate determinants for 
the multivariate model (fetal gender, parity, ethnicity, maternal age, maternal height, 
pre-pregnancy weight and smoking habits during pregnancy). The difference 
between the unadjusted curve for estimated fetal weight in this group of complete 
cases and the unadjusted curve for the total 8,162 subjects was less than 4 grams. 
All determinants had a significant contribution to the model and all interactions with 
gestational age were significant. For parity and maternal weight, the interaction with 
gestational age squared was significant. The coefficients of the multivariate model 
are given in the Appendix. In Table 4, the estimated differences in estimated fetal 
weight are presented, derived from this model. Because of the correlations between 
many of the determinants, most of the differences are smaller than the univariate 
differences. It appears that for a Moroccan Berber or a Turkish mother the expected 
estimated fetal weight is larger than for a Dutch or other European mother with all 
other characteristics equal. At 30 weeks gestation, maternal height and weight both 
had significant influence on estimated fetal weight, independent of each other. 
Filling in the individual maternal and fetal characteristics in the regression 
equation given in the Appendix provides an individually customised growth chart. 
The expected mean value and standard deviation of estimated fetal weight at a 
certain gestational age can be computed and these can be used to convert an 
observed estimated fetal weight into a standard deviation (SD) score and a 
percentile. These provide a measure of fetal size, relative to fetuses with the 
specified characteristics. The calculations can easily be done in an Excel-worksheet 
available on our website. 
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Table 1. Characteristics of the study population 
 Median (P5; P95) or percentage 
Male fetus 50.4% 
Primigravida 43.4% 
Nullipara 56.6% 
Ethnicity  
Dutch 59.4% 
Other European 5.9% 
Dutch Antilles 2.4% 
Cape Verdian 3.5% 
Moroccan-Arabic 1.9% 
Moroccan-Berber 3.7% 
Surinamese-Creole 3.2% 
Surinamese-Hindustani 3.4% 
Turkish 8.0% 
Others 8.6% 
Maternal age (year) 30.3 (20.4; 37.8) 
Maternal height (cm) 167 (155; 180) 
Pre-pregnancy weight (kg) 64 (50; 91) 
Paternal height (cm) 182 (169; 195) 
Maternal smoking during pregnancy 17.0% 
 
Table 2. Descriptives of the distribution of estimated fetal weight (EFW) and birth weight 
    90% Reference Interval 
 GA (weeks) Mean (gr) SD (gr) (P5; P95) Width 
20 326 29 (277; 374) 97 
28 1201 124 (998; 1405) 406 
EFW 
36 2568 291 (2091; 3046) 955 
Birth weight 40 3443 447 (2710; 4176) 1466 
The unadjusted reference for EFW is described by: 
mean EFW = 13735 -5.434·107*GA-2 + 4.297·107* GA-2·log(GA) -0.889·107*GA-2·(log(GA))2  and 
SD EFW = -24.659 + 0.00677*GA3. 
The unadjusted equation for birth weight, 36 < GA < 44 weeks, is described by: 
mean birth weight = 3443 + 178*(GA - 40) and SD birth weight = 447. 
GA = Gestational age, P5 = 5th percentile, P95 = 95th percentile. 
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As example, we examined a hypothetical observation for estimated fetal weight of 
1500 g, obtained at a gestational age of 32 weeks for a female fetus, first child of a 
Surinamese-Creole mother, with maternal height 155 cm, pre-pregnancy weight 
45 kg and age 20 yr. Using the unadjusted formula derived in our data (Table 2), the 
expected estimated fetal weight at 32 weeks is 1865 g and the SD 197 g. So an 
estimated fetal weight of 1500 g at 32 weeks is converted to an SD score of (1500 - 
1865) / 197 = - 1.85. The corresponding percentile is P3. When a customised growth 
chart is constructed, using the characteristics of this fetus, the expected estimated 
fetal weight at 32 weeks is 1669 g, with SD 191 g. So taking the physiological 
determinants into account, the SD score for this observed estimated fetal weight is 
(1500 - 1669) / 191 = - 0.89, corresponding percentile P19. 
The relation between the SD score from the unadjusted reference chart and the 
SD score from the individual customised growth chart for the same estimated fetal 
weight observation is depicted in figure 1. From the subgroup with complete data, 
for each fetus the SD scores of the ultrasound measurement in the third trimester 
(gestational age ≥ 27 weeks) was plotted (n = 5,300). Using the unadjusted 
reference, 495 fetuses were classified as too small (compartment A and B). However, 
using individually customised references, 80 of these (16%, A) were classified as 
normal. If the classification was based on individually customised references, 550 
were too small (compartment B and C) and 135 of them (25%, C) were missed when 
the unadjusted reference was used.  
A
n=80 
C
n=135
B
n=415
SD score unadjusted
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Figure 1. Relation between SD score obtained by the unadjusted reference (x-axis) and by 
individually customised references (y-axis). Reference lines are drawn at P10 and P90. 
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Discussion 
In this study, we developed a model to construct individually customised fetal growth 
charts. It is the first time that such a model is fitted using observations of estimated 
fetal weight obtained by ultrasound measurements in a large population-based 
prospective study. With the customised growth charts, fetal growth can be 
evaluated, taking into account the following physiological characteristics: fetal 
gender, parity, ethnicity, maternal height, pre-pregnancy weight and age. All effects 
increased with advancing gestational age. The effects were largest for parity and 
ethnicity. 
Our study cohort comprises contemporary urban children including about 40% 
from ethnic minorities in the Netherlands. The largest ethnic minority groups in this 
population are from the Turkish, Moroccan and Surinamese groups. Of all eligible 
children at birth, 61% participated in the study. National and regional registries do 
not have subject characteristics in all eligible children and their parents that enable 
detailed non-response analyses in our study. The percentages of mothers from 
ethnic minorities and lower socio-economic status among the participants were 
slightly lower than expected from the population figures in Rotterdam (21). This 
resulted in a more healthy study population, possibly affecting the generalizibility of 
the results. 
Pregnancy dating in this study was done by ultrasound measurements of CRL or 
BPD at first visit, which is found to be superior over dating by last menstrual period 
(22-25). However, this procedure neglects possible differences in CRL or BPD, which 
might be correlated with fetal size, at the time of dating. It is possible that this 
caused underestimation of the effects of the determinants, especially in early 
pregnancy. This bias is expected to be smaller when pregnancy dating is performed 
in early pregnancy. In the present study, we excluded pregnancies that were dated 
later than at a gestational age of 24 weeks. In total, in our study population 73% of 
the pregnancies was dated before 18 weeks of gestation. Therefore, we think 
underestimation of the effects in mid pregnancy is possible, but will be very small in 
relation to the effects in late pregnancy. 
We assumed that the formula for estimated fetal weight (17) is appropriate for the 
whole study group. This assumption could be questioned. Body-proportions may 
differ between subgroups. Schild et al. (33) derived formulas for each gender. In an 
evaluation group, these gender-specific formulas fitted better than established 
methods. Unfortunately, they did not derive and evaluate a not-gender-specific 
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formula from their data. As they stated, the gender-specific formulas need to be 
tested in different settings and population. Differences between ethnic groups might 
also be reasonable. To our knowledge, no different formulas for estimated fetal 
weight for ethnic groups or other subgroups are available and it might be doubted to 
which extend this would be realistic. 
The customised antenatal growth charts developed by Gardosi et al. (15) are 
based on a regression model for birth weight, fitted in a very large group of over 
40,000 neonates. The determinants in this model are maternal height and weight, 
ethnic origin, parity and fetal gender. After calculation of the “term optimal weight” 
for a child, a fetus-specific intra-uterine growth chart for estimated fetal weight can 
be constructed using a proportionality equation linking estimated fetal weight during 
gestation to birth weight. So an important assumption for this approach is that this 
proportionality equation is correct for each fetus. It also assumes that the effect of 
each determinant is proportional during pregnancy. Applying the model of Gardosi, 
we derived the effects of the determinants at gestational ages of 24 and 30 weeks 
and compared these with the effects estimated by our model. For example, using the 
model of Gardosi, the estimated difference between male and female fetuses at 24 
weeks is 18 g, using our model it is 5 gr. At 30 weeks these differences are 
estimated as 42 g and 15 g respectively. For the other determinants, our estimated 
effects were also smaller. The model of Gardosi does not include maternal age and 
parity is coded in a different way (separate effects for parity 1, 2, 3 and ≥ 4). This 
may influence the estimations of some effects (e.g. maternal weight, which might be 
related to maternal age), but not all (e.g. fetal gender). Because our model is based 
on estimated fetal weight derived from ultrasound measurements, like in clinical 
practice, we think our charts are better applicable than the charts of Gardosi. 
Other studies on factors influencing fetal growth, using ultrasound measurements, 
have been published before (4-8). Jacquemyn et al. (4) only studied the differences 
between some ethnic groups, while Schwärzler et al. (7) only studied sex-
differences. Mongelli et al. (5) compared different subgroups based on maternal 
weight, maternal height, fetal gender, parity or ethnicity, but did not develop a 
model with all determinants included. Pang et al. (6) developed models for BPD, HC, 
AC and FL but not for estimated fetal weight to avoid potential problems in 
erroneous estimation of fetal weight and to be able to assess growth restriction in 
biometric parameters separately. Most comparable to our study is the study of 
Johnson et al. (8). This study used data of 635 women visiting a low-risk antenatal 
clinic. It did not comprise different ethnic groups, the effects of maternal weight and 
parity were not significant and continuous determinants were categorised. 
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Using customised growth charts enables to identify pathological smallness instead 
of constitutional small size, with normal intrauterine growth. This can prevent 
unnecessary classification as growth restricted. On the other hand, studies have 
shown that failure to detect fetal growth restriction is an important reason for 
suboptimal perinatal care (34). It is not obvious, which factors should be taken into 
account when evaluating fetal growth. Some factors may represent both 
physiological and pathological effects. For example, ethnic differences exist in 
feeding habits and other life-style factors. However, ethnicity also reflects 
constitutional growth potential. Studies have shown, that in ethnic groups with lower 
mean birth weight, the optimal birth weight, defined as birth weight with the lowest 
perinatal mortality, is also lower (35, 36). Parity is another determinant of which 
inclusion in the model is debatable. We adjusted for parity, because it is a 
determinant of the growth potential of a fetus. However, nulliparous women are at 
higher risk of obstetric complications (37) and stillbirths (38). We are not aware of 
any study relating perinatal mortality of first born children and second or later born 
siblings to their birth weight. Therefore, it is not clear whether nulliparity must be 
seen as a physiological determinant, or should be considered as a possible cause of 
intrauterine growth restriction. The effects on estimated fetal weight of parity and 
ethnicity are the largest in our model. Our model can also be used when a 
customised growth chart adjusted for not all but only a selection of determinants is 
preferred. 
In conclusion, we developed a model for individual customised growth charts that 
can be used in clinical obstetric settings. This may improve fetal growth monitoring 
and prenatal care. Further studies are needed to examine whether and to what 
extend the use of customised growth charts can improve predicting which children 
are at risk for perinatal or later morbidity. 
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Appendix 
The formula for the mean estimated fetal weight of an individually customised growth chart is: 
EFW = 17877 – 62328362*GA-2 + 49529740* GA-2*ln(GA) – 10323705* GA-2*(ln(GA))2 
 15*Sexe + 150*Parity + 24*Age2 – 33*Age3 -2.58*Height + 11.27* Weight  
 + 32*Ethn2 + 68* Ethn3 + 30*Ethn4 – 38*Ethn5+130*Ethn6 +46*Ethn7 – 29*Ethn8 + 7*Ethn9 
 + GA* (0.78*Sexe -12.83*Parity – 52.45*Age1 – 53.58*Age2 – 50.76*Age3 
 + 0.1395*Height – 1.0473*Weight 
 - 1.35*Ethn2 - 3.48*Ethn3 - 1.28*Ethn4 + 2.02*Ethn5 – 6.60*Ethn6 
 - 2.63*Ethn7 + 1.57*Ethn8 – 0.37*Ethn9) 
 + GA2* (0.2694*Parity + 0.02476*Weight) 
 
EFW  Estimated Fetal Weight (gr) 
GA  Gestational age (weeks) 
Sexe  Female = -1, Male = 1 
Parity  Nulliparity = -1, Other = 1 
Agegroup Age1: <= 27 yr = 1, other = 0 
  Age2: 28 to 32 yr = 1, other = 0 
  Age3: >= 33 yr = 1, other = 0 
Height  Maternal height - 167 (cm) 
Weight  Pre-pregnancy weight - 64 (kg) 
Ethnicity Ethn2:  Dutch Antilles = 1, other = 0 
  Ethn3: Cape Verdian = 1, other = 0 
  Ethn4: Morrocan-Arabic = 1, other = 0 
  Ethn5: Morrocan-Berber = 1, other = 0 
  Ethn6: Surinamese-Creole = 1, other = 0 
  Ethn7: Surinamese-Hindustani = 1, other = 0 
  Ethn8: Turkish = 1, other = 0 
  Ethn9: Other non-European = 1, other = 0 
 
For construction of a chart without adjustment for one or more determinants, terms for sexe, parity, 
maternal height and weight can just be neglected, because these are centered around zero. For 
agegroup and ethnicity a reference category has to be chosen. 
 
The formula for the standard deviation (SD) for the individually customised growth charts is: 
SD EFW = - 23.0315 + 0.006523*GA 
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n During the last decade, several prediction models are presented in the medical 
literature to predict growth response to growth hormone (GH) treatment. In the 
statistical literature, progress is made in methodologies used to develop and validate 
prediction models. The general aim of the studies presented in this thesis was to join 
knowledge from these two fields. In this way, at one hand, we investigated how 
growth response prediction models can be improved and at the other hand, we 
explored how newly developed methods for modelling could be applied to predict 
growth response. 
This chapter provides a more general discussion of the main findings, considers 
general methodological issues and gives suggestions for further research. 
Validation and calibration of prediction models for 
growth response 
Several prediction models have been developed in order to predict the growth 
response to GH treatment in children with short stature due to GH deficiency (GHD) 
or other causes (1-10). It is well-known that prediction models often perform less 
well than expected when applied to new patients. 
We validated a widely used prediction model for first-year response to GH therapy 
in children with idiopathic GHD (4). As validation data, we used data of 136 children 
registered in the National Registry of Growth Hormone Treatment in Children by the 
Dutch Growth Foundation. Children were selected according to the same in- and 
exclusion criteria as were used for the cohort on which the prediction model was 
developed. 
The observed height velocities (HV) in the first year of GH treatment of the cases 
in the validation group were plotted versus the predicted values. The regression line 
through the points in this plot (called a calibration plot) was fitted (11). The line had 
a slope of 0.808 and was significantly different from the line of identity, where 
observed values are equal to predicted values. This indicated underestimation of the 
lowest predictions and overestimation of the highest predictions. This phenomenon, 
called overfitting or overoptimism of a prediction model, is common when the 
selection of predictors and the estimation of their coefficients in the model are both 
guided by the same data set (12, 13). The predictions obtained by a model that 
suffers from overfitting can be corrected using a simple formula that can be derived 
from the equation of the regression line in the calibration plot (11). This formula 
defines a modified, calibrated prediction model. Compared to the original predictions, 
the predictions obtained by the calibrated model are shrunk towards the mean. In 
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n our validation study, the corrections ranged from +0.92 cm/yr, if the predicted HV 
was 6.4 cm/yr (the lowest prediction in our validation group), to 1.2 cm/yr, if the 
predicted HV was 17.3 cm/yr (highest prediction). Corrections for predictions of in-
between values were smaller, and for a predicted HV of 11.2 cm/yr the correction 
term was zero. 
Subsequently, we obtained the standard deviation (SD) of the residuals (observed 
minus predicted value) of the validation data. As expected, this SD was higher than 
the SD that was reported for the cohort used for the development of the model (4). 
It is well-known that a prediction model is less precise for new data than for the data 
on which it was developed. Another important finding was the dependency of the SD 
of the residuals on the magnitude of the prediction. We found that the residual SD 
was ranging from 1.1 cm/yr for a predicted HV of 7.3 cm/yr (lowest prediction after 
correction) to 3.6 cm/yr when the predicted HV was 16.1 cm/yr (highest prediction 
after correction). This indicated that the higher a predicted HV, the less its accuracy. 
We gave the formula to calculate the residual SD depending on the value of the 
prediction. This SD should be used to calculate the prediction interval when a 
prediction of first-year HV is desired. 
The validity of the calibrated model that was obtained by the analysis presented in 
chapter 2 was checked in a third data set. Patient data (n = 226) were selected from 
another registration database. Predictions of first-year HV were calculated using the 
original prediction model as well as the calibrated model and the performance of 
both models was investigated. 
The analysis showed that, using the original prediction model, the regression line 
in the calibration plot was significantly different from the line of identity, indicating 
overfitting. In the calibration plot of the calibrated model, however, this difference 
was not significant. 
Thus, this study confirmed that, in an independent cohort of children, the 
calibrated prediction model, presented in Chapter 2, did not show overfitting, in 
contrast to the original prediction model. 
Previously reported prediction models for growth response were validated but 
none was adjusted based on the results of the validation. None of the models was 
validated according to the method we described in chapters 2 and 3. The issue of 
overfitting was not addressed. Only for the model presented by Albertsson-Wikland 
et al. (1), it was mentioned that prevention of overfitting was part of their method. 
Conclusion: Overfitting was present in a prediction model for first-year growth 
response to GH treatment. Using the results from the validation, a calibrated model 
was obtained. Predictions calculated with this calibrated model are corrected for 
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n overfitting and are less extreme compared to the original predictions. Validation of 
both the original and the calibrated model in a third data set confirmed the 
improvement of the model after calibration. These two studies showed that this 
method of validation and calibration is well applicable and improves the quality of 
prediction models. 
Since almost all growth prediction models currently used in practice are not 
corrected for overfitting, one should take care in using them, in particular if the 
resulting prediction is relatively large of small. 
Prediction of adult height in GH treated children with 
GHD 
Models to predict long-term growth response to GH treatment in children with GHD 
did not exist. We therefore developed models predicting adult height (AH). The 
models are described in chapter 4. It is desirable to have a prediction of AH before 
starting GH treatment, in order to get information about the long-term results of the 
treatment. Application of the prediction model (Start model) will give a patient his or 
her individual predicted value along with a prediction interval. It can identify patients 
with a high or low chance to benefit from GH treatment. Prior to our study, several 
studies found that the growth response in the first year of treatment is highly 
predictive for the response in the second year (4, 14) and in the third and fourth 
year (4, 14). Therefore, we also developed prediction models using the patient 
information available after one year of treatment (First-year model). 
For the development of the models, we used advanced statistical methods. This 
included dealing with missing data (15, 16), flexible modelling of the relationships 
between continuous determinants and the outcome (17), checking the significance of 
pre-specified interactions and correction for overfitting (18). Because of the large 
influence of puberty on growth, separate models were needed for prepubertal and 
for pubertal children. The data used in this study came from the National Registry of 
Growth Hormone Treatment in Children by the Dutch Growth Foundation. In total, 
342 patients were selected with a diagnosis of GHD or with a maximum GH response 
during provocation tests of less than 11 ng/ml. They should have been treated with 
biosynthetic GH for at least one year and should be at an age that guaranteed AH 
had been reached. Stepwise forward selection was used to determine the predictors 
in the models. For continuous predictors, we tested whether adding a transformation 
of the variable improved the model significantly (19). Next, the significance of some 
pre-specified interactions was tested. 
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first year of GH treatment) and target height (TH) SDS as most important predictive 
factors. In the models for prepubertal children, we found a positive effect of female 
gender and of multiple pituitary hormone deficiencies. The negative effect of bone 
age in the Start model for prepubertal children shows that start of GH treatment at a 
younger age gives a higher growth response. The positive coefficients for bone age 
delay (chronological age minus bone age) in the other three models reflect that 
children with delayed bone age have more growth potential. Maximum response to 
GH provocation tests is included in the Start model for prepubertal children (negative 
effect), but is not significant anymore in the First-year model. A similar finding was 
reported by Cole et al. (14). Both First-year models include change in height SDS 
during the first year, which is in line with several other studies (8, 10, 20, 21). 
In none of the models, GH dose was found to be a significant predictor variable. 
First of all, it should be noted that the data on which the models were developed 
were not suitable to estimate a dose effect of GH, as this can only be done in data 
from randomised clinical trials. Our data came from a registration database. The GH 
dose at start and during treatment was determined by the treating physician. The 
criteria used for dose assessments were unknown. It is possible that higher initial 
doses were prescribed to patients with supposed worse prospects, like children close 
to or entering puberty, children with only mild GHD or children with very short 
parents. During treatment, a change of GH dose might have been guided by the 
obtained growth response. Even if any GH dose effect would have been found, this 
could not be interpreted as a causal effect of GH dose on AH. Furthermore, although 
a significant positive effect of GH dose on short-term growth response is often found 
(4, 22, 23), a dose-effect on long-term response is less established (8, 20, 24). It 
might be that the short-term dose effect wanes over the years because other 
influences become more important. Or it might be that a high dose of GH treatment 
causes more acceleration of bone maturation on the long term, leading to earlier 
cessation of growth. 
We performed internal validation of the models by bootstrapping (25). This is a 
recently developed advanced statistical method to correct for overfitting. It is already 
a well-established method in biostatistics, while practical applications in medical 
research are still quite rare, especially in the field of growth research. To the best of 
our knowledge, we were the first to apply this method in the field of growth 
hormone research. 
This is a well-established statistical method to come to a prediction model 
corrected for overfitting. It results into a prediction formula in which the coefficients 
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values for the explained variance (R2) and for the residual SD. With these 
corrections, the true performance of the model in new data is given. 
For our models, the corrected percentages of explained variance in AH SDS 
ranged from 37% (prepubertal group, Start model) to 60% (pubertal group, First-
year model). Given the fact that the outcome AH is usually several years ahead from 
the moment of prediction, it was reasonable that a substantial part of the variance 
remained unexplained. During GH treatment, several factors, which are unknown at 
the time of prediction, may influence the growth of a child. 
One reason to develop the First-year models was to investigate if such a model 
could provide a criterion for the first-year growth response required to attain an AH 
in the normal range. Indeed, our study showed that change in height SDS during the 
first year of treatment is highly related to the attained AH. This might indicate that, 
as a positive correlation between GH dose and first-year response is well established 
(4, 14, 26), one might tend to give a high GH dose in order to increase the first-year 
response, with the idea that this will subsequently increase AH. However, we found 
an inverse relation between the GH dose in the first year and AH, although this did 
not reach significance. This indicates that a first-year growth response obtained by a 
high GH dose will give a lower predicted AH than the same response obtained by a 
low GH dose. The First-year models can be used as a response criterion for first-year 
growth response only when the GH dose given during the first year is determined in 
the same way as done for the patients in our data set and when the GH dose is in 
the same range. 
Conclusion: We developed models for AH prediction in children with GHD treated 
with GH. Separate models for prepubertal and pubertal children were developed, and 
models to obtain a prediction at start of treatment as well as models that provide a 
prediction using the available data after one year of treatment. These models can be 
a useful tool for decisions about GH treatment of children with GHD. 
Prediction of adult height in GH treated SGA children 
For children born SGA with persistent short stature, for which GH treatment is 
considered, it is very useful to get some information about the expected AH for an 
individual child and how this expected AH is related to the dosage of GH treatment. 
In chapter 5, we presented a model developed to predict height SDS at onset of 
puberty and AH. 
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n We used data of 150 SGA children who were involved in two clinical trials 
concerning GH treatment. Children were selected who were prepubertal for at least 
one year after start of GH treatment and had started or completed puberty. 
Furthermore, birth year had to be prior to a specified year, to avoid 
overrepresentation of children with early puberty. We developed a model for the 
outcomes height SDS at onset of puberty and AH SDS, using mixed effects repeated 
measurements analysis. 
The determinants for AH SDS were height SDS at start, TH SDS, GH dose, bone 
age delay at start (positive effects), and IGFBP-3 SDS at start (negative effect). A 
significant interaction was found between GH dose and IGFBP-3 SDS, with a negative 
coefficient. This means that the effect of a higher dose depends on the level of 
IGFBP-3 of the child: a lower IGFBP-3 SDS at start is related to a larger GH dose-
effect. For a child with an IGFBP-3 of -2 SDS, the expected difference in AH is 0.65 
SDS (approximately 4.6 cm) when treated with 0.067 mg GH / kg·day compared to 
0.033 mg GH / kg·day. For a child with an IGFBP-3 of 0 SDS, this difference is only 
0.11 SDS (0.8 cm). 
For height SDS at onset of puberty, the model explained 57% of the variance and 
for AH SDS 41%. These percentages gave a realistic presentation of the performance 
of the model because we did correct for overfitting, as explained before. 
When this prediction model is used in deciding on the GH dose to be prescribed, 
one has to determine the objective of GH treatment. This objective can be defined in 
terms of the absolute AH, for which the goal will generally be an AH above -2 SDS. 
The TH range, usually defined as the TH +/- 1.3 SDS, could also be taken as goal. 
Thirdly, a substantial gain in height SDS during treatment might be regarded as a 
reasonable goal. When, for an individual child, the predicted AH is unsatisfactory in 
case of a GH dose of 0.033 mg/kg·day, a higher dose might be considered. 
Conclusion: We developed a prediction model for long-term response to GH 
treatment in short children born SGA. The model included GH dose as determinant 
and the effect of GH dose was depending on the level of serum IGFBP-3. The model 
can be helpful in the decision about the optimal GH dose for a child. Because the 
data set used in this study was of limited size, it could be very useful to perform a 
meta-analysis combing data of several randomised clinical trials. This could possibly 
provide more information about the GH dose effect and its relation to certain patient 
characteristics. 
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Spontaneous growth of SGA children without early 
catch-up growth 
Eighty-five percent of children born SGA will show catch-up growth to a height in the 
normal range before 2 years of age. In the other 15%, there are some children with 
late catch-up growth. It would be very informative if, in an early stage, it could be 
predicted which children will have this catch-up growth and which children will not. 
In chapter 6, we presented a study of the growth of SGA children with a height 
still below -2 SDS at 2 years of age. These 97 children came from a cohort of 724 
SGA children, of whom the growth during the first two years of life was previously 
described (27). We found that 39% of these 97 children (6% of the original cohort) 
had catch-up growth to a normal height between 2 and 8 years of age. While during 
the first two years of life the percentage children with catch-up growth was highest 
in infants born full-term, in the period after 2 years of age, the percentage was 
highest in infants born preterm. 
Furthermore, we developed a model to predict the spontaneous growth of SGA 
children after 2 years of age using the prepubertal height measurements of these 
children between 2 and 8 years of age. Predicting factors in this model were the 
difference between height SDS at the age of 2 years and TH SDS, gender of the 
child, multiple birth and the difference between height SDS at the age of 2 years and 
birth length SDS. We showed how this model can be used to predict the height SDS 
at 8 years of age when a child is 2 years of age. In addition, the model provides the 
probability that, at 8 years of age, a height in the normal range will be reached. 
A larger data set may provide a prediction model with higher accuracy. However, 
long-term follow-up of untreated SGA children becomes increasingly scarce as many 
SGA children are nowadays treated with GH. Good registration of pre-treatment 
growth data of SGA children might be useful. 
Conclusion: Catch-up growth to a normal height occurred in 91% of SGA 
children, in 6% between 2 and 8 years of age. The difference between height SDS at 
2 years of age and TH SDS was the most important determinant. The presented 
prediction model can identify children with low or high probability of catch-up growth 
to a normal height. This may assist to determine which children require medical 
follow-up. 
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Determining mean adult height from incomplete follow-
up data 
In long-term growth studies with AH as outcome, often reporting is required while 
data are still incomplete because some participants have not yet reached AH whereas 
others might be lost to follow-up. Until now, there has not been any effort to analyse 
incomplete follow-up of growth data in a more sophisticated way than simply using 
the cases that have reached AH and disregarding the other cases. Also when 
reporting is done for patients from e.g. a registry, usually the same procedure is 
followed: cases that have reached AH are selected. However, in these situations, the 
subgroup used for analysis is not a representative selection of the complete group. 
This can give biased results because the AHs of the patients who did reach AH earlier 
in follow-up might be different from the AHs of the other patients. Using only the 
observed AHs also ignores all observed follow-up of the patients that did not yet 
reach AH, despite the fact that these data contain valuable information. 
In chapter 8, we introduced a more advanced method to estimate the mean AH of 
a group with partly incomplete follow-up data. The method was originally developed 
for cost-effectiveness analyses (28). We illustrated the validity of the method for 
growth data by applying it to artificially generated growth data in a simulation 
process. In that situation, the true mean and standard deviation (SD) of AH in the 
population is known. Furthermore, we showed results of the new method applied to 
two data sets. One data set was selected from the National Registry of Growth 
Hormone Treatment in Children by the Dutch Growth Foundation. Inclusion criteria 
were birth year and the availability of growth follow-up until AH. We censored the 
follow-up data artificially. We compared the mean AH obtained from the complete 
follow-up with the estimated means using the censored follow-up, based on the 
commonly used method as well as based on the presented new method. The other 
data set consisted of 39 children participating in a clinical trial and treated with 
biosynthetic GH until AH. These represented a realistic situation of a growth study. 
We computed the estimated mean AH for males and females using the data known 
at time points with two-year intervals during the last years of follow-up of the study. 
Again we compared the results with the estimated mean AH using the complete 
data. 
We showed that the new method gives estimated means with only very small bias, 
even in case of correlation between AH and the age of reaching AH. The efficiency of 
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deviation of the estimations. 
The method will give valid results, provided that eventual loss to follow-up is not 
related to the outcome AH. In practice, this assumption will be fulfilled, since almost 
all censoring is due to the patients not having reached AH yet at the time of the 
analysis. If drop-out is due to disappointing growth, the method cannot correct for 
this type of loss, nor can any other method. The method can be carried out in 
standard statistical software. 
Conclusion: Incompleteness of follow-up data in growth studies is until now 
more or less neglected. The method we presented provides valid mean AH 
estimations if complete actual measurements of AH are not (yet) available, provided 
that and loss to follow-up is not related to growth. While in this method also the 
observed data of study-participants with incomplete follow-up data are used, it 
makes more effective use of the data collected. More research on the analysis of 
incomplete growth follow-up data would be worthwhile. 
Individually customised fetal weight charts derived 
from ultrasound measurements 
While normal fetal growth is influenced by several characteristics of the fetus and its 
parents (29-35), fetal size should be evaluated taking into account important 
physiological characteristics, like gender, parental anthropometrics and ethnicity. 
Individually customised fetal growth curves are in fact reference growth charts that 
are adjusted for important characteristics. Use of these charts makes it possible to 
identify pathological smallness instead of constitutional small size with normal 
intrauterine growth. This can prevent unnecessary classification as growth restriction 
(36-39). On the other hand, studies have shown that failure to detect fetal growth 
restriction is an important reason for suboptimal perinatal care (40). 
In chapter 7, we presented a model that can be used to construct individually 
customised fetal growth charts. For the development of the model, we used data 
from the Generation R Study, a prospective, population-based cohort study. We 
included ultrasound measurements, taken repeatedly during pregnancy, of 5,473 
pregnancies. 
Our final model for estimated fetal weight between 18 and 36 weeks of 
gestational age included as determinants fetal gender, parity, ethnicity, maternal 
height, pre-pregnancy weight, age of the mother and smoking. The effects of the 
determinants all increased with advancing gestational age. We evaluated the fetal 
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n sizes measured in the third trimester of pregnancy (gestational age ≥ 27 weeks). In 
the group of fetuses classified as too small (≤ -1.28 SDS) using the unadjusted 
reference chart, 16% had a size in the normal range when individually customised 
reference charts were used. 
Our study was the first one fitting a model for customised fetal growth charts 
using observations of estimated fetal weight obtained by ultrasound measurements 
in a large population-based prospective study. 
It is not obvious which factors to take into account when evaluating fetal growth. 
Adjustment has to be done only for physiological factors, but some factors may 
represent both physiological as well as pathological effects. For example, ethnicity 
reflects constitutional growth potential, but may also represent differences in feeding 
habits and other life-style factors. Studies have shown that in ethnic groups with 
mean birth weight lower compared to other groups, the optimal birth weight, defined 
as birth weight with the lowest perinatal mortality, is also lower (41, 42). This points 
to the physiological aspect of ethnicity as determinant of fetal growth. Parity is 
another determinant of which inclusion in the model can be discussed. We adjusted 
for parity, because it is a determinant of the growth potential of a fetus. However, 
nulliparous women are at higher risk of obstetric complications (43) and stillbirths 
(44). We are not aware of any study relating perinatal mortality of first born children 
and second or later born siblings to their birth weight. Therefore, it is not clear 
whether nulliparity must be seen as a physiological determinant, or should be 
considered as a possible cause of intrauterine growth restriction. The 
parameterisation of our model makes it possible to disregard a determinant if one 
does not want to adjust for it. 
The customised antenatal growth charts developed by Gardosi et al. (45) were 
based on a regression model for birth weight, fitted in a very large group of over 
40,000 neonates. Some assumptions were needed to derive intrauterine growth 
charts from a calculated “optimal birth weight” for an infant. Our model is based on 
estimated fetal weights derived from ultrasound measurements. In clinical practice, 
fetal size is determined in the same way. Therefore, we think our curves suit better. 
Conclusion: Our study showed that individually customised fetal growth charts 
can very well be derived from ultrasound measurements collected during pregnancy. 
It has been demonstrated in other studies that the use of customised growth charts 
may improve fetal growth monitoring and prenatal care. Our model, derived using 
data from a large population based study comprising several ethnic groups, will 
contribute to this. 
  146
Ch
ap
te
r 
9 
- 
G
en
er
al
 d
is
cu
ss
io
n 
Prediction models for growth response: methodological 
aspects 
Imputation of missing values 
Imputation of missing values, which enables to perform analyses on a total data set, 
is hardly done for growth analyses, although the advantages are well established. 
Usually, the analysis is done on the subset of patients with complete data. This can 
lead to considerable bias and loss of power. Imputation methods can avoid the 
disadvantages of such a complete cases analysis. 
Imputation can be performed in an extensive way, using for example the 
procedure MICE (46), implemented in S-Plus and in Stata. With MICE, imputation can 
be performed in a multiple fashion using all relations between all variables in the 
data set. It is possible to specify which variables are categorical and to indicate 
which variables should be used as predictors for the imputation of others. Such an 
extensive procedure is worthwhile when a large data set can be imputed as a whole. 
The resulting set of imputed data sets (usually five) can be used for several analyses. 
In many cases, however, a data set is “dynamic”. For instance, in a registration 
database, patients are added continuously and follow-up of the registered patients is 
extending throughout the years. In longitudinal clinical studies, follow-up is 
increasing and analyses with the available data will often be performed before the 
study has finished. This means that the data set is continuously growing and it does 
not suffice to impute the data set only once, as one extensive project. 
The data sets we used in the studies presented in chapter 4, 5 and 6, were 
selections from larger databases, which will extend further in number of patients 
and/or in follow-up. We used the procedure Proc MI in SAS (47). This procedure 
assumes that all variables are normally distributed, and all can be correlated to each 
other. The correlations are estimated from the data and subsequently used for the 
imputation of the missings. We included all available variables that could hold 
information about variables with missings. The variables with missings in our data 
sets were all continuous variables. We checked the distribution of all variables and if 
needed a transformation was performed to get a normally distributed variable. The 
assumption of a normal distribution for a dichotomous variable like gender or for an 
ordinal variable, like severity of GHD is of course artificial, but is adequate for 
describing the relation with the continuous variables to be imputed. 
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if only cases with complete data are selected. It will improve the quality of growth 
prediction models. For situations that are not too complex, a simple imputation 
method will satisfy. 
Modelling continuous predictors 
Using only straight-line relations between a continuous determinant and the outcome 
in a regression model might be insufficient. Though this is the first relation to be 
considered, another type of relation might fit significantly better. For example, for 
treatment with small doses of GH, each unit increase in dose might have a 
substantial effect on the growth response, while in the range of higher doses the 
effect of one unit increase might be much smaller. One way to model such a relation 
more flexibly is the use of polynomial models, in practice adding a quadratic term of 
the determinant. This is, however, often unsatisfactory. Another simple possibility is 
to investigate the relation using a transformation of the determinant, like the 
logarithm. Royston and Altman (17) proposed to test a range of transformations of 
the covariable for possible superiority over the straight line relation. Then, next to a 
first term, the significance of adding a second term could be tested. So their 
proposed method involves comparing several models, e.g. when considering two 
terms, 36 models should be evaluated. 
Our analyses presented in chapters 4 and 5 included stepwise forward selection 
procedures, involving several continuous covariables. The selection procedures had 
to run automatically because they were repeated in the bootstrap procedure 
hundreds of times. Therefore we simplified the procedure of finding the best relation. 
If a continuous covariable was selected as determinant in a model, we tested the 
addition of a transformed term. In this way only a limited number of fractional 
polynomials with two terms were considered. In three of the models presented in 
chapter 4, quadratic terms of height SDS were included. The quadratic term was the 
term we tested first. In the model presented in chapter 5, no transformation terms 
turn out to be included. It might have been that the data set was too small to have 
sufficient power for a second term coming in. 
Conclusion: Growth prediction models will improve if more flexible relations 
between continuous predictors and the outcome will be considered. We used an 
approach related to the theory on fractional polynomials. For these types of analyses, 
this was a good compromise between the theoretical and the practical optimum. 
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Interactions terms 
In the development of growth prediction models, consideration of interaction terms is 
hardly done. One reason might be that this complicates the procedure. Another 
obstructing factor might be that interaction terms are often not well understood and 
sometimes criticized as artificial and incomprehensible. On the other hand, it is well 
recognised that there is heterogeneity in patient groups. Therefore, sometimes the 
size of the effect of a determinant depends on another determinant and it is not 
sufficient to estimate just one constant effect. For example, the effect of GH dose 
might be depending on the age of the child. In some situations, models are 
developed for different subgroups (48). However, the use of interaction terms is 
often much more efficient. 
For the models presented in chapter 4, we tested the interactions between age 
(chronological age and bone age) and TH SDS, and between age and the change in 
height SDS during the first year. For the model in chapter 5, all interactions with GH 
dose were tested. These possible interactions were pre-specified based on clinical 
knowledge and not on the data. 
Conclusion: Considering interaction terms and including them when relevant, will 
improve the quality of growth prediction models. With good explanation and 
illustration of the meaning of an interaction term, one will become more familiar with 
this extension of modelling. 
Correction for overfitting 
A growth prediction model developed on one specific data set should be corrected 
for overfitting. Only after such a correction, the model will give good predictions for 
other children and the predictive performance, indicated by the percentage of 
explained variability and the residual standard deviation, can be given correctly. 
Correction for overfitting of a linear regression model can be done either by internal 
validation, using bootstrapping (applied in chapters 4 and 5) or cross-validation, or 
by external validation (applied in chapter 2). A corrected model will give better 
predictions and will provide the actual accuracy of the prediction. For external 
validation of models, which is still very useful after internal validation and correction 
for overfitting, collaboration between research groups and organisations holding 
registries with data of GH-treated children, would be very helpful in order to obtain 
larger validation groups. 
Conclusion: Checking the presence of overfitting and correction for it is 
necessary for any growth prediction model. Adopting this as common practice, the 
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for children with growth impairment. 
Concluding remarks 
Application of prediction models for growth response 
In the last decade, progression has been made in the area of prediction of growth 
response to GH treatment. With caution, the following suggestions can be given for 
the use of the models presented in this thesis: 
In case a child with GHD is going to start GH treatment, it would be very 
informative to calculate the predicted HV during the first year of treatment, using the 
calibrated model (a correction of the KIGS model) presented in chapter 2, as well as 
the predicted AH, using the Start-model presented in chapter 4. Both predictions, 
with prediction interval, provide information for the patient, its parents and the 
treating physician, about the prospects on the short-term as well as on the long-
term. The prediction of first-year HV might be used to adjust the dose of GH, in case 
the standard dose gives a low prediction. However, one should be reluctant to give 
high doses. After one year of treatment, the first-year HV should be compared with 
its prediction. If the observed HV is substantially lower than the prediction, one 
should trace possible causes, like compliance and somatic or psychological factors 
influencing growth. Next, a new prediction of AH can be calculated using the First-
year model presented in chapter 4. Taking into account this new prediction for AH, 
one might decide about the continuation of GH treatment or adjustment of the dose. 
A higher dose might result in a higher growth response, but unfortunately we are not 
yet able to specify a quantitative dose effect. Also, it is likely that the effect of a 
higher dose depends on patient characteristics, for example age or the maximum 
response to GH provocation tests. When the patient has reached AH, it is interesting 
to compare the observed AH and the prediction and to look for explanations. This 
might provide information for the clinical care of future patients. 
For children born SGA with a height still below -2 SDS at 2 years of age, a 
prediction, along with prediction interval, of the height at 8 years of age should be 
calculated using the model presented in chapter 6. It might be that this prediction 
does not provide very specific information, because the predicted value is rather 
close to -2 SDS, so the prediction interval is more or less half in the normal range 
and half below. However, for some children, the prediction interval will be for the 
larger part, or as a whole, below the -2 SDS, indicating a very low chance that a 
normal height will be reached. This information can be given to the parents of the 
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prediction interval will mainly be in the normal range. The frequency of follow-up 
visits might be decreased for these children. When a short child born SGA starts GH 
treatment, predictions of height at start of puberty and of AH can now be calculated 
(chapter 5). Especially the prediction of AH should be used to determine whether a 
dose of 0.033 mg GH / kg·day (= 1 mg/m2·day) is sufficient. Otherwise, the required 
dose can be calculated using the provided formula, with a maximum of a 0.066 mg 
GH / kg·day. 
It is still the case that prediction models are an underused tool in clinical practice. 
One of the causes is that it takes some effort to compute a prediction, e.g. because 
patient characteristics have to be converted using reference data. It may be 
worthwhile to provide easy to use tools for the calculation of predictions. For patients 
registered in a central database, the treating physician can be provided with 
predictions for short-term as well as long-term response. Well-developed prediction 
models will certainly provide useful information. Regular use of prediction models 
and comparing predictions and observations of patients will in the long run show the 
value of a prediction model. 
Recommendations for future research 
The lack of evidence about the size of the GH dose effect on AH in children with GHD 
might be one of the challenges for the coming years. Only a few randomised clinical 
trials on GH dose in children with GHD(22, 23) have been published, and new trials, 
covering the whole period until AH will not easily be set up. It may be feasible, to set 
up a study in which randomisation into two or more doses is done based on the 
prediction of AH. For example, only patients with a prediction below a certain level 
could be randomised into a group receiving the standard dose and a group receiving 
a higher dose. The other patients could receive the standard dose. Trying to estimate 
the causal effect of the GH dose from non-randomised data sets is not impossible but 
very complicated and needs very large data sets with sufficient follow-up 
measurements. 
For the treatment of SGA children, we were able to estimate a dose effect, 
because we could use data of patients that were randomised into two doses of GH 
treatment (chapter 5). We found that the dose effect depends on the level of serum 
IGFBP-3. We realise, that the size of our sample was limited and recommend further 
analyses on larger data sets. 
Future research in larger patient groups may identify more significant 
determinants of AH in GH treated children. Continuous determinants may be 
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expected that information on genetic characteristics of children will contribute to 
better prediction (49). 
For the development of growth prediction models, data of sufficient quantity and 
quality are needed. Data of children using GH treatment are included in registries of 
some pharmaceutical industries and some national registries, like in the Dutch 
National Registry of Growth Hormone Treatment in Children. Although these 
registration databases comprise heterogeneous groups, the data sets are often large 
and they do reflect clinical practice. Detailed information on patient characteristics is 
preferable to provide high quality analyses. Collection and registration of data require 
financing, but the results of the analyses will improve our knowledge and will lead to 
recommendations that might save money. 
For indications for which GH treatment is approved, it will be more difficult and in 
some situations unethical to set up clinical trials with randomisation of patients into 
different treatment doses. However, studies could be set up for subgroups of 
patients, for which there is no consensus about the optimal dosing. Another 
possibility is to randomise the patients into different dosage strategies, for example 
constant dosing throughout the treatment period versus adjusting the dosage 
depending on the growth response. 
In conclusion, the recommendations of this thesis may serve to contribute more to 
the progress which has already been made during the last decade, in the prediction 
of growth response to GH treatment. However, many challenges still exist. The 
improvement of prediction models for growth response will be attributable to the 
greater availability of genetic and biochemical data, coupled with advanced methods 
for the development of such models. 
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y In Chapter 1, the background of the topics of this thesis is presented. Some aspects 
of growth, prenatal as well as postnatal, and growth regulation are described. The 
studies in this thesis concern two groups of children with impaired growth, namely 
children with growth hormone deficiency (GHD) and children born short for 
gestational age (SGA). Some information about these patient populations is given, 
including treatment with growth hormone (GH). The current state of art with regard 
to prediction models for growth response to GH treatment is described. 
 
Chapter 2 describes validation and calibration of a model published in 1999, for 
prediction of growth in children with idiopathic growth hormone deficiency (IGHD) 
during GH therapy. This model, predicting growth in the first year of GH therapy, 
was validated using data of 136 Dutch children with IGHD. We plotted the observed 
height velocities (HV) of the validation group versus the predicted HV in a calibration 
plot. A regression analysis was done with observed HV as outcome. The regression 
line was significantly different from the line of identity (where observed HV is equal 
to predicted HV) and the estimated slope was 0.808. This indicated that the model 
suffered from overfitting, a well-known phenomenon in the context of prediction 
models. Therefore, the estimated coefficients from the regression analysis were used 
to determine a calibration correction for the model. This correction was described by 
the formula: Ycal = Yorig + (2.153 - 0.192 * Yorig), where Ycal is the calibrated 
prediction and Yorig the original prediction. The calibrated prediction will be higher 
than the original prediction when the original prediction was below 11.2 cm/yr and 
lower otherwise. The variability of the prediction errors of the calibrated predictions 
was positively related to the value of the prediction (p < 0.001), described by the 
equation SDpred err = -1.017 + 0.286 * Ycal. 
Our modification of the original prediction rule will give better predictions for 
children with IGHD fulfilling the same criteria. 
 
In Chapter 3, we validated the modified prediction model from Chapter 2 in an 
independent cohort of 226 patients. For the modified as well as the original 
prediction method, observed first-year height velocity (HV) was plotted vs. predicted 
HV in a calibration plot. The regression line in the calibration plot of the modified 
model was not significantly different from the line of identity (p = 0.43), in contrast 
to the original model (p < 0.001). For the modified model, the mean (SD) prediction 
error was -0.11 (2.05) cm/yr and for the original model 0.28 (2.11) cm/yr. 
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original model, performed well in an independent patient sample and gave more 
accurate predictions than the original model. 
 
Since a prediction model for long-term response to GH treatment in children with 
GHD had not yet been presented, in Chapter 4 we describe models we developed 
for prediction of adult height (AH), using information available at start of GH 
treatment (Start model) or after one year of treatment (First-year model). Data were 
collected from the National Registry of Growth Hormone Treatment in Children, 
which contained data of Dutch children treated with GH. Main inclusion criterion was 
a diagnosis of GHD or a maximum GH response during provocation tests < 11 ng/ml. 
The children had to be treated with biosynthetic GH for at least one year. To be able 
to use the complete selection of 342 children for the development of the models, 
multiple imputation was used for missing values. The predictions models, obtained 
by stepwise forward selection of determinants, were corrected for overfitting by 
bootstrapping. We developed separate models for prepubertal and for pubertal 
children, with outcome AH SDS. 
In each prediction model TH SDS as well as current height SDS were significant 
determinants. In the First-year models, the change in height SDS during the first 
year proved to be an important predictor. The percentage explained variance, after 
correction for overfitting, ranged from 37% (prepubertal children, Start model) to 
60% (pubertal children, First-year model). 
In none of the models, GH dose was selected as significant predictor. For the 
patients in our data set, the GH dose at start and during treatment was assessed by 
the clinician based on unknown criteria. It is possible that higher initial doses were 
prescribed to patients with supposed worse prospects and that during treatment a 
change of GH dose might have been guided by the obtained growth response. Our 
data were therefore not suitable to estimate the effect of GH dose on AH SDS. 
The presented prediction models give accurate predictions of AH for children with 
GHD at start and after one year of GH treatment. They are useful tools in the 
treatment of these children. 
 
In Chapter 5, a model is presented for prediction of height at onset of puberty 
and of AH in short children born SGA and treated with GH. While GH treatment is 
approved for these children, the optimal dose is not yet established. 
Data to develop this model came from two GH trials in short SGA children. We 
selected 150 children with height at start of treatment below the -2 SDS, age 3 years 
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least one year of GH treatment prior to onset of puberty. In one of the trials, patients 
were randomly assigned to either 0.033 or 0.067 mg GH / kg·day; in the other trial 
all received 0.033 mg GH / kg·day. In 71 children, AH was reached. 
Important finding was the significant contribution of serum IGFBP-3 SDS at start 
and the significant interaction between GH dose and IGFBP-3 SDS, indicating a 
smaller GH dose effect for higher levels of IGFBP-3. The final model explained 57% 
of the variance in height SDS at onset of puberty and 41% of AH SDS (percentages 
corrected for overfitting). 
These findings implicated that measurement of IGFBP-3 in SGA children is needed 
to establish the effect of GH dose and to obtain a prediction for AH. The presented 
model provides useful information about the expected long-term growth. Because GH 
dose is one of the determinants, the model aids to determine the optimal GH dose 
for each child. 
 
Chapter 6 describes a study on catch-up growth in SGA children. While the 
majority of children born SGA has catch-up growth during the first years of life, 
about 10-15% still has a height below the normal range (< -2 SDS) at the age of 2 
years. The aim of this study was to determine the percentage of children with catch-
up growth to a normal height after the age of 2 years and to develop a prediction 
model for growth after that age. 
In a cohort of 724 SGA children, 109 had a height below -2 SDS at the age of 2 
years. Ninety-seven could be included in this study. Thirty-nine percent of them 
reached a height above -2 SDS between 2 and 8 years (6% of the total group). Most 
important determinant of growth after the age of 2 years was the difference between 
TH SDS and height SDS at 2 years of age. The residual SD was 0.54 and the 
percentage variance explained by the model was 44%. With a predicted value and 
SD, probabilities can be computed, for example, the probability to reach a height 
SDS at 8 years of age above -2.5, or above -2.0. 
The presented prediction model can identify children with low or high probability 
of catch-up growth. This may be useful to determine which children require medical 
follow-up. 
 
In long-term growth studies with adult height (AH) as outcome, often reporting is 
required while data are incomplete. Some participants have not yet reached AH 
whereas others might be lost to follow-up. Current practice is to analyse only 
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we describe a new method, developed for analyses of cost-effectiveness. 
The method requires growth data at fixed time intervals during follow-up. The 
mean AH is estimated using the estimated probability of still growing at the start of 
each interval and the mean growth in each interval. 
We illustrated the validity of the method for growth data by applying it to 
artificially generated growth data in a simulation process. In that situation we know 
the true mean and standard deviation (SD) of AH in the population. We used five 
different imaginary growth scenarios, with different relations between AH and the 
age at which AH is reached. With this simulation study, we showed that the 
proposed new method had only a very small bias (less than 0.2 cm) in each scenario. 
The standard deviations were smaller than those of the other methods used for 
censored data, showing that the method is statistically more efficient. 
We applied the method to data of patients from a registration database and data 
of a GH trial. The estimated means had smaller bias and standard error than 
estimations with commonly used methods. The method is not hampered by a 
correlation between AH and the age at reaching AH. So in contrast to commonly 
used methods, the new method provides valid results on mean AH when complete 
actual measurements of AH are not (yet) available. As it also uses observed data of 
children with incomplete follow-up, the method employs the data more effectively. 
 
Chapter 8 describes a model concerning prenatal growth. In clinical practice, size 
and weight of fetuses are evaluated using standard reference tables for fetal 
biometry measurements. However, this neglects normal variation in fetal growth due 
to characteristics like gender, parity, ethnicity, maternal weight, height and age, and 
paternal height, which are important determinants of fetal growth. Customisation of 
fetal growth charts attempts to adjust for physiological characteristics and so to 
estimate the growth potential for an individual fetus. We developed a model for the 
construction of fetus specific growth charts. 
Data for this study came from the Generation R Study, a prospective, population-
based cohort study, following children born in Rotterdam, the Netherlands, from 
early fetal life until young adulthood. We could use data of 8,162 singleton 
pregnancies of which 5,473 had complete data on all determinants in our final 
model. 
Determinants in the model, with outcome fetal weight, estimated using ultrasound 
measurements, were: fetal gender, parity, ethnicity, maternal age, height, weight. 
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a substantial adverse effect on fetal growth. 
This study was the first study fitting a model to obtain individually customised 
growth charts using ultrasound measurements in a large population-based study. 
The use of these charts may improve monitoring of fetal growth and prenatal care. 
 
Finally, in Chapter 9, the main findings from this thesis are discussed and 
recommendations are given for the development of future prediction models for 
growth response and their use in clinical practice. 
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proefschrift ter sprake komen. Enkele aspecten van groei, zowel prenataal als 
postnataal, en van groeiregulatie worden beschreven. De studies in dit proefschrift 
betreffen twee groepen van kinderen met groeistoornissen, nl. kinderen met 
groeihormoon deficiëntie (GHD) en kinderen die bij geboorte te klein zijn, gegeven 
de zwangerschapsduur (short for gestational age, SGA). Over deze groepen wordt 
enige informatie gegeven, o.a. over de behandeling met groeihormoon (GH). Ook 
wordt de huidige stand van zaken m.b.t. predictiemodellen voor groeirespons op GH 
behandeling beschreven. 
 
Hoofdstuk 2 beschrijft de validatie en calibratie van een model gepubliceerd in 
1999, voor het voorspellen van groei van kinderen met idiopathische groeihormoon 
deficiëntie (IGHD), tijdens GH behandeling. Dit model, dat de groei tijdens het eerste 
jaar GH behandeling voorspelt, hebben wij gevalideerd met data van 136 
Nederlandse kinderen met IGHD. Voor deze validatiegroep werd de geobserveerde 
groeisnelheid uitgezet tegen de voorspelde groeisnelheid in een zgn. calibratieplot. Er 
werd een regressie-analyse uitgevoerd met als uitkomst de geobserveerde 
groeisnelheid en als determinant de voorspelde groeisnelheid. De regressielijn was 
statistisch significant van de diagonaal y = x (waar de geobserveerde groeisnelheid 
gelijk is aan de voorspelde groeisnelheid) en de geschatte helling van de lijn was 
0.808. Dit betekent dat in het model overfitting aanwezig was, wat een bekend 
verschijnsel is bij predictiemodellen. Met de geschatte coëfficiënten van de 
regressielijn werd een calibratiecorrectie voor het model opgesteld. De formule voor 
deze correctie was: Ycal = Yorig + (2.153 - 0.192 * Yorig), met Ycal de gecalibreerde 
predictie en Yorig de originele predictie. De gecalibreerde predictie is hoger dan de 
originele predictie indien de originele predictie kleiner is dan 11.2 cm/jr en in de 
andere gevallen lager. Ook bleek dat de variantie van de predictiefouten positief 
gerelateerd was aan de waarde van de predictie (p < 0.001), volgens de vergelijking 
SDpred fout = -1.017 + 0.286 * Ycal. 
De gevonden modificatie van de originele predictieregel geeft betere predicties 
voor kinderen met IGHD die voldoen aan dezelfde criteria. 
 
Hoofdstuk 3 beschrijft de validatie van het aangepaste predictiemodel uit 
Hoofdstuk 2 in een nieuw onafhankelijk cohort van 226 patiënten. Zowel voor de 
aangepaste als voor de oorspronkelijke predictieregel werd de geobserveerde 
groeisnelheid in het eerste jaar uitgezet tegen de voorspelde groeisnelheid in een 
calibratieplot. De regressielijn in de calibratieplot van het aangepaste model was niet 
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oorspronkelijke model (p < 0.001). De gemiddelde (SD) predictiefout van het 
aangepaste model was -0.11 (2.05) cm/jr en voor het oorspronkelijke model 0.28 
(2.11) cm/jr. 
Geconcludeerd werd dat de aangepaste predictiemethode, verkregen door 
calibratie van het oorspronkelijke model, goed voldeed in een onafhankelijke groep 
patiënten en accuratere predicties gaf dan het oorspronkelijke model. 
 
Voor langetermijnrespons op GH behandeling van kinderen met GHD was nog 
geen predictiemodel voor handen. Wij ontwikkelden modellen, die worden 
beschreven in Hoofdstuk 4, voor de predictie van volwassen lengte. Het betreft 
zowel modellen die voorspellen op basis van gegevens die bekend zijn bij de start 
van de GH behandeling (Start model) als modellen die de gegevens na één jaar 
behandeling gebruiken (First-year model). De data voor het ontwikkelen van de 
modellen werden geselecteerd uit de Landelijke Registratie 
Groeihormoonbehandeling bij Kinderen, waarin alle kinderen in Nederland die 
behandeld worden met GH geregistreerd zijn. Belangrijk inclusiecriterium was de 
diagnose GHD of een maximum GH respons tijdens provocatietesten van minder dan 
11 ng/ml. De kinderen waren tenminste één jaar behandeld met biosynthetisch GH. 
Om de complete geselecteerde groep van 342 kinderen te kunnen gebruiken voor de 
ontwikkeling van de modellen, gebruikten we multipele imputatie voor het imputeren 
van missende gegevens. De predictiemodellen, die verkregen werden d.m.v. 
stepwise forward selectie van de determinanten, werden gecorrigeerd voor 
overfitting met bootstrapping. 
Alle predictiemodellen bevatten zowel de doellengte (target height,TH) SDS als de 
huidige lengte SDS. In de First-year modellen was de verandering in lengte SDS 
tijdens het eerste jaar een belangrijke predictor. De percentages verklaarde 
variantie, gecorrigeerd voor overfitting, lagen tussen de 37% (prepubertaire 
kinderen, Start model) en 60% (pubertaire kinderen, First-year model). 
In geen van de modellen werd de dosis GH geselecteerd als significante predictor. 
Voor de patiënten in onze dataset werd de GHdosis bij start en gedurende de 
behandeling vastgesteld door de behandelend arts, gebaseerd op niet-geregistreerde 
criteria. Mogelijk werd er vaak een hogere startdosis voorgeschreven aan patiënten 
voor wie de verwachtingen laag waren, en werd de GHdosis gedurende de 
behandeling gewijzigd afhankelijk van de geobserveerde groeirespons. Onze data 
waren daarom niet geschikt om een schatting te geven van het effect van GH 
dosering op volwassen lengte. 
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lengte voor kinderen met GHD, bij start of na een jaar GH behandeling en leveren 
daarmee nuttige informatie voor de behandeling van deze kinderen. 
 
In Hoofdstuk 5 wordt een model gepresenteerd voor predictie van de lengte bij 
de start van de puberteit en van de volwassen lengte van te klein geboren en te klein 
gebleven kinderen (SGA) die behandeld worden met GH. SGA is 2005 een indicatie 
voor GH behandeling maar de optimale GH dosis staat nog niet vast. 
Voor het ontwikkelen van dit model werd data gebruikt van twee GH studies. We 
selecteerden 150 kinderen met een lengte bij start van de behandeling onder de -2 
SDS en een leeftijd van 3 jaar of ouder, die geen tekenen van spontane inhaalgroei 
vertoonden. De lengte bij de start van de puberteit moest bekend zijn en de 
behandeling met GH diende tenminste één jaar vóór de start van de puberteit 
begonnen te zijn. In een van de studies waren de patiënten gerandomiseerd voor 
0.033 of 0.067 mg GH / kg·dag, in de andere studie werden alle kinderen behandeld 
met 0.033 mg GH / kg·dag. 71 kinderen hadden hun volwassen lengte bereikt. 
Een belangrijke bevinding was dat serum IGFBP-3 SDS bij start een significante 
determinant was en dat er een significante interactie was tussen GH dosis en 
IGFBP-3 SDS. Dit betekent dat bij hogere waarden van IGFBP-3 het effect van de GH 
dosis kleiner was. Met het model werd 57% verklaard van de variantie in lengte SDS 
bij start van de puberteit en 41% van de variantie in volwassen lengte SDS 
(percentages gecorrigeerd voor overfitting). 
Deze resultaten betekenen dat de bepaling van IGFBP-3 in SGA kinderen 
noodzakelijk is om het effect van GH dosis vast te kunnen stellen en om een 
predictie voor volwassen lengte te kunnen geven. Het model verschaft belangrijke 
informatie over de te verwachten langetermijngroei. Omdat de GH dosis een van de 
determinanten is, kan het model gebruikt worden bij het bepalen van de optimale GH 
dosis voor een kind. 
 
Hoofdstuk 6 beschrijft een studie naar de inhaalgroei van SGA kinderen. De 
meerderheid van te klein geboren kinderen vertoont inhaalgroei gedurende de eerste 
levensjaren, maar ongeveer 10-15% heeft op de leeftijd van 2 jaar nog een lengte 
onder het normale gebied (< -2 SDS). Het doel van deze studie was om het 
percentage kinderen die na de leeftijd van 2 jaar alsnog een voor de leeftijd normale 
lengte bereiken vast te stellen en om een predictiemodel te ontwikkelen voor groei 
vanaf 2 jaar. 
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g In een cohort van 724 SGA kinderen hadden er 109 een lengte onder de -2 SDS 
op de leeftijd van 2 jaar. Van hen konden er 97 worden geïncludeerd in deze studie. 
Negenendertig procent van hen bereikte een lengte boven de -2 SDS op een leeftijd 
tussen 2 en 8 jaar (6% van de totale groep). De belangrijkste determinant van groei 
na de leeftijd van 2 jaar was het verschil tussen doellengte SDS en lengte SDS op de 
leeftijd van 2 jaar. De residuele SD was 0.54 en het percentage verklaarde variantie 
was 44%. Met een voorspelling van de lengte SDS op 8 jarige leeftijd en de SD kan 
de kans worden bepaald dat de lengte op 8 jarige leeftijd bijvoorbeeld boven de -2.5 
SDS zal zijn, of boven de -2.0 SDS. 
Het beschreven predictiemodel kan identificeren welke kinderen een kleine of 
grote kans hebben op spontane inhaalgroei. Dit kan helpen om te bepalen welke 
kinderen in de kliniek gevolgd dienen te worden. 
 
In langetermijnstudies naar groei, met volwassen lengte als uitkomst, is het vaak 
nodig om al resultaten te rapporteren op een moment dat nog niet alle data 
compleet zijn. Enkele respondenten hebben hun volwassen lengte nog niet bereikt 
en/of anderen kunnen niet meer gevolgd worden. De huidige aanpak is om alleen de 
respondenten mét volwassen lengte te analyseren. Dit kan echter gemakkelijk 
verkeerde resultaten geven. In Hoofdstuk 7 wordt een nieuwe methode 
beschreven, oorspronkelijk ontwikkeld voor kosteneffectiviteitsanalyses. 
Voor deze methode zijn lengtemetingen nodig op vaste tijdstippen. De gemiddelde 
volwassen lengte wordt geschat m.b.v. de geschatte kans om nog aan het groeien te 
zijn aan het begin van ieder tijdsinterval en de gemiddelde groei in ieder interval. 
We lieten zien dat deze methode valide is voor groeidata door de methode toe te 
passen op kunstmatig gegenereerde groeigegevens in een simulatiestudie. In een 
dergelijke situatie zijn het werkelijke gemiddelde en de standaard deviatie (SD) van 
de volwassen lengte in de populatie bekend. Er werden vijf verschillende 
groeiscenario’s gebruikt, met verschillende relaties tussen volwassen lengte en de 
leeftijd waarop deze bereikt wordt. Met deze simulatie studie werd aangetoond dat 
de voorgestelde nieuwe methode in ieder scenario slechts een zeer klein verschil gaf 
met het bekende populatiegemiddelde (minder dan 0.2 cm). De standaard deviaties 
waren kleiner dan die van de andere methoden die gebruikt worden voor 
gecensureerde data. Dit toont aan dat de methode statistisch gezien efficiënter is. 
De methode werd toegepast op data van patiënten uit een registratie database en 
op data van een GH studie. De geschatte gemiddelden van de volwassen lengte 
waren minder onzuiver en hadden een kleinere standaard fout dan verkregen werd 
met de gebruikelijke methoden. De validiteit van de schattingen werd niet beïnvloed 
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wordt. 
Samenvattend geeft de nieuwe methode valide resultaten voor de gemiddelde 
volwassen lengte in situaties waarin (nog) niet alle volwassen lengtes geobserveerd 
zijn. Omdat de methode ook de geobserveerde gegevens meeneemt van kinderen 
van wie de follow-up niet compleet is, worden de data effectiever gebruikt. 
 
Hoofdstuk 8 beschrijft een model voor prenatale groei. In de klinische praktijk 
worden grootte en gewicht van een foetus beoordeeld aan de hand van standaard 
referentie tabellen voor foetale groeiparameters. Hierbij wordt geen rekening 
gehouden met de normale variatie in foetale groei die veroorzaakt wordt door 
eigenschappen als geslacht, pariteit, etniciteit, gewicht, lengte en leeftijd van de 
moeder en lengte van de vader, wat belangrijke determinanten zijn van foetale 
groei. Foetusspecifieke groeicurven daarentegen houden wel rekening met de 
eigenschappen van een foetus. Hiermee kan de groeipotentie voor een individuele 
foetus beter bepaald worden. Wij ontwikkelden een model voor de constructie van 
foetusspecifieke groeicurven. 
Data voor deze studie kwamen van de Generation R Studie, een prospectieve 
studie onder kinderen geboren in Rotterdam, waarin gegevens verzameld worden 
vanaf de vroege zwangerschap tot jongvolwassenheid. Er konden gegevens gebruikt 
worden van 8,162 eenlingen, van wie er 5,473 complete gegevens hadden voor alle 
determinanten die in het model gebruikt werden. 
De determinanten in het model, met als uitkomst het foetale gewicht, geschat 
o.b.v. echometingen, waren: foetaal geslacht, pariteit, etniciteit, leeftijd, lengte en 
gewicht van de moeder. Het model werd gecorrigeerd voor roken van de moeder 
gedurende de zwangerschap, omdat dit een substantieel negatief effect heeft op de 
foetale groei. 
Deze studie was de eerste waarin een model voor de constructie van 
foetusspecifieke groeicurven ontwikkeld werd gebruikmakend van echometingen uit 
een groot bevolkingsonderzoek. Het gebruik van deze curven kan leiden tot 
verbetering van de prenatale zorg. 
 
Tenslotte worden in Hoofdstuk 9 de belangrijkste bevindingen uit dit proefschrift 
besproken en worden aanbevelingen gedaan voor het gebruik van predictiemodellen 
in de klinische praktijk en voor het ontwikkelen van toekomstige predictiemodellen 
voor groeirespons. 
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